<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002946.pub2" GROUP_ID="MUSKEL" ID="468899120809422667" MERGED_FROM="" MODIFIED="2009-05-19 08:59:18 -0400" MODIFIED_BY="[Empty name]" REVIEW_NO="C040-R" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2009-05-19 08:57:55 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<TITLE>Glucosamine therapy for treating osteoarthritis</TITLE>
<CONTACT>
<PERSON ID="5472" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tanveer</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Towheed</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>tt5@queensu.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine and of Community Health and Epidemiology</DEPARTMENT>
<ORGANISATION>Queen's University</ORGANISATION>
<ADDRESS_1>Etherington Hall-Room 2066</ADDRESS_1>
<ADDRESS_2/>
<CITY>Kingston</CITY>
<ZIP>K7L 3N6</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+ 1 613 533 6896</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 533 2189</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-05-19 08:57:55 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="5472" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tanveer</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Towheed</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>tt5@queensu.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine and of Community Health and Epidemiology</DEPARTMENT>
<ORGANISATION>Queen's University</ORGANISATION>
<ADDRESS_1>Etherington Hall-Room 2066</ADDRESS_1>
<ADDRESS_2/>
<CITY>Kingston</CITY>
<ZIP>K7L 3N6</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+ 1 613 533 6896</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 533 2189</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17387" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Lara</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Maxwell</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinator, Cochrane Musculoskeletal Group</POSITION>
<EMAIL_1>cmsg@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613 562 5800 ext: 1977</PHONE_1>
<PHONE_2/>
<FAX_1>613 562 5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14887" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tassos</FIRST_NAME>
<MIDDLE_INITIALS>P</MIDDLE_INITIALS>
<LAST_NAME>Anastassiades</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>anastass@post.queensu.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medicine and Biochemistry</DEPARTMENT>
<ORGANISATION>Queen's University</ORGANISATION>
<ADDRESS_1>Room 2050 Etherington Hall</ADDRESS_1>
<ADDRESS_2/>
<CITY>Kingston</CITY>
<ZIP>K7L 3N6</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 533 2971</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5440" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D333B53282E26AA20080535F04EA1E25" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>JB</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Houpt</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jbhoupt@sympatico.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>University of Toronto</DEPARTMENT>
<ORGANISATION/>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP/>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>416-971-7730</PHONE_1>
<PHONE_2>416-489-9754</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13312" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Vivian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Welch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>vivian.welch@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street, Room 206</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562-5800 ext: 2921</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14948" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marc</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Hochberg</LAST_NAME>
<SUFFIX/>
<POSITION>Head, Division of Rheumatology and Clinical Immunology</POSITION>
<EMAIL_1>mhochber@umaryland.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Medicine</DEPARTMENT>
<ORGANISATION>University of Maryland</ORGANISATION>
<ADDRESS_1>10 S Pine St MSTF 8-34</ADDRESS_1>
<ADDRESS_2/>
<CITY>Baltimore</CITY>
<ZIP>21201</ZIP>
<REGION>MD</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>410-706-6474</PHONE_1>
<PHONE_2/>
<FAX_1>410-706-0231</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Research Reference Centre</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-12 17:46:56 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="12" MONTH="11" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="1" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-12 17:46:17 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-12 17:33:01 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>5 new studies included in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-12 17:46:17 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 17:46:17 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. C040-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Queens University Cochrane Network Site. Kingston, Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Ottawa</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-05-19 08:59:18 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-05-19 08:59:18 -0400" MODIFIED_BY="[Empty name]">
<TITLE>Glucosamine for osteoarthritis</TITLE>
<SUMMARY_BODY MODIFIED="2009-05-19 08:59:18 -0400" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of glucosamine on osteoarthritis.<B> </B>
</P>
<P>
<B>People with osteoarthritis who take glucosamine:</B>
</P>
<P>- may reduce their pain</P>
<P>- may improve their physical function</P>
<P>- will probably not have side effects</P>
<P>
<B>What is osteoarthritis and glucosamine?</B> </P>
<P>Osteoarthritis (OA) is the most common form of arthritis that can affect the hands, hips, shoulders and knees. In OA, the cartilage that protects the ends of the bones breaks down and causes pain and swelling. Drug and non-drug treatments are used to relieve pain and/or swelling.</P>
<P>Glucosamine can be found naturally in the body and is used by the body as one of the building blocks of cartilage.  Glucosamine can also be taken as a pill as a supplement to the diet, or sometimes as an injection.  It can come in combination with other supplements (such as chondroitin), or by itself in the form of glucosamine hydrochloride or sulphate.  The usual dose recommended on packages is 1500 mg per day or 500 mg three times a day.</P>
<P>In Europe, glucosamine is prescribed by health care providers.  But in North America, people can buy glucosamine supplements without a prescription.  This means that, in North America, glucosamine is not regulated and the pills may or may not truly contain the amount described on the label.<B> </B>
</P>
<P>
<B>Best estimate of what happens after about 6 months</B>
</P>
<P>Pain: The high quality studies showed that pain improved about the same whether people took glucosamine or fake pills. If all of the studies are examined (including low quality and old studies), then glucosamine improved pain more than fake pills.</P>
<P>People who took fake pills had a pain score of 7 points on a 0 to 100 scale. Pain may improve by 10 more points with glucosamine than with fake pills. </P>
<P>Studies testing only the Rotta brand of glucosamine (including low quality and older studies) showed that glucosamine improved pain more than fake pills. People who took fake pills had a pain score of 6 points on a 0 to 20 scale. People who took the Rotta brand of glucosamine rated their pain 3 points lower than people who did not take glucosamine.</P>
<P>Function: The high quality studies show that glucosamine improved function more than fake pills when measured by one type of scale, but improved the same amount as fake pills when measured by another scale.</P>
<P>Studies testing only the Rotta brand of glucosamine (including low quality and older studies) showed that glucosamine improved function more than fake pills. People who took fake pills had a function score of 22 points on a 0 to 68 scale. People who took the Rotta brand of glucosamine had their ability to function improve by 2 points compared to people who did not take glucosamine.</P>
<P>There was no difference in the number of people who had side effects.  Side effects mainly included stomach upset and other joint pain.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-08 12:22:29 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-11-07 05:37:30 -0500" MODIFIED_BY="[Empty name]">
<P>Osteoarthritis (OA) is a common form of arthritis and is often associated with significant disability and impaired quality of life. This is an update of a Cochrane review first published in 2001 and previously updated in 2005.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-08-24 19:55:05 -0400" MODIFIED_BY="[Empty name]">
<P>To review randomized controlled trials (RCTs) evaluating the effectiveness and toxicity of glucosamine in OA.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-07 05:41:17 -0500" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL and the Cochrane Database of Systematic Reviews (<I>The Cochrane Library</I>), MEDLINE, PREMEDLINE, EMBASE, AMED, ACP Journal Club, DARE (to January 2008); contacted content experts, and handsearched reference lists and pertinent review articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-11-07 05:41:37 -0500" MODIFIED_BY="[Empty name]">
<P>RCTs evaluating the effectiveness and safety of glucosamine in OA.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-07 05:41:57 -0500" MODIFIED_BY="[Empty name]">
<P>Data abstraction was performed independently by two review authors and investigators were contacted for missing data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-08 12:22:29 -0500" MODIFIED_BY="[Empty name]">
<P>This update includes 25 studies with 4963 patients. Analysis restricted to studies with adequate allocation concealment failed to show any benefit of glucosamine for pain (based on a pooled measure of different pain scales) and WOMAC pain, function and stiffness subscales; however, it was found to be better than placebo using the Lequesne index (standardized mean difference (SMD) -0.54; 95% confidence interval (CI) -0.96 to -0.12). Collectively, the 25 RCTs favoured glucosamine with a 22% (change from baseline) improvement in pain (SMD -0.47; 95% CI -0.72 to -0.23) and a 11% (change from baseline) improvement in function using the Lequesne index (SMD -0.47; 95% CI -0.82 to -0.12). However, the results were not uniformly positive and the reasons for this remain unexplained. WOMAC pain, function and stiffness outcomes did not reach statistical significance.</P>
<P>RCTs in which the Rotta preparation of glucosamine was compared to placebo found glucosamine superior for pain (SMD -1.11; 95% CI -1.66 to -0.57) and function (Lequesne index SMD -0.47; 95% CI -0.82 to -0.12). Pooled results for pain (SMD -0.05; 95% CI -0.15 to 0.05) and function using the WOMAC index (SMD -0.01; 95% CI -0.13 to 0.10) in those RCTs using a non-Rotta preparation of glucosamine did not reach statistical significance. Two RCTs using the Rotta preparation showed that glucosamine was able to slow radiological progression of OA of the knee over a three-year period (mean difference (MD) 0.32; 95% CI 0.05 to 0.58).</P>
<P>Glucosamine was as safe as placebo in terms of the number of participants reporting adverse reactions (relative risk ratio 0.99; 95% CI 0.91 to 1.07).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-07 05:48:59 -0500" MODIFIED_BY="[Empty name]">
<P>Pooled results from studies using a non-Rotta preparation or adequate allocation concealment failed to show benefit in pain and WOMAC function while those studies evaluating the Rotta preparation showed that glucosamine was superior to placebo in the treatment of pain and functional impairment resulting from symptomatic OA.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-12 17:35:29 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-07 06:09:23 -0500" MODIFIED_BY="[Empty name]">
<P>Osteoarthritis (OA) is the most common form of arthritis, and it is often associated with significant disability and an impaired quality of life ( <LINK REF="REF-Badley-1995" TYPE="REFERENCE">Badley 1995</LINK>; <LINK REF="REF-Moralestorres-1996" TYPE="REFERENCE">Moralestorres 1996</LINK>; <LINK REF="REF-Scott-1993" TYPE="REFERENCE">Scott 1993</LINK>; <LINK REF="REF-Towheed-1998" TYPE="REFERENCE">Towheed 1998</LINK>). An estimated 12.1% of Americans aged 25 years and older (nearly 21 million persons in 1990) have clinical signs and symptoms of OA (<LINK REF="REF-Lawrence-1998" TYPE="REFERENCE">Lawrence 1998</LINK>). Among US adults aged 30 years or older, symptomatic disease in the knee occurs in approximately 6% and symptomatic disease in the hip occurs in approximately 3% (<LINK REF="REF-Felson-2000" TYPE="REFERENCE">Felson 2000</LINK>). OA of the hip and knee can be especially disabling to lower extremity functioning because the hip and knee are large weight-bearing joints (<LINK REF="REF-Liang-1984" TYPE="REFERENCE">Liang 1984</LINK>). Advanced OA of the hip or knee is the most common reason for elective joint replacement (<LINK REF="REF-Hochberg-1996" TYPE="REFERENCE">Hochberg 1996</LINK>).</P>
<P>Although there are no curative therapies currently available for OA, individualized treatment programs are available to help relieve pain and stiffness and to maintain or improve functional status (<LINK REF="REF-ACR-2000" TYPE="REFERENCE">ACR 2000</LINK>; <LINK REF="REF-Creamer-1998" TYPE="REFERENCE">Creamer 1998</LINK>; <LINK REF="REF-Hochberg-1995a" TYPE="REFERENCE">Hochberg 1995a</LINK>; <LINK REF="REF-Hochberg-1995b" TYPE="REFERENCE">Hochberg 1995b</LINK>). Treatment strategies for OA have included both non-pharmacological and pharmacological modalities (<LINK REF="REF-Creamer-1997" TYPE="REFERENCE">Creamer 1997</LINK>). Non-pharmacological therapy is considered to be the foundation for the successful medical management of OA (<LINK REF="REF-Felson-1998" TYPE="REFERENCE">Felson 1998</LINK>; <LINK REF="REF-Puett-1994" TYPE="REFERENCE">Puett 1994</LINK>). These modalities include weight reduction (if obese), physiotherapy (for example muscle strengthening), and occupational therapy (for example, use of assistive devices for ambulation).</P>
<P>Non-steroidal anti-inflammatory drugs (NSAIDs) are considered by many physicians to be the preferred agents for the pharmacological management of OA. In support of this, randomized controlled trials (RCTs) attest to the superior efficacy of NSAIDs as compared with placebo (<LINK REF="REF-Towheed-1997a" TYPE="REFERENCE">Towheed 1997a</LINK>; <LINK REF="REF-Towheed-1997b" TYPE="REFERENCE">Towheed 1997b</LINK>; <LINK REF="REF-Towheed-2002" TYPE="REFERENCE">Towheed 2002</LINK>). However, there are certain disadvantages of routinely using NSAIDs in OA. For example, all NSAIDs (non-selective and COX-2 selective) are associated with significant potential toxicity, particularly in the elderly population (<LINK REF="REF-Deviere-2002" TYPE="REFERENCE">Deviere 2002</LINK>; <LINK REF="REF-Gabriel-1991" TYPE="REFERENCE">Gabriel 1991</LINK>; <LINK REF="REF-Garner-2002" TYPE="REFERENCE">Garner 2002</LINK>; <LINK REF="REF-Griffin-1991" TYPE="REFERENCE">Griffin 1991</LINK>; <LINK REF="REF-Wright-2002" TYPE="REFERENCE">Wright 2002</LINK>). COX-2 selective inhibitors have also been associated with an increased risk of cardiovascular disease. Rofecoxib, a COX-2 selective inhibitor, was recently withdrawn from the world market due to concerns in this regard (<LINK REF="REF-Sibbald-2004" TYPE="REFERENCE">Sibbald 2004</LINK>).</P>
<P>There is also a concern that NSAIDs may be toxic to articular cartilage (<LINK REF="REF-Herman-1986" TYPE="REFERENCE">Herman 1986</LINK>) and that they may accelerate the course of OA of the hip (<LINK REF="REF-Rashad-1989" TYPE="REFERENCE">Rashad 1989</LINK>). Given that OA is the most prevalent form of arthritis and that the number of persons affected with OA will increase significantly in the near future, finding alternative, safer pharmacological therapies for OA is of considerable importance.</P>
<P>Recent additions to the options for pharmacological therapy of OA have included biological compounds, such as hyaluronans, chondroitin sulfate, and glucosamine (<LINK REF="REF-Lozada-1997" TYPE="REFERENCE">Lozada 1997</LINK>). Although not yet proven, these compounds may also potentially be chondroprotective, in that they may favourably modify the natural progression and course of OA. Glucosamine compounds, in particular, have attracted a great deal of attention, mostly in the lay press and less so in the scientific literature (<LINK REF="REF-Anderson-2005" TYPE="REFERENCE">Anderson 2005</LINK>; <LINK REF="REF-Barclay-1998" TYPE="REFERENCE">Barclay 1998</LINK>; <LINK REF="REF-Da-Camara-1998" TYPE="REFERENCE">Da Camara 1998</LINK>; <LINK REF="REF-Towheed-1999" TYPE="REFERENCE">Towheed 1999</LINK>; <LINK REF="REF-Towheed-2000" TYPE="REFERENCE">Towheed 2000</LINK>; <LINK REF="REF-Towheed-2002" TYPE="REFERENCE">Towheed 2002</LINK>; <LINK REF="REF-Towheed-2003" TYPE="REFERENCE">Towheed 2003</LINK>, <LINK REF="REF-Towheed-2007" TYPE="REFERENCE">Towheed 2007</LINK>). There appears to be controversy as to the relative efficacy of glucosamine, and as to whether glucosamine can indeed modify the progression of OA (<LINK REF="REF-Reginister-2003" TYPE="REFERENCE">Reginister 2003</LINK>).</P>
<P>For the purposes of this review, GS refers to glucosamine sulfate and GH refers to glucosamine hydrochloride, whereas glucosamine refers to both compounds. GS is a natural substance and is the building block of the ground substance of the articular cartilage, the proteoglycans. The rationale for the use of GS in OA is based largely on in-vitro and animal models of osteoarthritis. For example, GS has been shown to normalize cartilage metabolism, rebuild experimentally damaged cartilage, and demonstrate mild anti-inflammatory properties (<LINK REF="REF-Bassleer-1992" TYPE="REFERENCE">Bassleer 1992</LINK>; <LINK REF="REF-McCarty-1994" TYPE="REFERENCE">McCarty 1994</LINK>; <LINK REF="REF-Roden-1956" TYPE="REFERENCE">Roden 1956</LINK>; <LINK REF="STD-Rovati-1993" TYPE="STUDY">Rovati 1993</LINK>; <LINK REF="REF-Setnikar-1991a" TYPE="REFERENCE">Setnikar 1991a</LINK>; <LINK REF="REF-Vidal-1978" TYPE="REFERENCE">Vidal 1978</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-07 06:09:58 -0500" MODIFIED_BY="[Empty name]">
<P>To assess the effectiveness and toxicity of glucosamine in the pharmacological management of OA. Both symptomatic effectiveness and structural effectiveness (that is, delay in radiological progression of OA) were evaluated.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-07 06:29:21 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-07 06:11:47 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-11-07 06:04:47 -0500" MODIFIED_BY="[Empty name]">
<P>Two levels of criteria were used to identify all relevant studies for this review. The first criteria were used to screen all citations that involved glucosamine in the management of OA. The second criteria were used to identify those studies that met the following additional requirements: 1) RCTs evaluating the efficacy and toxicity of glucosamine in OA, 2) both placebo-based and comparative studies were eligible, 3) both single-blinded and double-blinded trials were eligible, 4) studies to be included in the quantitative portion of the review (meta-analysis) must have presented suitable quantitative data for pooling across trials, 5) studies that enrolled participants with OA at any body site were eligible with the only exception being studies that evaluated glucosamine in temporomandibular joint (TMJ) disorders, 6) only studies which evaluated glucosamine-only preparations were included (studies which evaluated combination products containing glucosamine in association with other active compounds, for example chondroitin, were excluded), 7) glucosamine could have been administered by any route.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-07 06:05:27 -0500" MODIFIED_BY="[Empty name]">
<P>All adult (of age 18 years and older) humans with a diagnosis of either primary or secondary OA at any site, including the axial and peripheral skeleton. Studies that evaluated glucosamine in disorders of the temporomandibular joint (TMJ) were excluded from this review. Disorders of the TMJ have not been typically managed by arthritis experts and TMJ disease differs from other joints that are affected by OA in terms of its epidemiology and management.<B>
<BR/>
</B>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-11-07 06:06:19 -0500" MODIFIED_BY="[Empty name]">
<P>Only studies that evaluated the efficacy or toxicity, or both, of glucosamine in OA were eligible. Both placebo-controlled and comparative RCTs were included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-07 06:11:47 -0500" MODIFIED_BY="[Empty name]">
<P>At least one outcome measure must have been used to measure response to treatment. The main outcome measures of pain, range of motion, functional assessment, and global assessment satisfied this criterion. The hierarchy of outcomes (<LINK REF="REF-Bellamy-1997" TYPE="REFERENCE">Bellamy 1997</LINK>) that were extracted consisted of: 1) pain measured by any method, and 2) functional assessment measured by a validated health status questionnaire (for example, the WOMAC), 3) patient global assessment, 4) physician global assessment, and 5) range of motion of study joint. Structural benefits, defined as the ability of glucosamine to delay the natural radiological progression of OA, were studied. Toxicity of glucosamine was also considered to represent a relevant outcome measure (measured by the number of participants reporting any adverse events and by the number of participant withdrawals due to toxicity).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-07 06:19:59 -0500" MODIFIED_BY="[Empty name]">
<P>A MEDLINE search (1966 to November 1999) was used to identify all relevant RCTs for the first version of this Cochrane Review. For the second version of the Cochrane Review, all searches were updated (in January 2005). The same MEDLINE search strategy was extended for this updated version of the review (up to week 1, January 2008). MEDLINE In-Process and other non-indexed citations were also searched (January 2008); MEDLINE Daily Update was searched (January 2008). In addition, the Cochrane Central Register of Controlled Trials (CENTRAL) and the Cochrane Database of Systematic Reviews (CDSR) (<I>The Cochrane Library</I>), American College of Physicians (ACP) Journal Club, and Database of Abstracts of Reviews of Effectiveness (DARE) were searched (up to January 2008); Allied and Complementary Medicine (AMED) was searched (1985 to January 2008); and EMBASE was searched (1980 to week 2, January 2008). No language or age restrictions were used for any of the electronic searches. Reference lists of all identified citations were manually searched. In addition, letters were sent to authors and content experts for assistance in retrieving additional RCTs, especially those that were unpublished. A major manufacturer of glucosamine (Rotta Pharm) was also contacted for additional trials. For this version of the Cochrane Review, the search strategy was updated in January 2008.</P>
<P>The electronic search strategies for MEDLINE; EMBASE; CENTRAL, CDSR, ACP Journal Club, DARE; and AMED can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-07 06:29:21 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Study identification (identifying citations that involve GS or GH in the therapy of OA)</B> </P>
<P>Two review authors (TT and TP or LM) used the screening criteria to review all identified citations independently. All citations identified by either investigator were retrieved and analyzed for suitability. Authors of abstracts were contacted requesting the full manuscript, including the raw and final data incorporating the results.</P>
<P>
<B>Study selection (screening identified citations to see if they meet our additional criteria)</B> </P>
<P>Two review authors (TT and TP or LM) reviewed each relevant citation independently to see if it met the selection criteria described previously. At this stage, an emphasis was placed on selecting RCTs and excluding non-randomized treatment studies. If the randomization status was not clear, the article was withheld pending clarification from the principal author. In situations where authors were not available, then a consensus was reached amongst the investigators.</P>
<P>
<B>Data Extraction</B>
<BR/>Two review authors (TT and TP or LM) independently reviewed each RCT and extracted the raw data (for example, trial characteristics, participant demographics, outcome variables, results, features of trial quality) by using a standardized form. If outcome data were not reported in a form suitable for quantitative pooling in a meta-analysis, the primary author was contacted for access to this information. Data on adverse effects were also extracted from the RCTs. A consensus method was used in the event of disagreement.</P>
<P>
<B>Assessment of methodological quality</B>
<BR/>The individual criteria designed for a validated scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) along with the criterion of allocation concealment were used to assess the methodological quality of the 25 glucosamine RCTs that were included in this version of the Cochrane review. The reporting of the following individual components were assessed: description and method of generation of the randomization sequence, description and method of blinding, the number of and reasons for withdrawals and dropouts in both groups, and the method of allocation concealment. Each criterion was rated as 'met' or 'not met'. For generation of the randomization sequence, appropriate methods of randomization included random number tables or computer generated sequences; date of birth or hospital numbers were considered inappropriate randomization methods. Identical placebo or an active placebo were considered appropriate methods of double-blinding. For allocation concealment, 'met' meant that allocation concealment was adequately described in the RCT, while 'not met' meant an unclear or inadequate allocation concealment status.<BR/>
</P>
<P>
<B>Data analysis</B>
<BR/>For quantitative outcome data, standardized mean differences (SMD) were used to pool across RCTs (<LINK REF="REF-Hedges-1985" TYPE="REFERENCE">Hedges 1985</LINK>; <LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>). It is important to note that we used the end of study means and standard deviations for the meta-analyses. If either of these were not available in the trial report, the principal author was contacted for additional information. In the absence of this information, we estimated the end of study standard deviation by using the baseline standard deviation. For categorical outcome data with two categories, the relative risk ratio (RR) was calculated (<LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>). Heterogeneity was tested with a Chi<SUP>2</SUP> test and the I<SUP>2</SUP> statistic, available in RevMan 5.0. A fixed-effect model was used unless heterogeneity was significant (P &lt; 0.10), in which case the random-effects model was used.</P>
<P>
<B>Sensitivity and subgroup analysis</B>
<BR/>An ad-hoc sensitivity analysis was carried out to see if effect sizes varied on pain, function, and radiologic measures when only those studies with adequate allocation concealment were analyzed. An ad-hoc subgroup analysis was performed on those studies using the Rotta preparation of glucosamine versus those that did not use the Rotta preparation to determine if the effect sizes varied on pain and function.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-12 17:35:29 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-07 06:51:08 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Results of search strategy</B>
<BR/>The MEDLINE search strategy (1966 to November 1999) resulted in a total of 61 citations. From these 61 citations, 11 RCTs were identified that evaluated the efficacy of glucosamine (<LINK REF="STD-Crolle-1980" TYPE="STUDY">Crolle 1980</LINK>; <LINK REF="STD-D_x0027_ambrosio-1981" TYPE="STUDY">D'ambrosio 1981</LINK>; <LINK REF="STD-Drovanti-1980" TYPE="STUDY">Drovanti 1980</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Muller_x002d_FassBender-94" TYPE="STUDY">Muller-FassBender 94</LINK>; <LINK REF="STD-Noack-1994" TYPE="STUDY">Noack 1994</LINK>; <LINK REF="STD-Pujalte-1980" TYPE="STUDY">Pujalte 1980</LINK>; <LINK REF="STD-Qiu-1998" TYPE="STUDY">Qiu 1998</LINK>; <LINK REF="STD-Reichelt-1994" TYPE="STUDY">Reichelt 1994</LINK>; <LINK REF="STD-Vaz-1982" TYPE="STUDY">Vaz 1982</LINK>; <LINK REF="STD-Vajaradul-1981" TYPE="STUDY">Vajaradul 1981</LINK>). The updated MEDLINE search (1996 to week 3, November 2004) resulted in a total of 201 citations. An additional four RCTs were identified from this search (<LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Rindone-2000" TYPE="STUDY">Rindone 2000</LINK>). The EMBASE search (1980 to week 28, 2003) resulted in a total of 207 citations, of which one additional RCT was identified (<LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>). Another EMBASE search (1996 to week 2, 2005) resulted in a total of 280 references from which one additional RCT was identified (<LINK REF="STD-Usha-2004" TYPE="STUDY">Usha 2004</LINK>). The MEDLINE in-Process and other non-Indexed citations search (January 6, 2005) resulted in eight citations containing two additional RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>). MEDLINE daily update (November 17, 2004) did not identify any relevant citations. The CENTRAL,CDSR, ACP Journal Club, DARE search (October 2004) identified a total of 52 citations, but no additional RCTs were found. AMED identified 24 citations, but no additional RCTs were found. One unpublished full manuscript reporting a RCT was sent to us by Rotta Pharm; a reference to this study was available in abstract form (<LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>). This study was included in the meta-analysis since the full manuscript contained all the relevant details necessary for its critical appraisal and for inclusion in the quantitative portion of the review. Rotta Pharm also sent us three unpublished brief technical reports reporting RCTs evaluating their GS preparation. These three brief unpublished technical reports were not included in the meta-analyses. No additional RCTs were identified by contact with content experts. Therefore, collectively the search strategies resulted in a total of 20 English language RCTs (19 published and one unpublished) that were included in the meta-analysis.</P>
<P>For the January 2008 update of the electronic searches, the search strategies identified an additional five RCTs that met the inclusion criteria for this review (<LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Qiu-2005" TYPE="STUDY">Qiu 2005</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>).</P>
<P>
<B>Trial demographics and features</B>
<BR/>The 25 identified RCTs that were included in the meta-analysis are listed in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table. The years of publication (or reporting date) ranged from 1980 to 2008. Six RCTs were published in the 1980s, six were published (or reported) in the 1990s, eight were published in the years 2000 to 2004, and five were published in the years 2005 to 2008. All were double-blind, randomized parallel-group trials and contained a total of 4963 adults with a mean age of 60.7 years (69% were female). A total of 1905 participants were randomized to treatment with glucosamine and 3058 were randomized to the comparator groups (placebo or active comparator). The mean number of participants randomized in each of the 25 RCTs was 198 (76 to glucosamine groups and 122 to comparator groups). The mean number completing each of the RCTs was 164 (83% completed the RCTs). The mean trial duration was 25.5 weeks. The country of origin (number of RCTs) included: Italy (3), Germany (3), Canada (2), France (1), Thailand (1), China (2), Portugal (2), USA (4), UK (1), Philippines (1), Belgium (1), India (2), the Czech Republic (1), Spain (1), and the Netherlands (1). One RCT included participants from both Spain and Portugal (<LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>). Only six North American RCTs were found (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Rindone-2000" TYPE="STUDY">Rindone 2000</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>). All of the RCTs were published in the English language with the exception of the Qiu study (<LINK REF="STD-Qiu-2005" TYPE="STUDY">Qiu 2005</LINK>), which was published in Chinese but had an English abstract.</P>
<P>Twenty of the 25 RCTs compared glucosamine to a placebo (18 used GS and two used GH), whereas, five RCTs compared glucosamine to an NSAID (ibuprofen in three, piroxicam in one, and celecoxib in one). Two studies compared glucosamine to both an NSAID and placebo (<LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>). Only one RCT directly compared glucosamine to acetaminophen (<LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>). Only one RCT directly compared GS with GH (<LINK REF="STD-Qiu-2005" TYPE="STUDY">Qiu 2005</LINK>). One RCT (<LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>) compared GS with a polyherbal supplement. The method of administration of glucosamine was quite variable in the RCTs. Twenty-one exclusively used an oral route, two used an intra-articular (IA) route, three used an intramuscular (IM) route, one used an intravenous (IV) route, and two used multiple routes (IM or IA and IM or IV). The dosage of glucosamine used in the RCTs was also quite variable. In the 21 RCTs using an oral route, the dosage was 1500 mg/day, which was administered as either 1500 mg once daily (six RCTs), as 500 mg three times per day (14 RCTs), or as 750 mg two times per day (one RCT). In the RCTs using parenteral routes (IM, IA, IV), 400 mg of GS was administered either once daily (two RCTs), or twice weekly (one RCT).</P>
<P>The type and site of OA evaluated was also heterogeneous in the 25 RCTs. Twenty RCTs evaluated the knee exclusively, two evaluated OA at multiple sites (knee, hip, others), and two did not specify the location of OA that was being evaluated. Only one RCT exclusively evaluated the hip (<LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>). Participants with only primary OA were evaluated by eight RCTs; 17 RCTs did not make clear the distinction between primary and secondary OA. The method of classification of OA was not described in 14 RCTs, whereas, five used the Lequesne's Index, eight used the American College of Rheumatology (ACR) classification criteria, and two RCTs used both the ACR and Lequesne classification criteria. Radiographs of the target joints were obtained at baseline in 19 of the RCTs. Fourteen of these RCTs used published validated x-ray classification criteria for OA.</P>
<P>The outcome variables (number of RCTs) included: pain (25), range of motion (6), functional status (20), global patient derived (4), global investigator derived (11), radiographic assessment for changes in cartilage thickness (3), and health related quality of life (1). Eleven RCTs used the WOMAC instrument. Eight RCTs used the Lequesne Index.</P>
<P>The majority of the RCTs (14/25, or 56%) had some form of relationship (by evaluating the Rotta brand of GS or some other affiliation) with Rotta Pharm, an Italian pharmaceutical manufacturer of GS. Ten RCTs did not use the Rotta brand of glucosamine (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>; <LINK REF="STD-Rindone-2000" TYPE="STUDY">Rindone 2000</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Qiu-2005" TYPE="STUDY">Qiu 2005</LINK>; <LINK REF="STD-Usha-2004" TYPE="STUDY">Usha 2004</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>). One RCT used both a non-Rotta glucosamine preparation (about 90% of participants received this) and a Rotta glucosamine preparation (received by about 10% of participants) (<LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>). Fourteen of the RCTs (56%) only evaluated the Rotta brand of GS.</P>
<P>The four identified RCTs that were not included in the meta-analysis are listed in the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table (<LINK REF="STD-Braham-2003" TYPE="STUDY">Braham 2003</LINK>; <LINK REF="STD-Magi-1997" TYPE="STUDY">Magi 1997</LINK>; <LINK REF="STD-Pipitone-1997" TYPE="STUDY">Pipitone 1997</LINK>; <LINK REF="STD-Rovati-1993" TYPE="STUDY">Rovati 1993</LINK>). Reasons for their exclusion are also outlined in this table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-07 06:53:24 -0500" MODIFIED_BY="[Empty name]">
<P>An assessment of each study against the individual methodological quality criteria described in the methods section is provided in the table of methodological quality assessment (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>All studies were reported as 'randomized', but only 12 studies described the actual method of randomization. Twenty-one of the 25 included studies reported an appropriate method of blinding.</P>
<P>Most studies (76%) reported the reasons for withdrawals and dropouts in both comparator groups. Only 13 RCTs (52%) were rated as having adequate allocation concealment, whereas 12 RCTs (48%) were rated as having inadequate or unclear allocation concealment. There is evidence that inadequate allocation concealment may result in an overestimation of the true treatment effect (<LINK REF="REF-Schulz-1995a" TYPE="REFERENCE">Schulz 1995a</LINK>). A post-hoc sensitivity analysis was undertaken to assess the results in only those studies where an appropriate method of allocation concealment was described.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-12 17:35:29 -0500" MODIFIED_BY="[Empty name]">
<P>1. Comparing GS or GH versus placebo: results from 18 RCTs were pooled for the outcome variable of reduction in pain, where pain was measured by a number of different methods (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Crolle-1980" TYPE="STUDY">Crolle 1980</LINK>; <LINK REF="STD-D_x0027_ambrosio-1981" TYPE="STUDY">D'ambrosio 1981</LINK>; <LINK REF="STD-Drovanti-1980" TYPE="STUDY">Drovanti 1980</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Pujalte-1980" TYPE="STUDY">Pujalte 1980</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Rindone-2000" TYPE="STUDY">Rindone 2000</LINK>; <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Usha-2004" TYPE="STUDY">Usha 2004</LINK>; <LINK REF="STD-Vajaradul-1981" TYPE="STUDY">Vajaradul 1981</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>). The summary standardized mean difference (SMD) (random-effects model) was -0.47 (95% CI -0.72 to -0.23). A negative SMD in this case meant that glucosamine was significantly superior to placebo in terms of its ability to reduce levels of pain. The relative per cent change from baseline was 22% (using <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK> in the calculation as the most representative study). </P>
<P>2. Comparing GS to placebo for the Lequesne Index scores: results from five RCTs were pooled (<LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Noack-1994" TYPE="STUDY">Noack 1994</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reichelt-1994" TYPE="STUDY">Reichelt 1994</LINK>, <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>). The summary SMD (random-effects model) was -0.47 (95% CI -0.82 to -0.12). A negative SMD in this case meant that glucosamine was significantly superior to placebo in terms of its ability to improve Lequesne Index scores. The relative per cent change from baseline was 11% (using <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK> in the calculation as the most representative study).</P>
<P>3. Comparing GS to placebo for Lequesne Index scores in which the outcome was dichotomous (per cent responders based on change in Lequesne Index): relative risk ratios (RR) were pooled across two RCTs (<LINK REF="STD-Noack-1994" TYPE="STUDY">Noack 1994</LINK>; <LINK REF="STD-Reichelt-1994" TYPE="STUDY">Reichelt 1994</LINK>). The summary RR (fixed-effect model) for likelihood of being a responder was 1.52 (95% CI 1.20 to 1.91).</P>
<P>4. Comparing GS or GH to placebo for WOMAC pain subscale scores: the summary SMD (fixed-effect model) for 10 RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.06 (95% CI -0.14 to 0.03). In this outcome there was no statistical difference between glucosamine and placebo. </P>
<P>5. Comparing GS or GH to placebo for WOMAC stiffness subscale scores: the summary SMD (fixed-effect model) for seven RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.02 (95% CI -0.13 to 0.08). In this outcome there was no statistical difference between glucosamine and placebo.</P>
<P>6. Comparing GS or GH to placebo for WOMAC function subscale scores: the summary SMD (fixed-effect model) for 10 RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.08 (95% CI -0.17 to 0.00). In this outcome there was no statistical difference between glucosamine and placebo. </P>
<P>7. Comparing GS or GH to placebo for WOMAC total scores: the summary SMD (fixed-effect model) for six RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.18 (95% CI -0.31 to - 0.05). In this outcome there was a statistical difference favoring glucosamine over placebo.</P>
<P>8. Comparing GS to placebo for changes in minimum joint space width for the knee or hip: the summary mean difference (MD) (fixed-effect model) for two RCTs (<LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>) measuring minimum joint space width at the knee was 0.32 (95% CI 0.05 to 0.58). This was statistically significant in favour of glucosamine and showed that glucosamine slowed the natural radiological progression of OA. <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK> measured minimum joint space width changes in the hip and found inconsistent results in the four sites they measured; however, none of the 95% CI achieved a minimal clinically important change of 0.25 mm.</P>
<P>9. Comparing GS to placebo for patient global assessment: <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK> measured the patient assessment of disease status score on a 0 to 100 scale and found a non-statistically significant result (mean difference 1.10, 95% CI -2.77 to 4.97). <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK> asked patients to respond to whether they felt better than at the start of the trial and also found a non-statistically significant result (RR 1.21, 95% CI 0.80 to 1.82).</P>
<P>10. Comparing GS to placebo for physician global assessment: <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK> measured the physician assessment of disease status score on a 0 to 100 scale and found a non-statistically significant result (mean difference 0.80, 95% CI -2.78 to 4.38). This corresponds to a relative per cent change from baseline of -1.5% (95% CI -5.4%, 8.5%). The outcome measured in Drovanti 1980 and Pujalte 1980 was a physician rating of a good or excellent response of their patients. The pooled RR was 2.26 (95% CI 1.49 to 3.43) in favour of glucosamine.</P>
<P>11. Comparing GS to an NSAID (piroxicam, ibuprofen, celecoxib) for the outcome variable of pain, where pain was measured by a number of different methods: the summary pooled SMD (random-effects model) for four RCTs was -0.27 (95% CI -0.65 to 0.11) (<LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Qiu-1998" TYPE="STUDY">Qiu 1998</LINK>; <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>; <LINK REF="STD-Vaz-1982" TYPE="STUDY">Vaz 1982</LINK>). In this outcome there was no statistical difference between glucosamine and NSAIDs.</P>
<P>12. Comparing GS to an NSAID (piroxicam, ibuprofen) for the outcome variable of change in the Lequesne Index scores: the summary SMD (random-effects model) for two pooled studies was -0.36 (95% CI -1.07 to 0.35) (<LINK REF="STD-Muller_x002d_FassBender-94" TYPE="STUDY">Muller-FassBender 94</LINK>; <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>). In this outcome there was no statistical difference between glucosamine and placebo.</P>
<P>One RCT (<LINK REF="STD-Mehta-2007" TYPE="STUDY">Mehta 2007</LINK>) compared GS to a polyherbal supplement (reparagen) and, as such, this unique comparator was not included in the meta-analyses described above. In this study, a 20% reduction in WOMAC pain was found in 84% of glucosamine participants and 94% of participants taking the polyherbal supplement at eight weeks. The difference between the two groups was not statistically significant.</P>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analysis</HEADING>
<P>
<I>Adequate allocation concealment</I>
</P>
<P>13. Comparing GS or GH versus placebo in studies with adequate allocation concealment: results from 11 RCTs were pooled for the outcome variable of reduction in pain, where pain was measured by a number of different methods (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>). The summary SMD (random-effects model) was -0.16 (95% CI -0.36 to 0.04). In this outcome there was no statistical difference between glucosamine and placebo. This corresponds to a decrease in the treatment group of 0.70 points (95% CI 1.5 points lower to 0.17 points higher) on a 0 to 20 WOMAC scale (using <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK> for the calculation). The relative per cent change from baseline was -7% (95% CI -17%, 1.8%). </P>
<P>14. Comparing GS to placebo in studies with adequate allocation concealment for the Lequesne Index scores: results from four RCTs were pooled (<LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Noack-1994" TYPE="STUDY">Noack 1994</LINK>; <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>). The summary SMD (random-effects model) was -0.54 (95% CI -0.96 to -0.12). A negative SMD in this case meant that glucosamine was significantly superior to placebo in terms of its ability to improve Lequesne index scores.</P>
<P>15. Comparing GS to placebo in studies with adequate allocation concealment for Lequesne Index scores in which the outcome was dichotomous (per cent responders based on change in Lequesne index): The summary RR (fixed-effect model) from one RCT (<LINK REF="STD-Noack-1994" TYPE="STUDY">Noack 1994</LINK>) for likelihood of being a responder was 1.43 (95% CI 1.08 to 1.91).</P>
<P>16. Comparing GS or GH to placebo in studies with adequate allocation concealment for WOMAC pain subscale scores: the summary SMD (fixed-effect model) for 10 RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.06 (95% CI -0.14 to 0.03). In this outcome there was no statistical difference between glucosamine and placebo. This corresponds to a decrease in the treatment group of 0.25 points (95% CI 0.59 points lower to 0.13 points higher) on a 0 to 20 WOMAC scale (using <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK> for the calculation).</P>
<P>17. Comparing GS or GH to placebo in studies with adequate allocation concealment for WOMAC stiffness subscale scores: The summary SMD (fixed-effect model) for seven RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.02 (95% CI -0.13 to 0.08). In this outcome there was no statistical difference between glucosamine and placebo.</P>
<P>18. Comparing GS or GH to placebo in studies with adequate allocation concealment for WOMAC function subscale scores: the summary SMD (fixed-effect model) for 10 RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.08 (95% CI -0.17 to 0.00). In this outcome there was no statistical difference between glucosamine and placebo. This corresponds to a decrease in the treatment group of 1.02 points (95% CI 2.04 points lower to 0 points higher) on a 0 to 68 WOMAC scale. The relative per cent change from baseline was -3% (95% CI -6%, 0%).</P>
<P>19. Comparing GS or GH to placebo in studies with adequate allocation concealment for WOMAC total scores: the summary SMD (fixed-effect model) for six RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.18 (95% CI -0.31 to - 0.05). In this outcome, there was a statistically significant difference which favored glucosamine over placebo.</P>
<P>20. Comparing GS to placebo for changes in minimum joint space width for the knee or hip: the summary mean difference (MD) (fixed-effect model) for two RCTs (<LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>) measuring the minimum joint space width at the knee was 0.32 (95% CI 0.05 to 0.58). This was statistically significant in favour of glucosamine and showed that glucosamine slowed the natural radiological progression of OA. <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK> measured minimum joint space width changes in the hip and found inconsistent results in the four sites they measured; however, none of the 95% CIs achieved a minimal clinically important change of 0.25 mm.</P>
<P>The main outcomes for this comparison are summarized in the Summary of findings table 1.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>
<I>Rotta preparation</I>
<U>
<B>
<BR/>
</B>
</U>
<BR/>21. Comparing GS to placebo in studies using the Rotta preparation for pain: results from eight RCTs were pooled (<LINK REF="STD-Crolle-1980" TYPE="STUDY">Crolle 1980</LINK>; <LINK REF="STD-D_x0027_ambrosio-1981" TYPE="STUDY">D'ambrosio 1981</LINK>; <LINK REF="STD-Drovanti-1980" TYPE="STUDY">Drovanti 1980</LINK>; <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Pujalte-1980" TYPE="STUDY">Pujalte 1980</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>; <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>) for the outcome variable of reduction in pain. The summary SMD (random-effects model) was -1.11 (95% CI -1.66 to -0.57). A negative SMD in this case meant that glucosamine was significantly superior to placebo in terms of its ability to reduce pain. The relative per cent change from baseline was -42.2% (95% CI -63.0%, -21.6%) (using <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK> in the calculation as the most representative study).</P>
<P>22. Comparing GS to placebo in studies using the Rotta preparation for the Lequesne Index scores: results from five RCTs were pooled (<LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Noack-1994" TYPE="STUDY">Noack 1994</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reichelt-1994" TYPE="STUDY">Reichelt 1994</LINK>; <LINK REF="STD-Rovati-1997" TYPE="STUDY">Rovati 1997</LINK>). The summary SMD (random-effects model) was -0.47 (95% CI -0.82 to -0.12). A negative SMD in this case meant that glucosamine was significantly superior to placebo in terms of its ability to improve Lequesne Index scores.</P>
<P>23. Comparing GS to placebo in studies using the Rotta preparation for Lequesne Index scores in which the outcome was dichotomous (per cent responders based on change in Lequesne Index): the summary RR (fixed-effect model) from two RCTs (<LINK REF="STD-Noack-1994" TYPE="STUDY">Noack 1994</LINK>; <LINK REF="STD-Reichelt-1994" TYPE="STUDY">Reichelt 1994</LINK>) for likelihood of being a responder was 1.52 (95% CI 1.20 to 1.91).</P>
<P>24. Comparing GS to placebo in studies using the Rotta preparation for WOMAC pain subscale scores: results from three RCTs were pooled (<LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>). The summary SMD (fixed-effect model) was -0.17 (95% CI -0.32 to -0.01). In this outcome glucosamine was significantly superior to placebo in terms of its ability to improve WOMAC pain scores.</P>
<P>25. Comparing GS to placebo in studies using the Rotta preparation for WOMAC stiffness subscale scores: the result from one RCT (<LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>) was -0.22 (95% CI -0.50 to 0.06). In this outcome there was no statistical difference between glucosamine and placebo.</P>
<P>26. Comparing GS to placebo in studies using the Rotta preparation for WOMAC function subscale scores: results from three RCTs were pooled (<LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>). The summary SMD (fixed-effect model) was -0.19 (95% CI -0.35 to -0.03). In this outcome glucosamine was significantly superior to placebo in terms of its ability to improve WOMAC function scores. The relative per cent change from baseline was -7.6% (95% CI -14.0%, -1.2%) (using <LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK> in the calculation as the most representative study).</P>
<P>27. Comparing GS to placebo using the Rotta preparation for WOMAC total scores: the summary SMD (fixed-effect model) for three RCTs (<LINK REF="STD-Herrero_x002d_Beaumont-2007" TYPE="STUDY">Herrero-Beaumont 2007</LINK>; <LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>) was -0.25 (95% CI -0.40 to -0.09). A negative SMD in this case meant that glucosamine was statistically significantly superior to placebo.</P>
<P>The main outcomes for this comparison are summarized in the Summary of findings table 2.</P>
<P>
<I>Non-Rotta preparation</I>
<U>
<B>
<BR/>
</B>
</U>
<BR/>28. Comparing GS to placebo in studies using a non-Rotta preparation for pain: results from 10 RCTs were pooled (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Rindone-2000" TYPE="STUDY">Rindone 2000</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Usha-2004" TYPE="STUDY">Usha 2004</LINK>; <LINK REF="STD-Vajaradul-1981" TYPE="STUDY">Vajaradul 1981</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) for the outcome variable of reduction in pain. The summary SMD (fixed-effect model) was -0.05 (95% CI -0.15 to 0.05). In this outcome there was no statistical difference between glucosamine and placebo.</P>
<P>29. Comparing GS to placebo in studies using a non-Rotta preparation for WOMAC pain subscale scores: results from seven RCTs were pooled (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>). The summary SMD (fixed-effect model) was -0.01 (95% CI -0.11 to 0.10). In this outcome there was no statistical difference between glucosamine and placebo.</P>
<P>30. Comparing GS to placebo in studies using a non-Rotta preparation for WOMAC stiffness subscale scores: results from six RCTs were pooled (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>). The summary SMD (fixed-effect model) was 0.01 (95% CI -0.10 to 0.13). In this outcome there was no statistical difference between glucosamine and placebo.</P>
<P>31. Comparing GS to placebo in studies using a non-Rotta preparation for WOMAC function subscale scores: results from six RCTs were pooled (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>). The summary SMD (fixed-effect model) was -0.01 (95% CI -0.13 to 0.10). In this outcome there was no statistical difference between glucosamine and placebo.</P>
<P>32. Comparing GS or GH to placebo using the non-Rotta preparation for WOMAC total scores: the summary SMD (fixed-effect model) for three RCTs (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Zenk-2002" TYPE="STUDY">Zenk 2002</LINK>) was -0.02 (95% CI -0.27 to 0.22). In this outcome there was no statistical difference between glucosamine and placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Toxicity of glucosamine in OA</HEADING>
<P>The safety profile of glucosamine in the 25 RCTs was excellent. For example, out of the 1883 participants randomized to glucosamine treatment in the RCTs, only 62 (3.3%) were withdrawn because of toxicity. The total number of participants reporting an adverse reaction was 436 (30%) based on 21 RCTs (n = 1451). In the 1482 participants randomized to a placebo group, 70 (4.7%) were withdrawn because of toxicity and 418 (39%) reported an adverse reaction (n = 1061). Therefore, glucosamine was as safe as placebo.</P>
<P>33. Comparing GS or GH to placebo for number of participants reporting adverse reactions: the summary RR (fixed-effect model) for 13 RCTs was 0.99 (95% CI 0.91 to 1.07).</P>
<P>34. Comparing GS or GH to placebo for number of withdrawals due to toxicity: the summary RR (fixed-effect model) for 12 RCTs was 0.76 (95% CI 0.55 to 1.05).</P>
<P>35. Comparing GS to NSAIDs for number of participants reporting adverse reactions: the summary RR (fixed-effect model) for four RCTs was 0.29 (95% CI 0.19 to 0.44). Therefore, GS was significantly less likely than NSAIDs to produce adverse reactions.</P>
<P>36. Comparing GS to NSAIDs for number of withdrawals due to toxicity: the summary RR (random-effects model) for four RCTs was 0.16 (95% CI 0.02 to 1.46). Therefore, glucosamine was significantly less likely than NSAIDs to result in withdrawal due to toxicity.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-09 20:24:40 -0500" MODIFIED_BY="[Empty name]">
<P>The pooled SMD for pain reduction comparing glucosamine to placebo was 0.47, which represents a moderate clinically significant treatment benefit in favour of glucosamine and a relative difference in the change from baseline of 22%. SMDs can be interpreted as effect sizes. Cohen defined an effect size of 0.20 as small, of 0.50 as moderate, and of 0.80 or greater as large (<LINK REF="REF-Cohen-1977" TYPE="REFERENCE">Cohen 1977</LINK>). For function, measured by the Lequesne Index, the pooled SMD compared to placebo favoured glucosamine (SMD -0.47, 95% CI -0.82 to -0.12). This corresponds to a difference in the change from baseline between glucosamine and placebo of 1.2 units on the Lequesne scale, or 11% of baseline. The RCTs comparing GS to an NSAID collectively suggest that GS produces similar symptomatic benefits as NSAIDs, but with a much lower probability of resultant adverse reactions. These results are very important and suggest that glucosamine therapy may represent a significant breakthrough in the pharmacological management of OA. However, not all outcomes and not all RCTs demonstrated a consistent superiority of glucosamine over placebo. For example, in all of the analyzed RCTs collectively, none of the WOMAC outcomes of pain, function and stiffness showed a superiority of glucosamine over placebo. Furthermore, analysis restricted to those studies with adequate allocation concealment did not demonstrate a superiority of glucosamine over placebo for pain (based on a pooled measure of different pain scales), WOMAC pain or WOMAC function. Therefore, the results in favor of glucosamine are mixed, and further research is still needed to clarify the true efficacy of glucosamine in OA.</P>
<P>Subgroup analyses of the Rotta preparation showed significant benefit over placebo in terms of pain and in the outcomes of the Lequesne index as well as in the WOMAC pain and function scores. For non-Rotta preparations, the pooled results show that there was no statistically significant difference in terms of pain and WOMAC pain, stiffness and function scores.</P>
<P>Although most of the RCTs show clear superiority of glucosamine over placebo in OA, seven RCTs failed to show that glucosamine was better than placebo (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>; <LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>; <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK>; <LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>; <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>; <LINK REF="STD-Rindone-2000" TYPE="STUDY">Rindone 2000</LINK>; <LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>). It is not entirely clear how to reconcile the negative results from these RCTs with the favorable results from the other RCTs (<LINK REF="REF-McAlindon-2003" TYPE="REFERENCE">McAlindon 2003</LINK>; <LINK REF="REF-Towheed-2003" TYPE="REFERENCE">Towheed 2003</LINK>; <LINK REF="REF-Towheed-2007" TYPE="REFERENCE">Towheed 2007</LINK>). However, the seven negative RCTs did not use the Rotta brand of GS and also had either a limited or no affiliation with a manufacturer of glucosamine. (The trial by <LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK> did use the Rotta preparation but in only about 10% of the participants treated with glucosamine.) The study by <LINK REF="STD-Houpt-1999" TYPE="STUDY">Houpt 1999</LINK> was the first RCT that used glucosamine hydrochloride rather than glucosamine sulfate. Two subsequent RCTs also used the GH preparation. In the Clegg study (<LINK REF="STD-Clegg-2006" TYPE="STUDY">Clegg 2006</LINK>) GH was no better than placebo overall. However, exploratory analyses suggested that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate to severe knee pain.<B> </B>In the Qiu (<LINK REF="STD-Qiu-2005" TYPE="STUDY">Qiu 2005</LINK>) study, GS and GH were directly compared and the results showed that there was no significant differences in either efficacy or safety between the two glucosamine preparations. The study by <LINK REF="STD-Rindone-2000" TYPE="STUDY">Rindone 2000</LINK> had a mostly male population of enrolled participants (only 5% were female, which contrasts with the average female inclusion rate in the remaining RCTs of 69%). Furthermore, participants in this study tended to be older and heavier, with a longer duration of OA, and also had a greater degree of radiographic severity than participants evaluated in other RCTs. One additional important aspect of the <LINK REF="STD-Rindone-2000" TYPE="STUDY">Rindone 2000</LINK> study was that participants who were taking other analgesics at baseline were instructed to continue them for the duration of the study. However, no details are provided with respect to the actual usage of these analgesics during the course of the study or at the end of the study. The use of additional therapeutic interventions may have resulted in less power to be able to detect any significant differences in efficacy. The study by Hughes (<LINK REF="STD-Hughes-2002" TYPE="STUDY">Hughes 2002</LINK>) had almost 50% of the participants taking NSAIDs at baseline and these participants were allowed to continue using these drugs during the course of the trial. Once again, it is possible that the high frequency of additional therapy allowed may have affected the power to be able to detect any significant differences in efficacy.</P>
<P>Perhaps the major limitation with extrapolating the generally favorable results from the glucosamine RCTs lies in the fact that most of the studies (56%) in the Cochrane review exclusively evaluated the prescription medicine made by the Rotta Pharmaceutical Company (a GS preparation that is approved as a prescription drug for OA in the European Union countries). In North America, glucosamine is not considered a conventional prescription drug, rather it is considered as a dietary supplement which is widely available as an over-the-counter preparation. Since the content and purity of the various over-the-counter preparations is known to vary markedly, the relative efficacy and safety of the various preparations may also vary markedly (<LINK REF="REF-Adebowale-2000" TYPE="REFERENCE">Adebowale 2000</LINK>; <LINK REF="REF-Consumer-Reports-2002" TYPE="REFERENCE">Consumer Reports 2002</LINK>; <LINK REF="REF-Deal-1999" TYPE="REFERENCE">Deal 1999</LINK>; <LINK REF="REF-Russell-2002" TYPE="REFERENCE">Russell 2002</LINK>). Adebowale (<LINK REF="REF-Adebowale-2000" TYPE="REFERENCE">Adebowale 2000</LINK>) analyzed the actual content of glucosamine and chondroitin within several products in the marketplace with the objective of determining if the content deviated from the label claim. The amounts of glucosamine and chondroitin found after analysis were significantly different from the label claims in some products, with deviations ranging from as low as 0% to over 115%. Russell (<LINK REF="REF-Russell-2002" TYPE="REFERENCE">Russell 2002</LINK>) assessed the content of active ingredients in over-the-counter GS preparations. The amount of free base varied from 41% to 108% of the mg content stated on the label; the amount of glucosamine varied from 59% to 138% even when expressed as sulfate. These authors concluded that if GS is to be used as a therapeutic agent, it is important that the products conform to a standard in their description.</P>
<P>Glucosamine therapy for OA was found to be relatively well tolerated with a safety profile similar to placebo, and significantly better than NSAIDs. An open study carried out by 252 physicians throughout Portugal evaluated the tolerability of GS in 1208 patients (<LINK REF="REF-Tapadinhas-1982" TYPE="REFERENCE">Tapadinhas 1982</LINK>). Patients were treated with GS for a mean duration of 50 days (range 13 to 99 days). Eighty-eight per cent of the study population were free of any adverse effects. In the 12% experiencing adverse effects, the reactions were generally mild in severity and predominantly affected the gastrointestinal tract. All of the reported complaints were reversible after discontinuation of GS.</P>
<P>In a series of letters to the Editor of the Lancet, a number of possible adverse reactions with glucosamine were pointed out. Chan (<LINK REF="REF-Chan-2001" TYPE="REFERENCE">Chan 2001</LINK>) expressed concern about the potential adverse effects of long-term glucosamine therapy on glucose homeostasis, citing evidence that glucosamine may increase insulin resistance and/or impair insulin secretion (<LINK REF="REF-Monauni-2000" TYPE="REFERENCE">Monauni 2000</LINK>). They also described a case of a patient with metastatic insulinoma who achieved control of hypoglycemic episodes after starting GS for OA. They cautioned that glucose monitoring is warranted in people on long-term therapy, and that glucosamine should be used cautiously in patients with diabetes. These concerns have not appeared to be problems in the RCTs, however they do warrant further investigation and monitoring. A recently published three-month RCT further evaluated the possible effects of glucosamine supplementation on glycemic control in a selected population of patients with type 2 diabetes mellitus (<LINK REF="REF-Scroggie-2003" TYPE="REFERENCE">Scroggie 2003</LINK>). The main outcome measure was hemoglobin A1c levels before and after 90 days of therapy. This study demonstrated that oral glucosamine supplementation did not result in clinically significant alterations in glucose metabolism in patients with type 2 diabetes mellitus. A recently published prospective study by <LINK REF="REF-Tannis-2004" TYPE="REFERENCE">Tannis 2004</LINK> found that glucosamine supplementation, with normal recommended dosages, did not cause glucose intolerance in healthy adults. Pham et al (<LINK REF="REF-Pham-2007" TYPE="REFERENCE">Pham 2007</LINK>) reported that oral glucosamine in doses used to treat OA worsens insulin resistance in people without a known abnormality of glucose homeostasis. The methodology involved measuring fasting insulin and glucose, and vascular elasticity measurements using pulse wave analysis. Individuals with underlying poorer insulin sensitivity are at risk of worsening insulin resistance and vascular function with the use of glucosamine. Biggee et al (<LINK REF="REF-Biggee-2007" TYPE="REFERENCE">Biggee 2007</LINK>) also reported that glucosamine ingestion may affect glucose levels and consequent glucose uptake in patients who have untreated diabetes or glucose intolerance. In contrast, Muniyappa et al (<LINK REF="REF-Muniyappa-2006" TYPE="REFERENCE">Muniyappa 2006</LINK>) reported that oral glucosamine in standard doses for six weeks does not cause or significantly worsen insulin resistance or endothelial dysfunction in lean or obese subjects.</P>
<P>In the first report regarding the safety of glucosamine therapy in pregnancy, Sivojelezova et al (<LINK REF="REF-Sivojelezova-2007" TYPE="REFERENCE">Sivojelezova 2007</LINK>) were able to track the pregnancy-related outcomes of 54 women who used glucosamine during pregnancy. These limited data found no increased risk for major malformations or other adverse fetal effects following the use of glucosamine.</P>
<P>There are additional reports of possible glucosamine-related toxicity. Goldstein (<LINK REF="REF-Goldstein-2001" TYPE="REFERENCE">Goldstein 2001</LINK>) speculated that glucosamine may contribute to the development of atherosclerosis by stimulating proteoglycan production by the smooth muscle cells in the arterial wall. Although the theory seems intriguing, there is as yet no experimental or clinical evidence to support its validity. Swinburne (<LINK REF="REF-Swinburne-2001" TYPE="REFERENCE">Swinburne 2001</LINK>) reported the observation that glucosamine has a powerful stimulatory effect on the growth rate and toughness of the nails. The clinical significance of this observation as it pertains to the treatment of OA is not clear. Tallia (<LINK REF="REF-Tallia-2002" TYPE="REFERENCE">Tallia 2002</LINK>) reported a case of a possible asthma exacerbation associated with use of an oral glucosamine-chondroitin supplement. According to the authors, the cause and effect association in this case could not be confirmed definitively. Matheu (<LINK REF="REF-Matheu-1999" TYPE="REFERENCE">Matheu 1999</LINK>) reported a case of an immediate hypersensitivity reaction to glucosamine sulfate, manifesting with angioedema. Glucosamine therapy may also be associated with a risk of acute interstitial nephritis (<LINK REF="REF-Audimoolam-2006" TYPE="REFERENCE">Audimoolam 2006</LINK>).</P>
<P>The meta-analysis by <LINK REF="REF-McAlindon-2000" TYPE="REFERENCE">McAlindon 2000</LINK> provided a useful critical analysis of some of the pertinent methodological concerns associated with the published glucosamine trials. Their main finding was that although glucosamine is likely to be an effective therapy for OA, the actual degree of symptomatic benefit is probably less than that predicted by the available trials. This is because of methodological flaws in many of the published trials. These flaws have been associated with exaggerated estimates of treatment benefit. Methodological flaws identified in the trials included inadequate allocation concealment, absence of intention-to-treat analyses, and publication bias. Although it seems unlikely, it is still possible that these biases could significantly negate the supposed efficacy of glucosamine. The main differences between this systematic review and the McAlindon review are that this is a Cochrane Review and it includes the comparators, as opposed to the glucosamine versus placebo comparison alone. Also, the Cochrane review has been updated as of January 2008.</P>
<P>Another meta-analysis was published by <LINK REF="REF-Richy-2003" TYPE="REFERENCE">Richy 2003</LINK> comparing the structural and symptomatic efficacy of glucosamine and chondroitin in relation to placebo. Fifteen placebo-controlled RCTs, published or performed between 1980 and March 2002, were analyzed. The results of this high quality meta-analysis demonstrated that there was a highly significant structural and symptomatic efficacy of glucosamine on all outcomes studied, including joint space narrowing and WOMAC. The safety of glucosamine was excellent and was similar to placebo. The results of our Cochrane review corroborate the results obtained by <LINK REF="REF-Richy-2003" TYPE="REFERENCE">Richy 2003</LINK>.</P>
<P>The 12-week study by McAlindon (<LINK REF="STD-McAlindon-2004" TYPE="STUDY">McAlindon 2004</LINK>) deserves special mention since it is the only trial that was conducted exclusively over the Internet. Participants were recruited and followed entirely over the Internet. This is a unique method of conduct of a RCT and the authors have nicely demonstrated the efficiency and methodological aspects of this approach. The study by Cibere (<LINK REF="STD-Cibere-2004" TYPE="STUDY">Cibere 2004</LINK>) also deserves special mention since it is the only trial that was designed as a glucosamine discontinuation trial. All eligible participants must have been actively using glucosamine for OA for at least one month prior to study entry and they must also have reported having at least a moderate improvement in knee pain since starting on glucosamine. The results of this well-conducted study were negative and failed to demonstrate efficacy of continuing glucosamine versus a placebo over a 24-week period.</P>
<P>A recently published systematic review and analysis by Vlad et al (<LINK REF="REF-Vlad-2007" TYPE="REFERENCE">Vlad 2007</LINK>) attempted to identify factors that best explain the marked heterogeneity in trials of glucosamine in OA. They concluded that the heterogeneity with glucosamine is larger than would be expected by chance alone, and that GH is not effective. Among trials with industry involvement, effect sizes were consistently higher. Potential explanations included different glucosamine preparations, inadequate allocation concealment, and industry bias. These are some of the same issues that our Cochrane Review has also identified to be of significant importance in the proper interpretation of RCTs evaluating glucosamine in OA.</P>
<P>The mechanisms of action of glucosamine in OA are not known. However, glucosamine is a natural substance and a 'building block' of the glycosaminoglycans (GAG) and glycoproteins in the ground substance of the articular cartilage. In vitro studies have shown that adding GS to human chondrocytes results in increased proteoglycan synthesis (<LINK REF="REF-Bassleer-1992" TYPE="REFERENCE">Bassleer 1992</LINK>; <LINK REF="REF-Bassleer-1998" TYPE="REFERENCE">Bassleer 1998</LINK>; <LINK REF="REF-Setnikar-1992" TYPE="REFERENCE">Setnikar 1992</LINK>). GS has a beneficial effect on animal models of experimental arthritis and may also have anti-inflammatory properties (<LINK REF="REF-Conrozier-1998" TYPE="REFERENCE">Conrozier 1998</LINK>; <LINK REF="REF-Setnikar-1991a" TYPE="REFERENCE">Setnikar 1991a</LINK>; <LINK REF="REF-Setnikar-1991b" TYPE="REFERENCE">Setnikar 1991b</LINK>; <LINK REF="REF-Setnikar-2001" TYPE="REFERENCE">Setnikar 2001</LINK>). It has recently been speculated that the sulfate moiety of GS may actually mediate the clinical benefit of GS in OA (<LINK REF="REF-Hoffer-2002" TYPE="REFERENCE">Hoffer 2002</LINK>).</P>
<P>Pharmacokinetic studies on glucosamine and GS have been carried out primarily by investigators from the Rotta Research Laboratory in Italy (the sponsor of most of the RCTs reviewed here). Early work with 14C-glucosamine administered intravenously or orally in rats indicated that, after intravenous administration, radioactivity in the plasma declined in the first 30 minutes and reached a tissue peak in the second hour and then started to disappear, with half disappearance at 28 hours. Radioactivity was detected in all tissues (primarily liver and kidney), and early in skeletal tissues including cartilage (<LINK REF="REF-Setnikar-1984" TYPE="REFERENCE">Setnikar 1984</LINK>). About 50% of the expired 14C radioactivity appeared as expired CO<SUP>
<SUB>2</SUB>
</SUP> and 35% in the urine. After oral administration, there was only a small fecal excretion but 85% of the 14C radioactivity appeared as CO<SUP>
<SUB>2</SUB>
</SUP>, indicating that there was extensive breakdown of the 14C-glucosamine into smaller fragments. There were no measurements of free 14C-glucosamine reported in this study.</P>
<P>Pharmacokinetic studies in dog and in man (<LINK REF="REF-Setnikar-1986" TYPE="REFERENCE">Setnikar 1986</LINK>) with intravenously administered 14C-GS showed that there was a very rapid disappearance of the radioactivity due to glucosamine (t ½ = 0.28 hr) and that this was rapidly replaced by radioactivity originating from the plasma proteins, into which the 14C-glucosamine and its metabolites are incorporated. Free 14C-glucosamine was looked for but could not be detected, apparently at any time point, according to this report. The findings were similar with intramuscularly administered 14C-GS (<LINK REF="REF-Setnikar-1993" TYPE="REFERENCE">Setnikar 1993</LINK>). Only a very small proportion of the 14C radioactivity was found in the femoral cartilage compared to other organs. In the earlier study by Setnikar et al (<LINK REF="REF-Setnikar-1986" TYPE="REFERENCE">Setnikar 1986</LINK>), large amounts of non-radioactive GS were also administered intravenously and orally to six human volunteers. The ninhydrin amino-acid analyzer method was used for detection of the serum glucosamine (Optica instrument) with a detection limit of about 10 ug/ml. After 800 mg GS was administered intravenously, plasma levels fell rapidly with a first disappearance rate or half life (t ½) of 6.5 minutes and a terminal rate (t ½) of 2.1 hours. However, after oral administration of a single dose of 6000 mg of GS to the human volunteers, plasma glucosamine was below the detection limit at all tested times. It should be noted that the usual oral dosage of GS in the reviewed RCTs was 1500 mg/day. Further studies in six healthy human male volunteers were done with 14C-GS administered in single doses by the intravenous, intramuscular, and oral routes (<LINK REF="REF-Setnikar-1993" TYPE="REFERENCE">Setnikar 1993</LINK>). After intravenous administration, the radioactivity due to glucosamine declined rapidly with an initial t ½ of 0.28 hr. After one to two hours, the plasma radioactivity originated entirely from plasma proteins. Less than 1% of the radioactivity was found in the feces, and 28% was found in the urine. The pharmacokinetics of intramuscular administration of 14C-GS were similar to the intravenous route. Free glucosamine was not detected in the plasma. Much lower levels of radioactivity were found after oral administration, apparently due to metabolism to carbon dioxide (CO<SUP>
<SUB>2</SUB>
</SUP>), water and urea (<LINK REF="REF-Setnikar-1993" TYPE="REFERENCE">Setnikar 1993</LINK>).</P>
<P>More recent pharmacokinetic studies of glucosamine were reported by Biggee (<LINK REF="REF-Biggee-2006" TYPE="REFERENCE">Biggee 2006</LINK>), Laverty (<LINK REF="REF-Laverty-2005" TYPE="REFERENCE">Laverty 2005</LINK>), and Persiani (<LINK REF="REF-Persiani-2005a" TYPE="REFERENCE">Persiani 2005a</LINK>; <LINK REF="REF-Persiani-2005b" TYPE="REFERENCE">Persiani 2005b</LINK>). Biggee et al (<LINK REF="REF-Biggee-2006" TYPE="REFERENCE">Biggee 2006</LINK>) used high performance liquid chromatography with a high sensitivity Metrohm-Peak instrument for pulsed amperometric measurement of human serum glucosamine. The maximum concentration achieved after oral ingestion of 1500 mg of the Rotta preparation of glucosamine was only 11.5 uM (range 1.9 to 11.5 uM). Previous studies by these same authors have shown that, at this maximum concentration of 11.5 uM, one would expect that no more than 2% of the galactosamine incorporated into chondroitin sulfate would be derived from incubations of glucosamine with cultured human chondrocytes (<LINK REF="REF-Mroz-2004" TYPE="REFERENCE">Mroz 2004</LINK>). The authors concluded that insignificant trace amounts of glucosamine enter human serum after oral ingestion and that this amount is far below any amount that might contribute directly to chondroitin synthesis. Therefore, based on this study, glucosamine probably does not act in OA simply by acting as a 'building block' for the synthesis of glycosaminoglycans in the articular cartilage. Previously published in vitro studies generally used very high concentrations of glucosamine (&gt; 100 uM) to show positive effects in terms of the enhanced synthesis of glycosaminoglycans in the articular cartilage.</P>
<P>Laverty et al (<LINK REF="REF-Laverty-2005" TYPE="REFERENCE">Laverty 2005</LINK>) reported the first published animal data confirming that free glucosamine can be detected in the synovial fluid after administration. They measured free glucosamine concentrations both in the serum and in the synovial fluid of the radiocarpal joints in horses using a sensitive fluorophore-assisted carbohydrate electrophoresis. Two methods of administration of glucosamine were evaluated (via a nasogastric tube and intravenous administration). Following nasogastric administration, the maximum serum concentration of glucosamine was only 6.1 uM (range 4.4 to 7.6 uM). This is a result similar to that obtained by Biggee et al (<LINK REF="REF-Biggee-2006" TYPE="REFERENCE">Biggee 2006</LINK>). Following intravenous administration, the maximum concentration of glucosamine in serum reached 300 uM. Synovial fluid concentrations reached 9 to 15 uM with intravenous dosing, and 0.3 to 0.7 uM with nasogastric dosing. The authors concluded that clinically relevant dosing of glucosamine in the horse results in serum and synovial fluid concentrations that are at least 500 fold lower than those reported to modify chondrocyte activities in tissue and cell culture experiments. Persiani and colleagues (<LINK REF="REF-Persiani-2005a" TYPE="REFERENCE">Persiani 2005a</LINK>; <LINK REF="REF-Persiani-2005b" TYPE="REFERENCE">Persiani 2005b</LINK>) used a liquid chromatography method with mass spectrometry detection for the determination of glucosamine in the plasma of humans who ingested clinically relevant dosages of glucosamine. Maximum serum concentrations were again found to be only in the 10 uM range. Preliminary data from these authors were reported in an abstract from the 2005 EULAR meeting (<LINK REF="REF-Persiani-2005b" TYPE="REFERENCE">Persiani 2005b</LINK>). For the first time, free glucosamine was detected in the knee synovial fluid in two patients with OA who were assayed 24 hours post oral ingestion in a 15-day treatment course (1500 mg/day of GS), in concentrations of 497 and 1978 ng/ml. In these two patients, there was a good correlation between the plasma and synovial fluid levels. One cannot exclude the possibility that the observed low sustained concentrations of glucosamine in the synovial joint may have biological properties that are therapeutic in OA (for example anti-inflammatory effects or inhibition of IL-1 related effects, or both) (<LINK REF="REF-Largo-2003" TYPE="REFERENCE">Largo 2003</LINK>; <LINK REF="REF-Shikhman-2001" TYPE="REFERENCE">Shikhman 2001</LINK>).</P>
<P>Three RCTs have evaluated the ability of glucosamine to protect the cartilage from further loss, as defined by changes in radiographic joint cartilage width of the knee (<LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>; <LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>) and hip (<LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>). The two well-conducted prospective three-year RCTs by Pavelka (<LINK REF="STD-Pavelka-2002" TYPE="STUDY">Pavelka 2002</LINK>) and Reginster (<LINK REF="STD-Reginster-2001" TYPE="STUDY">Reginster 2001</LINK>) showed favourable responses with no significant progression of cartilage loss in participants assigned to therapy with GS. These RCTs represent the first clinical evidence that glucosamine may indeed modify the natural radiological progression of OA of the knee (<LINK REF="REF-Reginister-2003" TYPE="REFERENCE">Reginister 2003</LINK>). The most recent study by Rozendaal et al (<LINK REF="STD-Rozendaal-2008" TYPE="STUDY">Rozendaal 2008</LINK>) was not able to confirm a beneficial effect of a non-Rotta preparation of GS on radiological progression in participants with OA of the hip.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-07 08:41:39 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-07 08:39:12 -0500" MODIFIED_BY="[Empty name]">
<P>The previous review from 2005, with 20 studies and 2570 participants, showed that glucosamine sulphate taken orally in amounts of 1500 mg/day produced a 28% (per cent change from baseline) benefit in pain and an increase in function of 21% (per cent change in Lequesne Index from baseline) in osteoarthritis, without side effects.</P>
<P>If only the best designed studies are included, the benefit in pain and WOMAC function is no longer present; as shown in this update which includes 25 studies and 4963 patients. Inclusion of five new studies reduces the overall benefit on pain to 22% and function to 11% in the Lequesne Index. Pooled results from studies using a non-Rotta preparation or adequate allocation concealment failed to show benefit in pain and WOMAC function, while those studies evaluating the Rotta preparation showed that glucosamine was superior to placebo in the treatment of pain and functional impairment resulting from symptomatic OA. WOMAC outcomes of pain and function showed a superiority of glucosamine over placebo for only the Rotta preparation of glucosamine.</P>
<P>Some studies suggest the Rotta preparation of glucosamine sulfate may slow radiological progression of OA of the knee over a three-year period. The ability of glucosamine to improve symptoms and delay radiological progression of OA affecting other joint sites also needs further research.</P>
<P>Glucosamine was as safe as placebo.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-11-07 08:41:39 -0500" MODIFIED_BY="[Empty name]">
<P>Despite the availability of several RCTs, there are still a number of questions that remain unanswered regarding the use of glucosamine in OA. These questions represent areas for further research. First, are the various over-the-counter glucosamine preparations sold by different manufacturers equally effective (and equally safe) in the therapy of OA? Is there any further benefit obtained by using mixed glucosamine preparations that contain additional therapeutic products, such as chondroitin sulfate. Second, why are the trials no longer uniformly positive? Third, is glucosamine helpful for all patients with OA, involving different joints and at different stages of severity? Fourth, are the dose and route of administration of glucosamine important in maximizing efficacy and minimizing toxicity? Fifth, how does glucosamine work in the treatment of OA? Sixth, what are the patient-specific predictors of favorable effects on radiological progression of OA?</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Jessie McGowan for her assistance in providing the electronic search of the literature. The authors would also like to thank Lindi Jiang and Xiaohong Zhou for their assistance with data abstraction. Additionally, the authors would like to thank the Cochrane Musculoskeletal Editorial Team for their thoughtful comments and suggestions. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-11-07 08:46:59 -0500" MODIFIED_BY="[Empty name]">
<P>The current version of the 'Glucosamine for osteoarthritis' review on <I>The Cochrane Library</I> was last revised in 2005.</P>
<P>Dr Tassos Anastassiades submitted patents (Pub. No. US 2002/0045597 A1 and Pub. No. US 6,479,469 B2) for glucosamine type substances in August 2000. The patent protection is for chemically synthesized compounds with substitutions of chain length larger than the naturally occurring acetyl group in glucosamine.</P>
<P>Dr Tanveer Towheed was an invited speaker at the November 2002 ACR meeting. The accredited event, a post-meeting symposium, was coordinated by the CME department at the Case Western Reserve School of Medicine. Rotta Pharmaceuticals (whose product is glucosamine sulfate) provided an unrestricted educational grant in support of the program. Dr Towheed presented a review of all available published meta-analyses of various pharmacological therapies for OA. He received a one time honorarium for speaking at this symposium. There is no other association with Rotta Pharmaceuticals, or any other potential conflict of interest.</P>
<P>JB Houpt received an unrestricted grant-in-aid of research from Wampole Canada Inc for completion of a trial published in 1999. No industry or other support has been received since.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-07 08:42:40 -0500" MODIFIED_BY="[Empty name]">
<P>TT is responsible for the overall content of this review</P>
<P>TP did data abstraction and quality assessment and reviewed the inclusion criteria for selected trials and wrote some of the discussion regarding the pharmacokinetics of glucosamine</P>
<P>LM did data abstraction, assisted with data analysis and helped with the preparation of the final version</P>
<P>JH critically reviewed the results and helped to draft the final version of this review</P>
<P>BS was involved in quality assessment</P>
<P>VW provided analytic support, helped in the preparation of the final document and reviewed the final version</P>
<P>MH critically reviewed the results and helped to draft the final version of this review</P>
<P>GW provided methodological and statistical support</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-07 09:35:37 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-07 09:23:05 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-07 09:22:26 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cibere-2004" MODIFIED="2008-10-22 12:18:10 -0400" MODIFIED_BY="[Empty name]" NAME="Cibere 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-22 12:18:10 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, et al</AU>
<TI>Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis</TI>
<SO>Arthritis and Rheumatism (Arthritis Care and Research)</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>2</NO>
<PG>738-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clegg-2006" MODIFIED="2008-10-22 12:18:52 -0400" MODIFIED_BY="[Empty name]" NAME="Clegg 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-10-22 12:18:52 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al</AU>
<TI>Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>795-808</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crolle-1980" MODIFIED="2008-09-09 16:51:46 -0400" MODIFIED_BY="[Empty name]" NAME="Crolle 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-09-09 16:51:46 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crolle G, D'Este E</AU>
<TI>Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1980</YR>
<VL>2</VL>
<PG>104-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_ambrosio-1981" MODIFIED="2008-09-09 16:56:30 -0400" MODIFIED_BY="[Empty name]" NAME="D'ambrosio 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-09-09 16:56:30 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>D'Ambrosio E, Casa B, Bompani R, Scali G, Sclai M</AU>
<TI>Glucosamine sulphate: a controlled clinical investigation in arthrosis</TI>
<SO>Pharmatherapeutica</SO>
<YR>1981</YR>
<VL>2</VL>
<NO>8</NO>
<PG>504-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drovanti-1980" MODIFIED="2008-09-09 16:56:50 -0400" MODIFIED_BY="[Empty name]" NAME="Drovanti 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-09-09 16:56:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Drovanti A, Bignamini AA, Rovati L</AU>
<TI>Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: A placebo-controlled double-blind investigation</TI>
<SO>Clinical Therapeutics</SO>
<YR>1980</YR>
<VL>3</VL>
<NO>4</NO>
<PG>260-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herrero_x002d_Beaumont-2007" MODIFIED="2008-11-07 09:20:49 -0500" MODIFIED_BY="[Empty name]" NAME="Herrero-Beaumont 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-07 09:20:49 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Herrero-Beaumont G, Ivorra JAR, Trabado M, Blanco FJ, Benito P, Martin-Mola E, et al</AU>
<TI>Glucosamine sulfate in the treatment of knee osteoarthritis symptoms</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>2</NO>
<PG>555-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Houpt-1999" MODIFIED="2008-09-09 16:48:39 -0400" MODIFIED_BY="[Empty name]" NAME="Houpt 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-09-09 16:48:39 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Houpt J, McMillan R, Wein C, Paget-Dellio SD</AU>
<TI>Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee</TI>
<SO>Journal of Rheumatology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>11</NO>
<PG>2423-2430</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-2002" MODIFIED="2008-09-09 16:57:23 -0400" MODIFIED_BY="[Empty name]" NAME="Hughes 2002" YEAR="">
<REFERENCE MODIFIED="2008-09-09 16:57:23 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hughes R, Carr A</AU>
<TI>A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee</TI>
<SO>Rheumatology</SO>
<YR>2002</YR>
<VL>41</VL>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McAlindon-2004" NAME="McAlindon 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K</AU>
<TI>Effectiveness of Glucosamine for symptoms of knee osteoarthritis: Results from an Internet-based randomized double-blind controlled trial</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>117</VL>
<PG>643-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehta-2007" MODIFIED="2008-10-22 12:19:50 -0400" MODIFIED_BY="[Empty name]" NAME="Mehta 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-10-22 12:19:50 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mehta K, Gala J, Bhasale S, Naik S, Modak M, Thakur H, et al</AU>
<TI>Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial</TI>
<SO>BMC Complementary and Alternative Medicine</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>34</NO>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller_x002d_FassBender-94" MODIFIED="2008-09-09 16:57:58 -0400" MODIFIED_BY="[Empty name]" NAME="Muller-FassBender 94" YEAR="1994">
<REFERENCE MODIFIED="2008-09-09 16:57:58 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Muller-Fasbender H, Bach GL, Haase W, Rovati L, Setnikar I</AU>
<TI>Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1994</YR>
<VL>2</VL>
<PG>61-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noack-1994" MODIFIED="2008-09-09 16:58:08 -0400" MODIFIED_BY="[Empty name]" NAME="Noack 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-09-09 16:58:08 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Noack W, Fischer M, Forster K, Rovati L, Setnikar I</AU>
<TI>Glucosamine sulfate in osteoarthritis of the knee</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1994</YR>
<VL>2</VL>
<PG>51-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavelka-2002" MODIFIED="2008-09-09 16:58:44 -0400" MODIFIED_BY="[Empty name]" NAME="Pavelka 2002" YEAR="">
<REFERENCE MODIFIED="2008-09-09 16:58:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC</AU>
<TI>Glucosamine sulfate use and delay of progression of knee osteoarthritis. A 3-year, randomized, placebo-controlled, double-blind study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>2113-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pujalte-1980" MODIFIED="2008-09-09 17:00:38 -0400" MODIFIED_BY="[Empty name]" NAME="Pujalte 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-09-09 17:00:38 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pujalte JM, Llavore EP, Ylescupidez FR</AU>
<TI>Double-blind clinical trial evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1980</YR>
<VL>7</VL>
<NO>2</NO>
<PG>110-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qiu-1998" MODIFIED="2008-09-09 17:01:44 -0400" MODIFIED_BY="[Empty name]" NAME="Qiu 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-09 17:01:44 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I</AU>
<TI>Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis</TI>
<SO>Arzneimittelforschung/Drug Resistance Updates</SO>
<YR>1998</YR>
<VL>48</VL>
<NO>1</NO>
<PG>469-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qiu-2005" MODIFIED="2008-10-22 12:34:15 -0400" MODIFIED_BY="[Empty name]" NAME="Qiu 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-22 12:34:15 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Qiu G, Weng X, Zhang K, Zhou Y, Wang LS, Li W, et al</AU>
<TI>A multicentral, randomized, controlled clinical trial of glucosamine hydrochloride/sulfate in the treatment of knee osteoarthritis</TI>
<SO>National Medical Journal of China</SO>
<YR>2005</YR>
<VL>85</VL>
<NO>43</NO>
<PG>3067-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reginster-2001" MODIFIED="2008-09-09 17:05:28 -0400" MODIFIED_BY="[Empty name]" NAME="Reginster 2001" YEAR="">
<REFERENCE MODIFIED="2008-09-09 17:05:28 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al</AU>
<TI>Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>251-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichelt-1994" NAME="Reichelt 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Reichelt A, Forster KK, Fischer M, Rovati L, Setnikar I</AU>
<TI>Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee</TI>
<SO>Arzneimmittelforschung/Drug Resistance Updates</SO>
<YR>1994</YR>
<VL>44</VL>
<NO>1</NO>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rindone-2000" MODIFIED="2008-09-09 17:05:47 -0400" MODIFIED_BY="[Empty name]" NAME="Rindone 2000" YEAR="">
<REFERENCE MODIFIED="2008-09-09 17:05:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G</AU>
<TI>Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee</TI>
<SO>Western Journal of Medicine</SO>
<YR>2000</YR>
<VL>172</VL>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rovati-1997" MODIFIED="2008-11-07 09:22:26 -0500" MODIFIED_BY="[Empty name]" NAME="Rovati 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-07 09:22:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rovati LC</AU>
<TI>The clinical profile of glucosamine sulfate as a selective symptom-modifying drug in osteoarthritis: current data and perspectives</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1997</YR>
<VL>5</VL>
<PG>72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rozendaal-2008" MODIFIED="2008-10-22 12:34:57 -0400" MODIFIED_BY="[Empty name]" NAME="Rozendaal 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-10-22 12:34:57 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rozendaal RM, Koes BW,m van Osch G, Uitterlinden EJ, Garling EH, Willemsen SP, et al</AU>
<TI>Effect of glucosamine sulfate on hip osteoarthritis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2008</YR>
<VL>148</VL>
<PG>268-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Usha-2004" NAME="Usha 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Usha PR, Naidu MUR</AU>
<TI>Randomized, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis</TI>
<SO>Clinical Drug Investigation</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>6</NO>
<PG>353-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vajaradul-1981" MODIFIED="2008-09-09 17:06:55 -0400" MODIFIED_BY="[Empty name]" NAME="Vajaradul 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-09-09 17:06:55 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vajaradul Y</AU>
<TI>Double-blind clinical evaluation of intra-articular glucosamine in outpatients with gonarthrosis</TI>
<SO>Clinical Therapeutics</SO>
<YR>1981</YR>
<VL>3</VL>
<NO>5</NO>
<PG>336-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaz-1982" MODIFIED="2008-09-09 16:50:07 -0400" MODIFIED_BY="[Empty name]" NAME="Vaz 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-09-09 16:50:07 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vaz AL</AU>
<TI>Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1982</YR>
<VL>8</VL>
<PG>145-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zenk-2002" MODIFIED="2008-09-09 17:07:24 -0400" MODIFIED_BY="[Empty name]" NAME="Zenk 2002" YEAR="">
<REFERENCE MODIFIED="2008-09-09 17:07:24 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zenk JL, Helmer TR, Kuskowski MA</AU>
<TI>The effects of milk protein concentrate on the symptoms of osteoarthritis in adults: an exploratory, randomized, double-blind, placebo-controlled trial</TI>
<SO>Current Therapeutic Research</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>7</NO>
<PG>430-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-07 09:23:05 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Braham-2003" MODIFIED="2008-11-07 09:23:05 -0500" MODIFIED_BY="[Empty name]" NAME="Braham 2003" YEAR="">
<REFERENCE MODIFIED="2008-11-07 09:23:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braham R, Dawson B, Goodman C</AU>
<TI>The effect of glucosamine supplementation on people experiencing regular knee pain</TI>
<SO>British Journal of Sports Medicine</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>45-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Magi-1997" NAME="Magi 1997" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Magi D, Giacovelli G, Rovati LC</AU>
<TI>Clinical Study on the activity of glucosamine sulfate on osteoarthritis, in comparison with placebo, in patients suffering from osteoarthritis of the knee by means of imaging techniques (NMR, ecotomography, radiology) and computer processing of the such obtained images</TI>
<SO>Unpublished technical report prepared by Rottapharm</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Pipitone-1997" NAME="Pipitone 1997" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Pipitone V, Giacovelli G, Rovati LC</AU>
<TI>Clinical study on the activity of glucosamine sulfate on the evolution of osteoarthritis in patients with osteoarthritis of the knee</TI>
<SO>Unpublished technical report prepared by Rottapharm</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Rovati-1993" NAME="Rovati 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Rovati LC, Poma A, Biavati G, et al</AU>
<TI>A multicenter, randomized, double-blind, parallel-group study to investigate efficacy and safety of oral glucosamine sulfate in osteoarthritis of the spine</TI>
<SO>Unpublished technical report prepared by Rottapharm</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-07 09:35:37 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-07 09:35:37 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACR-2000" MODIFIED="2008-10-22 12:35:21 -0400" MODIFIED_BY="[Empty name]" NAME="ACR 2000" TYPE="JOURNAL_ARTICLE">
<AU>American College of Rheumatology (ACR) Subcommittee on osteoarthritis guidelines</AU>
<TI>Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<PG>1905-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adebowale-2000" NAME="Adebowale 2000" TYPE="JOURNAL_ARTICLE">
<AU>Adebowale AO, Cox DS, Liang Z, Eddington ND</AU>
<TI>Analysis of glucosamine and chondroitin sulfate content in marketed products and the caco-2 permeability of chondroitin sulfate raw materials</TI>
<SO>Journal of the American Nutraceutical Association</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>1</NO>
<PG>Spring Issue</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-2005" NAME="Anderson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JW, Nicolosi RJ, Borzelleca JF</AU>
<TI>Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy</TI>
<SO>Food and Chemical Toxicology</SO>
<YR>2005</YR>
<VL>43</VL>
<PG>187-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Audimoolam-2006" NAME="Audimoolam 2006" TYPE="JOURNAL_ARTICLE">
<AU>Audimoolam VK, Bhandari S</AU>
<TI>Acute interstitial nephritis induced by glucosamine</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>7</NO>
<PG>2031</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Badley-1995" MODIFIED="2008-11-07 09:24:23 -0500" MODIFIED_BY="[Empty name]" NAME="Badley 1995" TYPE="JOURNAL_ARTICLE">
<AU>Badley EM</AU>
<TI>The effect of osteoarthritis on disability and health care use in Canada</TI>
<SO>Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>22 Suppl 43</VL>
<PG>19-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barclay-1998" MODIFIED="2008-09-09 17:16:48 -0400" MODIFIED_BY="[Empty name]" NAME="Barclay 1998" TYPE="JOURNAL_ARTICLE">
<AU>Barclay TS, Tsourounis C, McCart GM</AU>
<TI>Glucosamine</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1998</YR>
<VL>32</VL>
<PG>574-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bassleer-1992" MODIFIED="2008-09-09 17:16:58 -0400" MODIFIED_BY="[Empty name]" NAME="Bassleer 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bassleer C, Henrotin Y, Franchimont P</AU>
<TI>In-vitro evaluation of drugs proposed as chondroprotective agents</TI>
<SO>International Journal of Tissue Reactions</SO>
<YR>1992</YR>
<VL>14</VL>
<PG>231-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bassleer-1998" MODIFIED="2008-11-07 09:24:55 -0500" MODIFIED_BY="[Empty name]" NAME="Bassleer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bassleer C, Rovati L, Franchimont P</AU>
<TI>Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic cartilage in vitro</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>1998</YR>
<VL>6</VL>
<PG>427-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellamy-1997" NAME="Bellamy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bellamy N, Kirwan J, Boers M, et al</AU>
<TI>Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>799-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Biggee-2006" MODIFIED="2008-11-07 09:28:54 -0500" MODIFIED_BY="[Empty name]" NAME="Biggee 2006" TYPE="JOURNAL_ARTICLE">
<AU>Biggee E, Blinn CM, McAlindon TE, Nuite M, Silbert JE</AU>
<TI>Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Biggee-2007" MODIFIED="2008-09-09 17:17:59 -0400" MODIFIED_BY="[Empty name]" NAME="Biggee 2007" TYPE="JOURNAL_ARTICLE">
<AU>Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon TE</AU>
<TI>Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>2</NO>
<PG>260-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2001" NAME="Chan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chan NN, Baldeweg S, Tan TM, Hurel S</AU>
<TI>Glucosamine sulphate and osteoarthritis (letter)</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1617</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1977" NAME="Cohen 1977" TYPE="BOOK_SECTION">
<AU>Cohen J</AU>
<TI>Statistical power analysis for the behavioural sciences</TI>
<SO>Statistical power analysis for the behavioural sciences</SO>
<YR>1977</YR>
<PB>Academic Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conrozier-1998" MODIFIED="2008-11-07 09:26:17 -0500" MODIFIED_BY="[Empty name]" NAME="Conrozier 1998" TYPE="JOURNAL_ARTICLE">
<AU>Conrozier T, Mathieu P, Piperno M, et al</AU>
<TI>Glucosamine sulfate significantly reduced cartilage destruction in a rabbit model os osteoarthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1998</YR>
<VL>41 Suppl</VL>
<PG>147</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Consumer-Reports-2002" MODIFIED="2008-09-09 17:18:29 -0400" MODIFIED_BY="[Empty name]" NAME="Consumer Reports 2002" TYPE="JOURNAL_ARTICLE">
<AU>No authors listed</AU>
<TI>Joint Remedies</TI>
<SO>Consumer Reports</SO>
<YR>2002</YR>
<VL>67</VL>
<NO>1</NO>
<PG>18-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creamer-1997" MODIFIED="2008-09-09 17:18:43 -0400" MODIFIED_BY="[Empty name]" NAME="Creamer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Creamer P, Hochberg MC</AU>
<TI>Osteoarthritis</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>503-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creamer-1998" MODIFIED="2008-09-09 17:18:57 -0400" MODIFIED_BY="[Empty name]" NAME="Creamer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Creamer P, Flores R, Hochberg MC</AU>
<TI>Management of osteoarthritis in older adults</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>1998</YR>
<VL>14</VL>
<NO>3</NO>
<PG>434-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Da-Camara-1998" MODIFIED="2008-09-09 17:19:09 -0400" MODIFIED_BY="[Empty name]" NAME="Da Camara 1998" TYPE="JOURNAL_ARTICLE">
<AU>Da Camara C, Dowless GV</AU>
<TI>Glucosamine sulfate for osteoarthritis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1998</YR>
<VL>32</VL>
<PG>580-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deal-1999" MODIFIED="2008-09-09 17:19:22 -0400" MODIFIED_BY="[Empty name]" NAME="Deal 1999" TYPE="JOURNAL_ARTICLE">
<AU>Deal CL, Moskowitz RW</AU>
<TI>Neutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chrondroitin sulfate and collagen hydrolysate</TI>
<SO>Rheumatic Diseases Clinics of North America</SO>
<YR>1999</YR>
<VL>25</VL>
<PG>379-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deviere-2002" MODIFIED="2008-11-07 09:27:03 -0500" MODIFIED_BY="[Empty name]" NAME="Deviere 2002" TYPE="JOURNAL_ARTICLE">
<AU>Deviere J</AU>
<TI>Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?</TI>
<SO>European Journal of Gastroenterology and Hepatology</SO>
<YR>2002</YR>
<VL>14 Suppl 1</VL>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1998" NAME="Felson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Felson D</AU>
<TI>Nonmedicinal therapies for osteoarthritis</TI>
<SO>Bulletin on the Rheumatic Diseases</SO>
<YR>1998</YR>
<VL>47</VL>
<NO>2</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-2000" MODIFIED="2008-09-09 17:19:51 -0400" MODIFIED_BY="[Empty name]" NAME="Felson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG</AU>
<TI>Osteoarthritis: new insights. Part 1: the disease and its prevalence and impact</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>133</VL>
<NO>8</NO>
<PG>635-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gabriel-1991" MODIFIED="2008-09-09 17:20:19 -0400" MODIFIED_BY="[Empty name]" NAME="Gabriel 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gabriel S, Jaakkimainen L, Bombardier C</AU>
<TI>Risk factors for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. A meta-analysis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>115</VL>
<PG>787-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garner-2002" MODIFIED="2008-06-20 18:33:43 -0400" MODIFIED_BY="[Empty name]" NAME="Garner 2002" TYPE="COCHRANE_REVIEW">
<AU>Garner S, Fidan D, Frankish R, Judd M, Shea B, Towheed T, Wells G, Tugwell P</AU>
<TI>Celecoxib for rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<PB>Wiley</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2008-06-20 18:33:34 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-06-20 18:33:34 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003831"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-2001" MODIFIED="2008-10-22 12:36:11 -0400" MODIFIED_BY="[Empty name]" NAME="Goldstein 2001" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein MR</AU>
<TI>Glucosamine sulphate and osteoarthritis (letter)</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1617-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Griffin-1991" MODIFIED="2008-10-22 12:36:19 -0400" MODIFIED_BY="[Empty name]" NAME="Griffin 1991" TYPE="JOURNAL_ARTICLE">
<AU>Griffin M, Piper J, Daugherty J, et al</AU>
<TI>Non-steroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>114</VL>
<PG>257-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedges-1985" NAME="Hedges 1985" TYPE="BOOK">
<AU>Hedges L, Olkin I</AU>
<SO>Statistical methods for meta-analysis</SO>
<YR>1995</YR>
<PB>Academic Press</PB>
<CY>San Diego, CA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herman-1986" MODIFIED="2008-10-22 12:36:26 -0400" MODIFIED_BY="[Empty name]" NAME="Herman 1986" TYPE="JOURNAL_ARTICLE">
<AU>Herman J, Appel A, Khosla R, et al</AU>
<TI>The in vitro effect of select classes of non-steroidal anti-inflammatory drugs on normal cartilage metabolism</TI>
<SO>Journal of Rheumatology</SO>
<YR>1986</YR>
<VL>13</VL>
<PG>1014-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-1995a" MODIFIED="2008-10-22 12:36:35 -0400" MODIFIED_BY="[Empty name]" NAME="Hochberg 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Altman R, Brandt K, et al</AU>
<TI>Guidelines for the medical management of osteoarthritis. Part 1. Osteoarthritis of the hip</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>11</NO>
<PG>1535-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-1995b" MODIFIED="2008-10-22 12:36:46 -0400" MODIFIED_BY="[Empty name]" NAME="Hochberg 1995b" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Altman R, Brandt K, et al</AU>
<TI>Guidelines for the medical management of osteoarthritis. Part 2. Osteoarthritis of the knee</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>11</NO>
<PG>1541-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-1996" MODIFIED="2008-11-07 09:31:23 -0500" MODIFIED_BY="[Empty name]" NAME="Hochberg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Perlmutter D, Hudson J, et al</AU>
<TI>Preferences in the management of osteoarthritis of the hip and knee: Results of a survey of community-based rheumatologists in the United States</TI>
<SO>Arthritis Care and Research</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>3</NO>
<PG>170-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoffer-2002" MODIFIED="2008-10-22 12:37:10 -0400" MODIFIED_BY="[Empty name]" NAME="Hoffer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M</AU>
<TI>Sulfate could mediate the therapeutic effect of glucosamine sulfate</TI>
<SO>Metabolism</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>7</NO>
<PG>767-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-10-22 12:37:17 -0400" MODIFIED_BY="[Empty name]" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carrol D, et al</AU>
<TI>Assessing the quality of reports of randomized trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Largo-2003" MODIFIED="2008-11-07 09:31:42 -0500" MODIFIED_BY="[Empty name]" NAME="Largo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Largo R, Alvarez-Soria MA, Diez-Ortego I, et al</AU>
<TI>Glucosamine inhibits IL-1 beta induced NFKB activation in human osteoarthritic chondrocytes</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2003</YR>
<VL>11</VL>
<PG>290-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laverty-2005" MODIFIED="2008-10-22 12:37:52 -0400" MODIFIED_BY="[Empty name]" NAME="Laverty 2005" TYPE="JOURNAL_ARTICLE">
<AU>Laverty S, Sandy JD, Celeste C, Vachon P, Marier JF, Plaas AHK</AU>
<TI>Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<PG>181-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawrence-1998" NAME="Lawrence 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH</AU>
<TI>Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>5</NO>
<PG>778-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liang-1984" MODIFIED="2008-10-22 12:41:58 -0400" MODIFIED_BY="[Empty name]" NAME="Liang 1984" TYPE="JOURNAL_ARTICLE">
<AU>Liang M, Larsen M, Thomson M, Eaton H, Mcnamara E, Katz R et al</AU>
<TI>Costs and outcoes in rheumatoid arthritis and osteoarthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>5</NO>
<PG>522-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lozada-1997" NAME="Lozada 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lozada C, Altman R</AU>
<TI>Chrondroprotection in osteoarthritis</TI>
<SO>Bulletin on the Rheumatic Diseases</SO>
<YR>1997</YR>
<VL>46</VL>
<PG>5-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matheu-1999" MODIFIED="2008-10-22 12:42:19 -0400" MODIFIED_BY="[Empty name]" NAME="Matheu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Matheu V, Gracia Bara MT, Pelta R, Vivas E, Rubio M</AU>
<TI>Immediate-hypersensitivity reaction to glucosamine sulfate</TI>
<SO>Allergy</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>643-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McAlindon-2000" NAME="McAlindon 2000" TYPE="JOURNAL_ARTICLE">
<AU>McAlindon TE, LaValley MP, Gulin JP, Felson DT</AU>
<TI>Glucosamine and Chondroitin for Treatment of Osteoarthritis</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>11</NO>
<PG>1469-1475</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McAlindon-2003" NAME="McAlindon 2003" TYPE="JOURNAL_ARTICLE">
<AU>McAlindon T</AU>
<TI>Why are clinical trials of glucosamine no longer uniformly positive?</TI>
<SO>Rheumatic Diseases Clinics of North America</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>4</NO>
<PG>789-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCarty-1994" NAME="McCarty 1994" TYPE="JOURNAL_ARTICLE">
<AU>McCarty M</AU>
<TI>The neglect of gulcosamine as a treatment for osteoarthritis. A personal perspective</TI>
<SO>Medical Hypotheses</SO>
<YR>1994</YR>
<VL>42</VL>
<PG>323-327</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Monauni-2000" MODIFIED="2008-10-22 12:42:37 -0400" MODIFIED_BY="[Empty name]" NAME="Monauni 2000" TYPE="JOURNAL_ARTICLE">
<AU>Monauni T, Zenti MG, Cretti A, Daniels MC, Targher G, Caruso B, et al</AU>
<TI>Effects of glucosamine infusion on insulin secretion and insulin action on humans</TI>
<SO>Diabetes</SO>
<YR>2000</YR>
<VL>49</VL>
<NO>6</NO>
<PG>926-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moralestorres-1996" NAME="Moralestorres 1996" TYPE="JOURNAL_ARTICLE">
<AU>Moralestorres J, Reginster J, Hochberg MC</AU>
<TI>Rheumatic and musculoskeletal diseases and impared quality of life. A challenge for rheumatologists</TI>
<SO>Journal of Rheumatology</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>1</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mroz-2004" MODIFIED="2008-10-22 12:43:04 -0400" MODIFIED_BY="[Empty name]" NAME="Mroz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mroz PJ, Silbert JE</AU>
<TI>Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<PG>3574-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muniyappa-2006" NAME="Muniyappa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Muniyappa R, Karne RJ, Hall G, Crandon SK, Bronstein JA, Ver MR, et al</AU>
<TI>Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects</TI>
<SO>Diabetes</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>11</NO>
<PG>3142-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Persiani-2005a" MODIFIED="2008-11-07 09:32:33 -0500" MODIFIED_BY="[Empty name]" NAME="Persiani 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A</AU>
<TI>Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2005</YR>
<VL>13</VL>
<PG>1041-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Persiani-2005b" MODIFIED="2008-10-22 12:43:43 -0400" MODIFIED_BY="[Empty name]" NAME="Persiani 2005b" TYPE="CONFERENCE_PROC">
<AU>Persiani S, Rotini R, Rovati LC, Locatelli M, Roda A</AU>
<TI>Glucosamine plasma and synovial fluid concentrations before and oral administration of crystalline glucosamine sulfate in man</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>Suppl III</NO>
<PG>490</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petitti-1994" MODIFIED="2008-06-20 18:36:15 -0400" MODIFIED_BY="[Empty name]" NAME="Petitti 1994" TYPE="BOOK_SECTION">
<AU>Petitti D</AU>
<TI>Meta-analysis, Decision analysis, and Cost-Effectiveness analysis</TI>
<SO>Monographs in Epidemiology and Biostatistics</SO>
<YR>1994</YR>
<VL>24</VL>
<PB>Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pham-2007" NAME="Pham 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH</AU>
<TI>Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance</TI>
<SO>American Journal of the Medical Sciences</SO>
<YR>2007</YR>
<VL>333</VL>
<NO>6</NO>
<PG>333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puett-1994" MODIFIED="2008-10-22 12:43:57 -0400" MODIFIED_BY="[Empty name]" NAME="Puett 1994" TYPE="JOURNAL_ARTICLE">
<AU>Puett D, Griffin M</AU>
<TI>Published trials of nonmedicinal and noninvasive therapies for hip and knee osteoarthritis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>133-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rashad-1989" MODIFIED="2008-11-07 09:32:58 -0500" MODIFIED_BY="[Empty name]" NAME="Rashad 1989" TYPE="JOURNAL_ARTICLE">
<AU>Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F</AU>
<TI>Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>519-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reginister-2003" MODIFIED="2008-11-07 09:33:22 -0500" MODIFIED_BY="[Empty name]" NAME="Reginister 2003" TYPE="JOURNAL_ARTICLE">
<AU>Reginister J, Bruyere O, Lecart M, Henroitin Y</AU>
<TI>Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis</TI>
<SO>Current Opinion in Rheumatology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>5</NO>
<PG>651-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richy-2003" MODIFIED="2008-10-22 12:45:39 -0400" MODIFIED_BY="[Empty name]" NAME="Richy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin, Reginster JY</AU>
<TI>Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. A comprehensive meta-analysis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<PG>1514-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roden-1956" NAME="Roden 1956" TYPE="JOURNAL_ARTICLE">
<AU>Roden L</AU>
<TI>Effect of hexosamines on the synthesis of chrondroitin sulphruic acid in vitro</TI>
<SO>Arkhiv Foer Kemi</SO>
<YR>1956</YR>
<VL>10</VL>
<PG>345-352</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Russell-2002" MODIFIED="2008-10-22 12:45:53 -0400" MODIFIED_BY="[Empty name]" NAME="Russell 2002" TYPE="JOURNAL_ARTICLE">
<AU>Russell AS, Aghazadeh-Habashi A, Jamali F</AU>
<TI>Active ingredient consistency of commercially available glucosamine sulfate products</TI>
<SO>Journal of Rheumatology</SO>
<YR>2002</YR>
<VL>29</VL>
<NO>11</NO>
<PG>2407-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995a" MODIFIED="2008-06-21 09:10:31 -0400" MODIFIED_BY="[Empty name]" NAME="Schulz 1995a" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman D</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-1993" MODIFIED="2008-10-22 12:46:18 -0400" MODIFIED_BY="[Empty name]" NAME="Scott 1993" TYPE="BOOK_SECTION">
<AU>Scott JC, Hochberg MC</AU>
<TI>Arthritic and other musculoskeletal diseases</TI>
<SO>Chronic Disease Epidemiology and Control</SO>
<YR>1993</YR>
<ED>Brownson RC, Remington PL, Davis JR</ED>
<PB>American Public Health Association</PB>
<CY>Washington</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scroggie-2003" MODIFIED="2008-10-22 12:46:40 -0400" MODIFIED_BY="[Empty name]" NAME="Scroggie 2003" TYPE="JOURNAL_ARTICLE">
<AU>Scroggie DA, Albright A, Harris MD</AU>
<TI>The effect of glucosamine-chondroitin supplementation on glycosylated hemaglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized controlled trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>13</NO>
<PG>1587-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Setnikar-1984" MODIFIED="2008-11-07 09:34:12 -0500" MODIFIED_BY="[Empty name]" NAME="Setnikar 1984" TYPE="JOURNAL_ARTICLE">
<AU>Setnikar I, Giachetti C, Zanolo G</AU>
<TI>Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of 14C-glucosamine to the rat</TI>
<SO>Pharmatherapeutica</SO>
<YR>1984</YR>
<VL>3</VL>
<PG>523-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Setnikar-1986" MODIFIED="2008-10-22 12:46:51 -0400" MODIFIED_BY="[Empty name]" NAME="Setnikar 1986" TYPE="JOURNAL_ARTICLE">
<AU>Setnikar I, Giachetti C, Zanolo G</AU>
<TI>Pharmacokinetics of glucosamine in dog and man</TI>
<SO>Arzneimittelforschung</SO>
<YR>1986</YR>
<VL>36</VL>
<PG>729-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Setnikar-1991a" MODIFIED="2008-10-22 12:49:31 -0400" MODIFIED_BY="[Empty name]" NAME="Setnikar 1991a" TYPE="JOURNAL_ARTICLE">
<AU>Setnikar I, Pacini M, Revel L</AU>
<TI>Antiarthritic effects of glucosamine sulfate studied in animal mdoels</TI>
<SO>Arzneimittelforschung</SO>
<YR>1991</YR>
<VL>41</VL>
<PG>542-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Setnikar-1991b" MODIFIED="2008-10-22 12:47:11 -0400" MODIFIED_BY="[Empty name]" NAME="Setnikar 1991b" TYPE="JOURNAL_ARTICLE">
<AU>Setnikar I, Cereda R, pacini MA, Revel L</AU>
<TI>Antireactive properties of glucosamine sulfate</TI>
<SO>Arneimittelforschung</SO>
<YR>1991</YR>
<VL>41</VL>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Setnikar-1992" MODIFIED="2008-10-22 12:47:19 -0400" MODIFIED_BY="[Empty name]" NAME="Setnikar 1992" TYPE="JOURNAL_ARTICLE">
<AU>Setnikar I</AU>
<TI>Antireactive properties of chondroprotective drugs</TI>
<SO>International Journal of Tissue Reactions</SO>
<YR>1992</YR>
<VL>24</VL>
<PG>253-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Setnikar-1993" MODIFIED="2008-10-22 12:47:38 -0400" MODIFIED_BY="[Empty name]" NAME="Setnikar 1993" TYPE="JOURNAL_ARTICLE">
<AU>Setnikar I, Palumbo R, Canali S, Zanolo G</AU>
<TI>Pharmacokinetics of glucosamine in man</TI>
<SO>Arzneimittelforschung</SO>
<YR>1993</YR>
<VL>43</VL>
<PG>1109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Setnikar-2001" NAME="Setnikar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Setnikar I, Rovati LC</AU>
<TI>Absorption, distribution, metabolism and excretion of glucosamine sulfate</TI>
<SO>Arzneimittelforschung/Drug Resistance Updates</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>2</NO>
<PG>699-725</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shikhman-2001" MODIFIED="2008-10-22 12:48:22 -0400" MODIFIED_BY="[Empty name]" NAME="Shikhman 2001" TYPE="JOURNAL_ARTICLE">
<AU>Shikhman AR, Kuhn K, Alaaeddine N, Lotz M</AU>
<TI>N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes</TI>
<SO>Journal of Immunology</SO>
<YR>2001</YR>
<VL>166</VL>
<PG>5155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibbald-2004" NAME="Sibbald 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sibbald B</AU>
<TI>Rofecoxib (Vioxx) voluntarily withdrawn from market</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2004</YR>
<VL>171</VL>
<NO>9</NO>
<PG>1027-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sivojelezova-2007" NAME="Sivojelezova 2007" TYPE="JOURNAL_ARTICLE">
<AU>Sivojelezova A, Koren G, Einarson A</AU>
<TI>Glucosamine use in pregnancy: an evaluation of pregnancy outcome</TI>
<SO>Journal of Women's Health</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>3</NO>
<PG>345-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swinburne-2001" NAME="Swinburne 2001" TYPE="JOURNAL_ARTICLE">
<AU>Swinburne LM</AU>
<TI>Glucosamine sulphate and osteoarthritis (letter)</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1617</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tallia-2002" MODIFIED="2008-10-22 12:48:35 -0400" MODIFIED_BY="[Empty name]" NAME="Tallia 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tallia AF, Cardone DA</AU>
<TI>Asthma exacerbation associated with glucosamine-chondroitin supplement</TI>
<SO>The Journal of the American Board of Family Practice</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>481-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tannis-2004" NAME="Tannis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Tannis AJ, Barban J, Conquer JA</AU>
<TI>Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentration in healthy individuals</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>6</NO>
<PG>506-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tapadinhas-1982" MODIFIED="2008-10-22 12:48:46 -0400" MODIFIED_BY="[Empty name]" NAME="Tapadinhas 1982" TYPE="JOURNAL_ARTICLE">
<AU>Tapadinhas MJ, Rivera IC, Bignamini AA</AU>
<TI>Oral glucosamine sulphate in the management of arthrosi: report on a mult-centre open investigation in Portugal</TI>
<SO>Pharmacotherapeutica</SO>
<YR>1982</YR>
<VL>3</VL>
<PG>157-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-1997a" MODIFIED="2008-10-22 12:48:58 -0400" MODIFIED_BY="[Empty name]" NAME="Towheed 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE, Hochberg MC</AU>
<TI>A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip</TI>
<SO>Journal of Rheumatology</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>549-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-1997b" MODIFIED="2008-10-22 12:49:10 -0400" MODIFIED_BY="[Empty name]" NAME="Towheed 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE, Hochberg MC</AU>
<TI>A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>1997</YR>
<VL>26</VL>
<PG>755-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-1998" MODIFIED="2008-10-22 12:50:09 -0400" MODIFIED_BY="[Empty name]" NAME="Towheed 1998" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE</AU>
<TI>Impact of musculoskeletal disorders in Canada</TI>
<SO>Annals of the Royal College of Physicians and Surgeons of Canada</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>5</NO>
<PG>229-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-1999" MODIFIED="2008-10-22 12:50:23 -0400" MODIFIED_BY="[Empty name]" NAME="Towheed 1999" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE, Anatassiades TP</AU>
<TI>Glucosamine therapy for osteoarthritis (editorial)</TI>
<SO>Journal of Rheumatology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>11</NO>
<PG>2294-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-2000" MODIFIED="2008-10-22 12:50:32 -0400" MODIFIED_BY="[Empty name]" NAME="Towheed 2000" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE</AU>
<TI>Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>11</NO>
<PG>1483-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-2002" MODIFIED="2008-11-07 09:35:37 -0500" MODIFIED_BY="[Empty name]" NAME="Towheed 2002" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE</AU>
<TI>Published meta-analyses of pharmacological therapies for osteoarthritis</TI>
<SO>Osteoarthritis and Cartilage</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>11</NO>
<PG>836-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-2003" MODIFIED="2008-10-22 12:50:48 -0400" MODIFIED_BY="[Empty name]" NAME="Towheed 2003" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE</AU>
<TI>Current Status of glucosamine therapy in osteoarthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>4</NO>
<PG>601-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Towheed-2007" MODIFIED="2008-10-22 12:51:17 -0400" MODIFIED_BY="[Empty name]" NAME="Towheed 2007" TYPE="JOURNAL_ARTICLE">
<AU>Towheed TE, Anastassiades T</AU>
<TI>Glucosamine therapy for osteoarthritis: An update</TI>
<SO>Journal of Rheumatology</SO>
<YR>2007</YR>
<VL>34</VL>
<NO>9</NO>
<PG>1787-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vidal-1978" MODIFIED="2008-10-22 12:58:25 -0400" MODIFIED_BY="[Empty name]" NAME="Vidal 1978" TYPE="JOURNAL_ARTICLE">
<AU>Vidal Y, Plana R, Bizzarri D, Rovati AL</AU>
<TI>Articular cartilage pharmacology. In vitro studies on glucosamine and non-steroidal anti-inflammatory drugs</TI>
<SO>Pharmacological Research Communications</SO>
<YR>1978</YR>
<VL>10</VL>
<PG>557-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vlad-2007" MODIFIED="2008-10-22 12:57:13 -0400" MODIFIED_BY="[Empty name]" NAME="Vlad 2007" TYPE="JOURNAL_ARTICLE">
<AU>Vlad SC, LaValley MP, McAlindon TE, Felson DT</AU>
<TI>Glucosamine for pain in osteoarthritis: why do trial results differ?</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2007</YR>
<VL>56</VL>
<NO>7</NO>
<PG>2105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-2002" MODIFIED="2008-10-22 12:58:37 -0400" MODIFIED_BY="[Empty name]" NAME="Wright 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wright JM</AU>
<TI>The double-edged sword of COX-2 selective NSAIDs</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2002</YR>
<VL>167</VL>
<NO>10</NO>
<PG>1131-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-08 12:12:12 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-08 12:12:12 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-07 09:12:13 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cibere-2004">
<CHAR_METHODS MODIFIED="2008-11-07 09:12:13 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Discontinuation trial<BR/>Multicenter trial<BR/>Parallel group<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 08:48:48 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with OA of the knee<BR/>Country: Canada<BR/>N = 137<BR/>In order to qualify for study entry, subjects must have been users of glucosamine and have experienced at least a moderate improvement in knee pain since starting on glucosamine<BR/>Mean age = 64.5 years<BR/>Female: 60%<BR/>Male: 40%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-22 11:49:26 -0400" MODIFIED_BY="[Empty name]">
<P>GS = 1500 mg/day vs placebo for 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Proportion of disease flares<BR/>Time to disease flare and severity of disease flare<BR/>WOMAC pain<BR/>WOMAC stiffness<BR/>WOMAC function<BR/>WOMAC total<BR/>Analgesic medication usage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:36:14 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 08:50:13 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clegg-2006">
<CHAR_METHODS MODIFIED="2008-11-07 08:48:16 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Multicenter (NIH Funded in the USA)<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-22 11:49:37 -0400" MODIFIED_BY="[Empty name]">
<P>Outpatients with symptomatic OA of the knee<BR/>Country: USA<BR/>N = 1583<BR/>Mean age = 58.6 years<BR/>Female: 64%<BR/>Male: 36%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 08:49:42 -0500" MODIFIED_BY="[Empty name]">
<P>GH 500 mg PO TID versus chondroitin sulfate 1200 mg/day versus GH + chondroitin sulfate versus Celebrex 200 mg/day versus placebo<BR/>Duration: 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 08:50:13 -0500" MODIFIED_BY="[Empty name]">
<P>WOMAC pain, OMERACT-OARSI responders, WOMAC stiffness, WOMAC function, HAQ Disability, HAQ pain, Patient global assessment, Physician's global assessment of disease status, joint swelling, effusion, usage of acetaminophen</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:36:21 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-08 12:12:12 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crolle-1980">
<CHAR_METHODS MODIFIED="2008-11-07 08:50:41 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Single center<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 08:50:48 -0500" MODIFIED_BY="[Empty name]">
<P>Inpatients with osteoarthritis<BR/>Country: Italy<BR/>N = 30<BR/>mean age: 72.7 years<BR/>Female: 73%<BR/>Male: 27%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 12:12:12 -0500" MODIFIED_BY="[Empty name]">
<P>GS = 400 mg OD IM (12)<BR/>intra-articular injection given once every 7 days followed by GS = 500 mg TID<BR/>versus IM OD (piperazine plus chlorbutanol) x 7 days followed two weeks of oral placebo<BR/>Duration = 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 08:53:13 -0500" MODIFIED_BY="[Empty name]">
<P>Pain (at rest)<BR/>Pain (active range of motion)<BR/>Pain (passive range of motion)<BR/>scored from 0 to 3 scale<BR/>Restricted function, time to walk 20 m<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:36:30 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:05:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-D_x0027_ambrosio-1981">
<CHAR_METHODS MODIFIED="2008-11-07 08:54:33 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Single center<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 08:54:41 -0500" MODIFIED_BY="[Empty name]">
<P>Inpatients with chronic degenerative osteoarthrotic disorders (site not specified)<BR/>Country: Italy<BR/>N = 30<BR/>Mean age = 74.7 years<BR/>Female: 77%<BR/>Male: 23%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 08:54:58 -0500" MODIFIED_BY="[Empty name]">
<P>GS 400 mg OD (IV or IM) for 7 days followed by two weeks of GS 500 mg PO TID versus (piperazine plus chlorbutanol) x 7 days followed two weeks of oral placebo<BR/>Duration: 3 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 09:05:11 -0500" MODIFIED_BY="[Empty name]">
<P>Pain (at rest)<BR/>Pain (during passive range of motion )<BR/>Pain (active range of motion) 0 to 3 scale<BR/>Functional limitation 0 to 3 scale<BR/>Safety<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:36:36 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 08:55:39 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drovanti-1980">
<CHAR_METHODS MODIFIED="2008-11-07 08:55:27 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Single Center<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 08:55:34 -0500" MODIFIED_BY="[Empty name]">
<P>Inpatients with osteoarthritis at multiple sites<BR/>Country: Italy<BR/>N = 80<BR/>Mean age: 60 years<BR/>Female: 78%<BR/>Male: 22%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 08:55:39 -0500" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus placebo PO TID<BR/>Duration: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-22 11:51:49 -0400" MODIFIED_BY="[Empty name]">
<P>Pain (0 to 4 scale)<BR/>Joint tenderness<BR/>Swelling<BR/>Restriction of active movement and restriction of passive movement<BR/>Physician global rating<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:36:43 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 08:56:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herrero_x002d_Beaumont-2007">
<CHAR_METHODS MODIFIED="2008-11-07 08:56:04 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Multicenter<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-22 11:52:07 -0400" MODIFIED_BY="[Empty name]">
<P>Outpatients with primary symptomatic OA of the knee<BR/>Country: Spain and Portugal<BR/>N = 325<BR/>Mean age: 63.9 years<BR/>87% female<BR/>13% male<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 08:56:23 -0500" MODIFIED_BY="[Empty name]">
<P>GS 1500 mg/day versus acetaminophen 3 gm/day versus placebo<BR/>Duration: 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 08:56:29 -0500" MODIFIED_BY="[Empty name]">
<P>Lequesne Index, WOMAC total WOMAC pain, WOMAC function, OARSI A and B responder criteria, Global-patient derived</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:36:49 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 08:57:20 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Houpt-1999">
<CHAR_METHODS MODIFIED="2008-11-07 08:57:00 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Single center<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 08:57:07 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with primary osteoarthritis of the knee<BR/>Country: Canada<BR/>N = 118<BR/>Mean age: 64.5 years<BR/>Female: 62%<BR/>Male: 38%<BR/>Age range: 40 to 85 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 08:57:20 -0500" MODIFIED_BY="[Empty name]">
<P>GH 500 mg PO TID versus placebo PO TID<BR/>Duration: 8 weeks with an additional 8 weeks follow-up period (open label)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-22 11:52:58 -0400" MODIFIED_BY="[Empty name]">
<P>WOMAC<BR/>Daily pain diary<BR/>Global patient derived<BR/>Improvement on knee examination<BR/>Use of acetaminophen<BR/>Perception as to what group the subject were randomized to<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:36:56 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 08:58:17 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hughes-2002">
<CHAR_METHODS MODIFIED="2008-11-07 08:57:54 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Single Center<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 08:58:17 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: UK<BR/>N = 80<BR/>Mean age = 62.3 years<BR/>Female: 68%<BR/>Male: 32%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-22 11:58:08 -0400" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus placebo PO TID<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>VAS global pain<BR/>VAS pain on movement<BR/>VAS pain at rest<BR/>WOMAC pain<BR/>WOMAC stiffness<BR/>WOMAC function<BR/>McGill Pain Questionnaire (Affective) <BR/>McGill Pain Questionnaire (Sensory)<BR/>OARSI Response Criteria<BR/>Knee range of motion</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:37:04 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 08:59:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McAlindon-2004">
<CHAR_METHODS MODIFIED="2008-11-07 08:59:10 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled Internet conducted trial<BR/>Double blinded<BR/>Single center<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-22 11:53:44 -0400" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: USA<BR/>N = 205<BR/>Mean age = NA<BR/>64% female <BR/>36% male<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 08:59:27 -0500" MODIFIED_BY="[Empty name]">
<P>GS 1500 mg/day versus placebo<BR/>Duration: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC pain<BR/>WOMAC stiffness<BR/>WOMAC function<BR/>WOMAC total<BR/>Changes in analgesic usage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:37:17 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:00:01 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mehta-2007">
<CHAR_METHODS MODIFIED="2008-11-07 08:59:49 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Multicenter<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Outpatients with OA of the knee<BR/>Country: India<BR/>N = 95<BR/>Female: 75%<BR/>Male: 25%<BR/>Mean age = 53.5 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:00:01 -0500" MODIFIED_BY="[Empty name]">
<P>GS 750 mg PO BID versus Reparagen (a polyherbal) PO BID<BR/>Duration: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC pain<BR/>WOMAC function<BR/>WOMAC stiffness<BR/>WOMAC total<BR/>OMERACT/OARSI responder, VAS pain, Rescue medication usage<BR/>Patient global assessment<BR/>Physician global assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:37:24 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:00:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muller_x002d_FassBender-94">
<CHAR_METHODS MODIFIED="2008-11-07 09:00:36 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Multicenter<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-22 11:54:21 -0400" MODIFIED_BY="[Empty name]">
<P>Inpatients with active osteoarthritis of the knee<BR/>Country :Germany<BR/>N = 200<BR/>Mean age: 54 years<BR/>Female: 48%<BR/>Male: 52%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:00:48 -0500" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus Ibuprofen 400 PO TID<BR/>Duration: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne Index<BR/>Global investigator derived <BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:37:31 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:01:19 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Noack-1994">
<CHAR_METHODS MODIFIED="2008-11-07 09:01:08 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Multicenter<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:01:14 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: Germany<BR/>N = 252<BR/>Mean age: 55 years<BR/>Female: 60%<BR/>Male: 40%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:01:19 -0500" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus placebo PO TID<BR/>Duration: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne Index<BR/>Global investigator derived <BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:37:37 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:01:58 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavelka-2002">
<CHAR_METHODS MODIFIED="2008-11-07 09:01:45 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Parallel group<BR/>Single center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:01:58 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: Prague, Czech Republic<BR/>N = 202<BR/>Mean age = 62.3 years<BR/>Female: 78%<BR/>Male: 22%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-22 11:55:35 -0400" MODIFIED_BY="[Empty name]">
<P>GS 1500 mg PO OD versus placebo PO OD<BR/>Duration: 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC pain<BR/>WOMAC stiffness<BR/>WOMAC function<BR/>WOMAC total<BR/>Lequesne Index<BR/>Joint space narrowing (x-ray)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:37:43 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:02:42 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pujalte-1980">
<CHAR_METHODS MODIFIED="2008-11-07 09:02:29 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Single center<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:02:36 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with established osteoarthrosis of the knee<BR/>Country: Philippines<BR/>N = 20<BR/>Mean age: 61.7 years<BR/>Female: 85%<BR/>Male: 15%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:02:42 -0500" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus placebo PO TID<BR/>Duration: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-22 11:59:56 -0400" MODIFIED_BY="[Empty name]">
<P>Articular pain (1 to 4 scale)<BR/>Joint tenderness (1 to 4 scale)<BR/>Joint swelling (1 to 4 scale)<BR/>Restricted movement (1 to 4 scale)<BR/>Global investigator derived<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:37:50 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:06:17 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qiu-1998">
<CHAR_METHODS MODIFIED="2008-11-07 09:03:08 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Multicenter<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:03:36 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: China<BR/>N = 178<BR/>Mean age: 56.4 years<BR/>Female: 79%<BR/>Male: 21%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:04:07 -0500" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus ibuprofen 400 mg PO TID<BR/>Duration: 4 weeks of treatment and 2 weeks of follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 09:06:17 -0500" MODIFIED_BY="[Empty name]">
<P>Knee pain (at rest, movement, tenderness) 0 to 3 scale<BR/>Knee swelling 0 to 3 scale<BR/>Global investigator derived<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:37:56 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:13:22 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qiu-2005">
<CHAR_METHODS MODIFIED="2008-11-07 09:13:22 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Parallel group<BR/>Multicenter</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:06:47 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: China<BR/>N =142<BR/>Mean age = 57 ± 10 years<BR/>Female: 92%<BR/>Male: 8%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:06:59 -0500" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus GH 480 mg PO TID<BR/>Duration: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-21 07:29:17 -0400" MODIFIED_BY="[Empty name]">
<P>Knee pain at rest, on movement and pressure, swelling, morning stiffness, and walking ability according to Lequesne criteria. Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:03 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:07:47 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reginster-2001">
<CHAR_METHODS MODIFIED="2008-11-07 09:07:33 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Parallel group<BR/>Single center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:07:47 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: Belgium<BR/>N = 212<BR/>Mean age: 65.8 years<BR/>Female: 76%<BR/>Male: 24%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-22 12:01:59 -0400" MODIFIED_BY="[Empty name]">
<P>GS 1500 mg PO OD versus placebo PO OD<BR/>Duration: 3 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC pain<BR/>WOMAC stiffness<BR/>WOMAC function<BR/>Mean joint space narrowing (x-ray)<BR/>Minimum joint space narrowing (x-ray)<BR/>WOMAC total</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:12 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:08:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reichelt-1994">
<CHAR_METHODS MODIFIED="2008-11-07 09:08:15 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Multicenter<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:08:22 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: Germany<BR/>N = 155<BR/>Mean age: 56.5 years<BR/>Female: 65%<BR/>Male: 35%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:08:48 -0500" MODIFIED_BY="[Empty name]">
<P>GS 400 mg IM x two per week versus placebo IM x two per week<BR/>Duration: 6 weeks of treatment and two weeks of follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne Index<BR/>Global investigator derived<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:18 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:09:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rindone-2000">
<CHAR_METHODS MODIFIED="2008-11-07 09:09:17 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Parallel group<BR/>Single center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:09:28 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: USA<BR/>N = 114<BR/>Female: 5%<BR/>Male: 95%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-22 12:05:01 -0400" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus placebo PO TID<BR/>Duration: 2 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>VAS pain at rest<BR/>VAS pain while walking<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:24 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:10:45 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rovati-1997">
<CHAR_METHODS MODIFIED="2008-11-07 09:10:04 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Multicenter<BR/>Parallel group<BR/>This study is unpublished at this time (the authors have provided us data from this study in the form of a full manuscript ). Preliminary data from the study were also presented in abstract form by Rovati LC, 1997</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:10:23 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with primary osteoarthritis of the knee<BR/>Country: France<BR/>N = 319<BR/>Mean age: 65.5 years<BR/>Female: 75%<BR/>Male: 25%<BR/>Age range = 45-85 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:10:45 -0500" MODIFIED_BY="[Empty name]">
<P>GS 1500 mg per day versus piroxicam 20 mg per day versus the combination of the two versus double placebo<BR/>Duration 12 weeks of treatment and 8 weeks of follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lequesne Index<BR/>Pain (VAS)<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:32 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:11:52 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rozendaal-2008">
<CHAR_METHODS MODIFIED="2008-11-07 09:11:26 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Parallel group<BR/>Single center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-22 12:06:26 -0400" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the hip<BR/>Country: Netherlands<BR/>N = 222<BR/>69% female<BR/>31% male<BR/>Mean age = 63.4 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:11:37 -0500" MODIFIED_BY="[Empty name]">
<P>GS 1500 mg per day versus placebo<BR/>Duration: 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-07 09:11:52 -0500" MODIFIED_BY="[Empty name]">
<P>WOMAC pain, WOMAC stiffness, WOMAC function, VAS pain, joint space narrowing, usage of pain medication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:38 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:15:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Usha-2004">
<CHAR_METHODS MODIFIED="2008-11-07 09:14:45 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial </P>
<P>Double blinded<BR/>Parallel group<BR/>Single center</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:14:50 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with mild to moderate osteoarthritis of the knee<BR/>Country: India<BR/>N =118<BR/>Mean age = 51 years<BR/>60% female<BR/>40% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:15:05 -0500" MODIFIED_BY="[Empty name]">
<P>GS versus MSM versus GS+MSM versus placebo<BR/>Duration: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain, Lequesne Index, walk time, joint swelling, usage of rescue analgesics, global patient, global investigator</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:44 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:15:59 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vajaradul-1981">
<CHAR_METHODS MODIFIED="2008-11-07 09:15:37 -0500" MODIFIED_BY="[Empty name]">
<P>Controlled trial (query randomized)<BR/>Double blinded<BR/>Multicenter<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:15:46 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: Thailand<BR/>N = 60<BR/>Mean age: 52.6 years<BR/>Female: 83%<BR/>Male: 17%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:15:59 -0500" MODIFIED_BY="[Empty name]">
<P>GS IA weekly versus placebo IA weekly<BR/>Duration: 5 weeks and 4 weeks follow up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-22 12:11:56 -0400" MODIFIED_BY="[Empty name]">
<P>Pain spontaneous (0 to 2 scale)<BR/>Pain on standing (0 to 2 scale)<BR/>Pain on walking (0 to 2 scale)<BR/>Range of motion<BR/>Time to climb five steps<BR/>Knee joint circumference<BR/>Safety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:50 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:16:47 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaz-1982">
<CHAR_METHODS MODIFIED="2008-11-07 09:16:25 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Single center<BR/>Parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:16:30 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee<BR/>Country: Portugal<BR/>N = 40<BR/>Mean age: 57.8 years<BR/>Female: 74%<BR/>Male: 26%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-07 09:16:47 -0500" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus ibuprofen 400 mg PO TID<BR/>Duration: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-22 12:12:26 -0400" MODIFIED_BY="[Empty name]">
<P>Articular pain (0 to 3 scale)<BR/>Swelling<BR/>Global investigator derived</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:38:57 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-07 09:17:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zenk-2002">
<CHAR_METHODS MODIFIED="2008-11-07 09:17:18 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>Double blinded<BR/>Parallel group<BR/>Single center<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-07 09:17:33 -0500" MODIFIED_BY="[Empty name]">
<P>Outpatients with osteoarthritis of the knee and/or hip<BR/>Country: USA<BR/>N = 42<BR/>Mean age = 59 years<BR/>Female: 81%<BR/>Male: 19%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-22 12:13:13 -0400" MODIFIED_BY="[Empty name]">
<P>GS 500 mg PO TID versus placebo versus milk protein concentrate 2000 mg PO TID<BR/>Duration: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>WOMAC pain<BR/>WOMAC stiffness<BR/>WOMAC function<BR/>WOMAC total</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-06-21 07:39:04 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>GS = Glucosamine sulfate<BR/>GH = Glucosamine hydrochloride<BR/>OD = per day<BR/>IM = Intramuscular<BR/>IA = intrarticular<BR/>IV = Intravenous<BR/>TID = three times per day<BR/>BID = two times per day<BR/>PO = oral<BR/>WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index<BR/>OARSI = Osteoarthritis Research Society International Responder Criteria<BR/>MSM = methylsulfonylmethane<BR/>NA = not available</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-07 09:18:02 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-07 09:18:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Braham-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-07 09:18:02 -0500" MODIFIED_BY="[Empty name]">
<P>This RCT compared glucosamine to placebo in subjects who experienced regular knee pain. However, the cause of the knee pain was not clearly established, and may possibly not have been caused by OA of the knee.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Magi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unpublished brief technical report prepared by Rottapharm primarily for regulatory authorities. Report describes a pilot long-term feasibility study in subjects with OA of the knee. This was a phase 3 RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pipitone-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unpublished brief technical report prepared by Rottapharm primarily for regulatory authorities. Report describes a pilot long-term feasibility study in subjects with OA of the knee. This was a phase 3 RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rovati-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unpublished brief technical report prepared by Rottapharm primarily for regulatory authorities. Report describes a pilot short-term in subjects with OA of the spine. This was a phase 3 RCT.<BR/>Some of the data from this study was published in abstract form by Foerster KK in the 2000 September Supplemental Issue of Arthritis and Rheumatism.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cibere-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Clegg-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Crolle-1980">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-D_x0027_ambrosio-1981">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Drovanti-1980">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Herrero_x002d_Beaumont-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Houpt-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hughes-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-McAlindon-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Mehta-2007">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Muller_x002d_FassBender-94">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Noack-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pavelka-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Pujalte-1980">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Qiu-1998">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Qiu-2005">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Reginster-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Reichelt-1994">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Rindone-2000">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rovati-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rozendaal-2008">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Usha-2004">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Vajaradul-1981">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Vaz-1982">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Zenk-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-11-12 17:36:17 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2008-11-12 17:36:09 -0500" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2008-11-12 17:36:09 -0500" MODIFIED_BY="[Empty name]">Summary of findings (adequate allocation concealment)</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>Glucosamine versus placebo for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with treating osteoarthritis</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> Glucosamine versus placebo (adequate allocation concealment)</P>
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Glucosamine versus placebo (adequate allocation concealment)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain based on WOMAC pain scale</B>
<BR/>Scale from: 0 (no pain) to 20 (worst pain).<BR/>(follow-up: mean 6 months)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean pain based on womac pain scale in the control groups was<BR/>
<B>6.6 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Pain based on WOMAC pain scale in the intervention groups was<BR/>
<B>0.7 lower</B>
<BR/>(1.5 lower to 0.17 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2173<BR/>(11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.16 (95% CI -0.36 to 0.04, see outcome 3.1). Relative per cent change from baseline is -7% (95% CI -17%, 1.8%). Note that when all studies are pooled together, the result is statistically significant: SMD=-0.47 (95% CI -0.72, -0.23, see outcome 1.1). This corresponds to a 10 point improvement on a 0 to 100 scale. When studies using the Rotta preparation are pooled together, the result is statistically significant: SMD=-1.11 ( 95% CI -1.66, -0.57, see outcome 4.1 and Summary of Findings Table 2).<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>WOMAC Function Subscale </B>
<BR/>Scale from: 0 to 68.<BR/>(follow-up: median 6 months)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean womac function subscale in the control groups was<BR/>
<B>31.6 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean WOMAC Function Subscale in the intervention groups was<BR/>
<B>1.02 lower</B>
<BR/>(2.04 lower to 0 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2017<BR/>(9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.08 (95% CI -0.17 to 0.00, see outcome 3.6). Relative per cent change from baseline is -3% (95% CI -6%, 0%). Note that when studies using the Rotta preparation are pooled together, the SMD is -0.19 (95% CI -0.35, -0.03, see outcome 4.6) which is statistically significant. See Summary of Findings Table 2.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Physician Global Assessment</B>
<BR/>100 mm visual analogue scale. Scale from: 0 to 100.<BR/>(follow-up: 6 months)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean physician global assessment in the control groups was<BR/>
<B>37.1 mm</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Physician Global Assessment in the intervention groups was<BR/>
<B>0.80 higher</B>
<BR/>(2.78 lower to 4.38 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>630<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P> MD 0.80 (95% CI -2.78, 4.38). Relative per cent change from baseline is -1.5% (95% CI -5.4%, 8.5%)See Results section, #10.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Patient Global Assessment</B>
<BR/>(patients rated whether they were better at the end of trial than at the start of the trial)<BR/>(follow-up: mean 6 months)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.21 </B>
<BR/>(0.8 to 1.82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>118<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>40 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>48 per 100</B>
<BR/>(32 to 73)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Minimum Joint Space Width</B>
<BR/>mm<BR/>(follow-up: mean 3 years)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean minimum joint space width in the control groups was<BR/>
<B>3.55 mm</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Minimum Joint Space Width in the intervention groups was<BR/>
<B>0.32 higher</B>
<BR/>(0.05 to 0.58 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>414<BR/>(2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>MD 0.32 (95% CI 0.05 to 0.58, see outcome 3.8). </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Toxicity (Number of Patients Reporting Adverse Events)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.99 </B>
<BR/>(0.91 to 1.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1640<BR/>(9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 100</B>
<BR/>(48 to 57)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Toxicity (Number of Withdrawals due to Adverse Events)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.76 </B>
<BR/>(0.54 to 1.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2435<BR/>(12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>4 per 100</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>3 per 100</B>
<BR/>(2 to 5)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Heterogeneity fairly high; I-squared=79%</P>
<P>
<SUP>2</SUP> Only 1 study and wide confidence interval</P>
<P>
<SUP>3</SUP> Few events; only 1 study</P>
<P>
<SUP>4</SUP> Confidence interval crosses threshold for appreciable benefit or harm of a RRR or RRI of 25%. Also, number of events is less than 300.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2008-11-12 17:36:17 -0500" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2008-11-12 17:36:17 -0500" MODIFIED_BY="[Empty name]">Summary of findings (Rotta preparation)</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TD COLSPAN="7">
<P>
<B>Glucosamine versus placebo (Rotta preparation) for treating osteoarthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B> Patient or population:</B> patients with treating osteoarthritis</P>
<P>
<B> Settings:</B> </P>
<P>
<B> Intervention:</B> Glucosamine versus placebo (Rotta preparation)</P>
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Glucosamine versus placebo (Rotta preparation)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P> </P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain based on WOMAC scale</B>
<BR/>Scale from: 0 (no pain) to 20 (worst pain).<BR/>(follow-up: mean 6 months)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean pain based on womac scale in the control groups was<BR/>
<B>6 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean Pain based on WOMAC scale in the intervention groups was<BR/>
<B>3.33 lower</B>
<BR/>(4.98 to 1.71 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>940<BR/>(8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Statistically significant. SMD -1.11 (-1.66 to -0.57, see outcome 4.1). Relative per cent change from baseline is -42.2% (95% CI -63.0%, -21.6%).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>WOMAC Function Subscale</B>
<BR/>Scale from: 0 to 68.<BR/>(follow-up: mean 6 months)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean womac function subscale in the control groups was<BR/>
<B>21.66 points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean WOMAC Function Subscale in the intervention groups was<BR/>
<B>2.07 lower</B>
<BR/>(3.81 to 0.33 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>624<BR/>(3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Statistically significant. SMD -0.19 (-0.35 to -0.03, see outcome 4.6). Relative per cent change from baseline is -7.6% (95% CI -14.0%, -1.2%).</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidance<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> High heterogeneity, I-squared=92%</P>
<P>
<SUP>2</SUP> Funnel plot asymmetrical in favour of positive studies</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2008-10-22 13:15:05 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-22 13:15:05 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-06-21 06:26:59 -0400" MODIFIED_BY="[Empty name]">Methodological quality assessment</TITLE>
<TABLE COLS="7" ROWS="26">
<TR>
<TD>
<P>Study</P>
</TD>
<TD>
<P>Method of allocation concealment described and appropriate</P>
</TD>
<TD>
<P>Study described as 'randomized'</P>
</TD>
<TD>
<P>Method of randomization described and appropriate</P>
</TD>
<TD>
<P>Study described as 'double blind'</P>
</TD>
<TD>
<P>Method of blinding described and appropriate</P>
</TD>
<TD>
<P># and reason for withdrawals described in each group</P>
</TD>
</TR>
<TR>
<TD>
<P>Cibere 2004</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Clegg 2006</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
</TR>
<TR>
<TD>
<P>Crolle 1980</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
</TR>
<TR>
<TD>
<P>D'ambrosio 1981</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
</TR>
<TR>
<TD>
<P>Drovanti 1980</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
</TR>
<TR>
<TD>
<P>Herrero-Beaumont 2007</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Houpt 1999</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
</TR>
<TR>
<TD>
<P>Hughes 2002</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>McAlindon 2004</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Mehta 2007</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Muller-FassBender 94</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Noack 1994</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Pavelka 2002</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Pujalte 1980</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Qiu 1998</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Qiu 2005</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Reginster 2001</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Reichelt 1994</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Rindone 2000</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>NM</P>
</TD>
</TR>
<TR>
<TD>
<P>Rovati 1997</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Rozendaal 2008</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Usha 2004</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Vajaradul 1981</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Vaz 1982</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
<TR>
<TD>
<P>Zenk 2002</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>NM</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
<TD>
<P>M</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>M = criteria met; NM = criteria not met</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-11 23:01:52 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-08-04 22:58:18 -0400" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Glucosamine versus placebo</NAME>
<CONT_OUTCOME CHI2="136.1343986328305" CI_END="-0.22619185832278688" CI_START="-0.7191689375321769" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4726803979274819" ESTIMABLE="YES" I2="87.51234062020512" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="1.7090904758929805E-4" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.21945808897345406" TOTALS="YES" TOTAL_1="1276" TOTAL_2="1267" UNITS="" WEIGHT="100.00000000000001" Z="3.7585380546361087">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33598585567694017" CI_START="-0.33426480199530306" EFFECT_SIZE="8.605268408185565E-4" ESTIMABLE="YES" MEAN_1="129.72" MEAN_2="129.62" ORDER="8834" SD_1="113.23" SD_2="118.02" SE="0.170985452528489" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="6.359628908447867"/>
<CONT_DATA CI_END="0.1413518156593127" CI_START="-0.17100613591755937" EFFECT_SIZE="-0.014827160129123324" ESTIMABLE="YES" MEAN_1="149.3" MEAN_2="151.0" ORDER="8850" SD_1="115.9" SD_2="113.1" SE="0.07968461513596978" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="7.004199096326615"/>
<CONT_DATA CI_END="-0.4850577420152552" CI_START="-2.07639481120975" EFFECT_SIZE="-1.2807262766125027" ESTIMABLE="YES" MEAN_1="0.21" MEAN_2="1.13" ORDER="8835" SD_1="0.43" SD_2="0.89" SE="0.4059607936030352" STUDY_ID="STD-Crolle-1980" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.115944920951997"/>
<CONT_DATA CI_END="-3.7134659239650682" CI_START="-6.940697000101388" EFFECT_SIZE="-5.327081462033228" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="1.2" ORDER="8836" SD_1="0.12" SD_2="0.19" SE="0.8232883618250914" STUDY_ID="STD-D_x0027_ambrosio-1981" TOTAL_1="15" TOTAL_2="15" WEIGHT="1.7626987449808174"/>
<CONT_DATA CI_END="-0.9082085725744987" CI_START="-1.8911551068594425" EFFECT_SIZE="-1.3996818397169706" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="1.88" ORDER="8837" SD_1="0.82" SD_2="0.44" SE="0.2507562746148145" STUDY_ID="STD-Drovanti-1980" TOTAL_1="40" TOTAL_2="40" WEIGHT="5.601828335304894"/>
<CONT_DATA CI_END="-0.025379230972806865" CI_START="-0.5694445904166039" EFFECT_SIZE="-0.29741191069470535" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="6.0" ORDER="8851" SD_1="3.03" SD_2="3.0" SE="0.13879473391738703" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="6.625287286620142"/>
<CONT_DATA CI_END="0.2735347817391287" CI_START="-0.5218541742172914" EFFECT_SIZE="-0.12415969623908137" ESTIMABLE="YES" MEAN_1="7.14" MEAN_2="7.65" ORDER="8838" SD_1="4.01" SD_2="4.13" SE="0.2029090744091082" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="6.068377298557043"/>
<CONT_DATA CI_END="0.47616054074363307" CI_START="-0.4115892476304209" EFFECT_SIZE="0.03228564655660611" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.35" ORDER="8839" SD_1="4.81" SD_2="4.38" SE="0.22647094420522798" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="5.841620550917582"/>
<CONT_DATA CI_END="0.3265229057260645" CI_START="-0.22119178870229833" EFFECT_SIZE="0.0526655585118831" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.6" ORDER="8840" SD_1="3.3" SD_2="4.2" SE="0.13972570382636273" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" WEIGHT="6.61809886739126"/>
<CONT_DATA CI_END="0.14905859627306614" CI_START="-0.4031188395109486" EFFECT_SIZE="-0.12703012161894126" ESTIMABLE="YES" MEAN_1="4.61" MEAN_2="5.03" ORDER="8841" SD_1="3.45" SD_2="3.13" SE="0.14086417917357663" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="6.609264311386441"/>
<CONT_DATA CI_END="-0.7364458486257748" CI_START="-2.892384263887514" EFFECT_SIZE="-1.8144150562566443" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="2.36" ORDER="8842" SD_1="0.25" SD_2="0.79" SE="0.5499943958836759" STUDY_ID="STD-Pujalte-1980" TOTAL_1="10" TOTAL_2="10" WEIGHT="3.030168493048881"/>
<CONT_DATA CI_END="0.19112506963873596" CI_START="-0.3475281057110372" EFFECT_SIZE="-0.07820151803615064" ESTIMABLE="YES" MEAN_1="156.1" MEAN_2="164.2" ORDER="8843" SD_1="101.9" SD_2="104.5" SE="0.13741404933932477" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="6.635888081836307"/>
<CONT_DATA CI_END="0.3167615683181636" CI_START="-0.47550830461059157" EFFECT_SIZE="-0.07937336814621399" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.4" ORDER="8844" SD_1="2.5" SD_2="2.5" SE="0.20211337534211823" STUDY_ID="STD-Rindone-2000" TOTAL_1="49" TOTAL_2="49" WEIGHT="6.075890294637719"/>
<CONT_DATA CI_END="-0.8936109932290024" CI_START="-1.5801671348656527" EFFECT_SIZE="-1.2368890640473276" ESTIMABLE="YES" MEAN_1="24.3" MEAN_2="50.0" ORDER="8845" SD_1="19.3" SD_2="22.0" SE="0.17514509119864383" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" WEIGHT="6.3230226985293125"/>
<CONT_DATA CI_END="0.29352599391686374" CI_START="-0.23268166989018768" EFFECT_SIZE="0.03042216201333804" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="34.4" ORDER="8849" SD_1="26.8" SD_2="25.6" SE="0.1342391156056209" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="6.659988505964487"/>
<CONT_DATA CI_END="-0.1540231993132215" CI_START="-1.2159345454638881" EFFECT_SIZE="-0.6849788723885548" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="1.16" ORDER="8846" SD_1="0.71" SD_2="0.76" SE="0.27090072943352217" STUDY_ID="STD-Usha-2004" TOTAL_1="30" TOTAL_2="28" WEIGHT="5.40081164991583"/>
<CONT_DATA CI_END="-0.22035777750709318" CI_START="-1.3303287707044493" EFFECT_SIZE="-0.7753432741057713" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.69" ORDER="8847" SD_1="0.16" SD_2="0.92" SE="0.28316106876265734" STUDY_ID="STD-Vajaradul-1981" TOTAL_1="28" TOTAL_2="26" WEIGHT="5.278371899946829"/>
<CONT_DATA CI_END="0.8919460976094586" CI_START="-0.7574158044584813" EFFECT_SIZE="0.06726514657548861" ESTIMABLE="YES" MEAN_1="-74.7" MEAN_2="-76.5" ORDER="8848" SD_1="26.3" SD_2="25.1" SE="0.42076331888695306" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="3.9889100552359906"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="28.672218886427327" CI_END="-0.12042038644627745" CI_START="-0.8204915459933517" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.47045596621981456" ESTIMABLE="YES" I2="86.049213645291" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="9.112252093435025E-6" P_Q="1.0" P_Z="0.00843265513690806" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.13656386214621394" TOTALS="YES" TOTAL_1="479" TOTAL_2="472" UNITS="" WEIGHT="100.0" Z="2.6342372129695666">
<NAME>Lequesne Index</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07336516615764449" CI_START="-0.6184990662542025" EFFECT_SIZE="-0.3459321162059235" ESTIMABLE="YES" MEAN_1="7.97" MEAN_2="8.96" ORDER="8856" SD_1="3.07" SD_2="2.61" SE="0.1390673258275419" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="20.458420595765432"/>
<CONT_DATA CI_END="0.0529036046255113" CI_START="-0.4533952767244798" EFFECT_SIZE="-0.20024583604948426" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="8.4" ORDER="8852" SD_1="5.5" SD_2="4.4" SE="0.12916025124533206" STUDY_ID="STD-Noack-1994" TOTAL_1="120" TOTAL_2="121" WEIGHT="20.813177743998207"/>
<CONT_DATA CI_END="-0.100983159917506" CI_START="-0.6576293058659679" EFFECT_SIZE="-0.3793062328917369" ESTIMABLE="YES" MEAN_1="7.25" MEAN_2="8.12" ORDER="8853" SD_1="2.3" SD_2="2.27" SE="0.14200417720407507" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="20.350669575535388"/>
<CONT_DATA CI_END="0.13390073990719475" CI_START="-0.5258885009818807" EFFECT_SIZE="-0.19599388053734296" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="8.3" ORDER="8854" SD_1="6.9" SD_2="8.3" SE="0.1683166747178542" STUDY_ID="STD-Reichelt-1994" TOTAL_1="73" TOTAL_2="69" WEIGHT="19.342935558184575"/>
<CONT_DATA CI_END="-0.931017954189491" CI_START="-1.6211907720212866" EFFECT_SIZE="-1.2761043631053888" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="9.7" ORDER="8855" SD_1="2.8" SD_2="3.7" SE="0.17606772963069495" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" WEIGHT="19.034796526516395"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.3718194900809073" CI_END="1.9123149812897131" CI_START="1.2006076784275854" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5152359717577109" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.2815594273592995" LOG_CI_START="0.0794011165378182" LOG_EFFECT_SIZE="0.18048027194855887" METHOD="MH" NO="3" P_CHI2="0.5420144410935464" P_Q="0.0" P_Z="4.6598756150123544E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="205" TOTAL_2="202" WEIGHT="100.0" Z="3.4995823966054056">
<NAME>Lequesne Index</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9062887840018614" CI_START="1.0798999351472292" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" LOG_CI_END="0.2801886926287751" LOG_CI_START="0.03338351509181402" LOG_EFFECT_SIZE="0.15678610386029457" ORDER="8857" O_E="0.0" SE="0.14497458299054317" STUDY_ID="STD-Noack-1994" TOTAL_1="126" TOTAL_2="126" VAR="0.021017629713281888" WEIGHT="66.23931623931624"/>
<DICH_DATA CI_END="2.508030192447947" CI_START="1.1161037112332381" EFFECT_SIZE="1.6730875068794717" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="23" LOG_CI_END="0.3993327603622724" LOG_CI_START="0.04770455223916652" LOG_EFFECT_SIZE="0.22351865630071946" ORDER="8858" O_E="0.0" SE="0.20654815003921445" STUDY_ID="STD-Reichelt-1994" TOTAL_1="79" TOTAL_2="76" VAR="0.04266213828462184" WEIGHT="33.76068376068376"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.7427689261233255" CI_END="0.031129352907401896" CI_START="-0.1436319858238589" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.0562513164582285" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-06-21 09:22:32 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8561306493954493" P_Q="1.0" P_Z="0.20704704412311548" Q="0.0" RANDOM="NO" SCALE="1.0388418732929412" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1010" TOTAL_2="1007" UNITS="" WEIGHT="100.0" Z="1.2617270517780919">
<NAME>WOMAC Pain Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33598585567694017" CI_START="-0.33426480199530306" EFFECT_SIZE="8.605268408185565E-4" ESTIMABLE="YES" MEAN_1="129.72" MEAN_2="129.62" ORDER="8859" SD_1="113.23" SD_2="118.02" SE="0.170985452528489" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="6.7985489397213055"/>
<CONT_DATA CI_END="0.1413518156593127" CI_START="-0.17100613591755937" EFFECT_SIZE="-0.014827160129123324" ESTIMABLE="YES" MEAN_1="149.3" MEAN_2="151.0" ORDER="8867" SD_1="115.9" SD_2="113.1" SE="0.07968461513596978" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="31.302973503041112"/>
<CONT_DATA CI_END="-0.025379230972806865" CI_START="-0.5694445904166039" EFFECT_SIZE="-0.29741191069470535" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="6.0" ORDER="8866" SD_1="3.03" SD_2="3.0" SE="0.13879473391738703" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="10.317834920748345"/>
<CONT_DATA CI_END="0.2735347817391287" CI_START="-0.5218541742172914" EFFECT_SIZE="-0.12415969623908137" ESTIMABLE="YES" MEAN_1="7.14" MEAN_2="7.65" ORDER="8860" SD_1="4.01" SD_2="4.13" SE="0.2029090744091082" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="4.827603715140473"/>
<CONT_DATA CI_END="0.47616054074363307" CI_START="-0.4115892476304209" EFFECT_SIZE="0.03228564655660611" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.35" ORDER="8861" SD_1="4.81" SD_2="4.38" SE="0.22647094420522798" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="3.875337857419288"/>
<CONT_DATA CI_END="0.3265229057260645" CI_START="-0.22119178870229833" EFFECT_SIZE="0.0526655585118831" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.6" ORDER="8862" SD_1="3.3" SD_2="4.2" SE="0.13972570382636273" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" WEIGHT="10.180800813052707"/>
<CONT_DATA CI_END="0.14905859627306614" CI_START="-0.4031188395109486" EFFECT_SIZE="-0.12703012161894126" ESTIMABLE="YES" MEAN_1="4.61" MEAN_2="5.03" ORDER="8863" SD_1="3.45" SD_2="3.13" SE="0.14086417917357663" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="10.01690176112278"/>
<CONT_DATA CI_END="0.19112506963873596" CI_START="-0.3475281057110372" EFFECT_SIZE="-0.07820151803615064" ESTIMABLE="YES" MEAN_1="156.1" MEAN_2="164.2" ORDER="8864" SD_1="101.9" SD_2="104.5" SE="0.13741404933932477" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="10.526215988221104"/>
<CONT_DATA CI_END="0.25039912046134666" CI_START="-0.2757829511563314" EFFECT_SIZE="-0.012691915347492342" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="32.3" ORDER="8868" SD_1="24.1" SD_2="23.0" SE="0.13423258686591566" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="11.031095205647157"/>
<CONT_DATA CI_END="0.8919460976094586" CI_START="-0.7574158044584813" EFFECT_SIZE="0.06726514657548861" ESTIMABLE="YES" MEAN_1="-74.7" MEAN_2="-76.5" ORDER="8865" SD_1="26.3" SD_2="25.1" SE="0.42076331888695306" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.1226872958857437"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.969772309548826" CI_END="0.08435929417856954" CI_START="-0.1262223277711748" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.020931516796302632" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.5476959352739865" P_Q="1.0" P_Z="0.696806229929126" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="697" TOTAL_2="693" UNITS="" WEIGHT="100.0" Z="0.38963532223471115">
<NAME>WOMAC Stiffness Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3776063617435915" CI_START="-0.2927218500065695" EFFECT_SIZE="0.042442255868511" ESTIMABLE="YES" MEAN_1="56.06" MEAN_2="54.0" ORDER="8869" SD_1="47.46" SD_2="49.12" SE="0.17100523709558552" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="9.86883612410344"/>
<CONT_DATA CI_END="0.15815314409059308" CI_START="-0.15420056557471631" EFFECT_SIZE="0.001976289257938382" ESTIMABLE="YES" MEAN_1="70.6" MEAN_2="70.5" ORDER="8875" SD_1="52.2" SD_2="48.8" SE="0.07968353299578859" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="45.45143468640151"/>
<CONT_DATA CI_END="0.20903068268109531" CI_START="-0.5874038205963175" EFFECT_SIZE="-0.1891865689576111" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="3.73" ORDER="8870" SD_1="1.81" SD_2="1.76" SE="0.2031758005656192" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="6.99102411365993"/>
<CONT_DATA CI_END="0.6558465238866641" CI_START="-0.23443281263685908" EFFECT_SIZE="0.21070685562490252" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="3.15" ORDER="8871" SD_1="2.34" SD_2="1.64" SE="0.22711624895812704" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="5.594848691580173"/>
<CONT_DATA CI_END="0.05755394023802565" CI_START="-0.49574164927754905" EFFECT_SIZE="-0.21909385451976168" ESTIMABLE="YES" MEAN_1="1.94" MEAN_2="2.26" ORDER="8872" SD_1="1.47" SD_2="1.44" SE="0.14114942771395284" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="14.48526737941484"/>
<CONT_DATA CI_END="0.2671449964096006" CI_START="-0.2590322329719757" EFFECT_SIZE="0.004056381718812432" ESTIMABLE="YES" MEAN_1="38.2" MEAN_2="38.1" ORDER="8874" SD_1="25.5" SD_2="23.6" SE="0.1342313515789053" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="16.016839850741036"/>
<CONT_DATA CI_END="1.2432622893539196" CI_START="-0.4258407675429788" EFFECT_SIZE="0.40871076090547037" ESTIMABLE="YES" MEAN_1="-59.6" MEAN_2="-70.0" ORDER="8873" SD_1="27.1" SD_2="20.6" SE="0.42579942031143686" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.5917491540990738"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.684191421139586" CI_END="0.00393818070007429" CI_START="-0.17088715653665631" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08347448791829101" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2008-06-28 13:52:06 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.771062318254903" P_Q="1.0" P_Z="0.06125334859902103" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1010" TOTAL_2="1007" UNITS="" WEIGHT="100.0" Z="1.871662226239374">
<NAME>WOMAC Function Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33842518385221926" CI_START="-0.33182591089201435" EFFECT_SIZE="0.003299636480102473" ESTIMABLE="YES" MEAN_1="419.85" MEAN_2="418.64" ORDER="8876" SD_1="362.09" SD_2="367.42" SE="0.17098556402849457" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="6.8035203057816815"/>
<CONT_DATA CI_END="0.1339257918203895" CI_START="-0.17843757120947712" EFFECT_SIZE="-0.022255889694543826" ESTIMABLE="YES" MEAN_1="531.8" MEAN_2="540.3" ORDER="8883" SD_1="388.6" SD_2="374.1" SE="0.07968599563403944" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="31.32481893773729"/>
<CONT_DATA CI_END="-0.004297077451081155" CI_START="-0.547943853896361" EFFECT_SIZE="-0.27612046567372106" ESTIMABLE="YES" MEAN_1="18.57" MEAN_2="21.66" ORDER="8884" SD_1="11.4" SD_2="10.89" SE="0.13868795057804537" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="10.34129946971749"/>
<CONT_DATA CI_END="0.3153553387407999" CI_START="-0.47958818796505254" EFFECT_SIZE="-0.0821164246121263" ESTIMABLE="YES" MEAN_1="25.98" MEAN_2="27.17" ORDER="8877" SD_1="14.7" SD_2="14.1" SE="0.20279544241023445" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="4.836555714061979"/>
<CONT_DATA CI_END="0.6339480734630959" CI_START="-0.2558269500752697" EFFECT_SIZE="0.18906056169391308" ESTIMABLE="YES" MEAN_1="26.6" MEAN_2="23.32" ORDER="8878" SD_1="19.1" SD_2="15.01" SE="0.2269875953223624" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="3.8605424114129923"/>
<CONT_DATA CI_END="0.10876638338596237" CI_START="-0.4398065756328786" EFFECT_SIZE="-0.1655200961234581" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="27.0" MODIFIED="2008-06-28 13:52:06 -0400" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="11.2" SD_2="12.8" SE="0.13994465289819466" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" WEIGHT="10.156403754854736"/>
<CONT_DATA CI_END="0.06907668281992704" CI_START="-0.4840452767520258" EFFECT_SIZE="-0.2074842969660494" ESTIMABLE="YES" MEAN_1="16.04" MEAN_2="18.3" ORDER="8879" SD_1="10.67" SD_2="11.03" SE="0.14110513354707235" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="9.990033572847908"/>
<CONT_DATA CI_END="0.18576265371240305" CI_START="-0.3529203396313505" EFFECT_SIZE="-0.08357884295947374" ESTIMABLE="YES" MEAN_1="580.1" MEAN_2="610.8" ORDER="8880" SD_1="364.2" SD_2="367.8" SE="0.13742165611021842" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="10.532760761885905"/>
<CONT_DATA CI_END="0.2004824002965484" CI_START="-0.3258257634372189" EFFECT_SIZE="-0.06267168157033527" ESTIMABLE="YES" MEAN_1="32.6" MEAN_2="34.1" ORDER="8882" SD_1="24.2" SD_2="23.5" SE="0.1342647538131361" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="11.033887108503553"/>
<CONT_DATA CI_END="0.9827429621021682" CI_START="-0.6690699715486685" EFFECT_SIZE="0.15683649527674978" ESTIMABLE="YES" MEAN_1="-73.0" MEAN_2="-77.0" ORDER="8881" SD_1="26.9" SD_2="21.1" SE="0.4213885935354237" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.1201779631964641"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8886532247207573" CI_END="-0.048427282683795536" CI_START="-0.31336933045919135" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18089830657149344" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.71714742925247" P_Q="1.0" P_Z="0.007440315749301141" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="442" TOTAL_2="440" UNITS="" WEIGHT="99.99999999999999" Z="2.676465806174981">
<NAME>WOMAC Total</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3415703569959785" CI_START="-0.328682057498898" EFFECT_SIZE="0.006444149748540228" ESTIMABLE="YES" MEAN_1="605.62" MEAN_2="602.26" ORDER="8885" SD_1="506.58" SD_2="531.04" SE="0.17098590070576347" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="15.625179067410008"/>
<CONT_DATA CI_END="-0.014859082831001957" CI_START="-0.5587116836150114" EFFECT_SIZE="-0.2867853832230067" ESTIMABLE="YES" MEAN_1="25.43" MEAN_2="29.67" ORDER="8890" SD_1="15.17" SD_2="14.27" SE="0.1387404577517366" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="23.732274226098735"/>
<CONT_DATA CI_END="0.29523963965479566" CI_START="-0.4998953855137384" EFFECT_SIZE="-0.10232787292947138" ESTIMABLE="YES" MEAN_1="36.57" MEAN_2="38.57" ORDER="8886" SD_1="19.5" SD_2="19.3" SE="0.20284429495655473" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="11.102480240246152"/>
<CONT_DATA CI_END="0.07745917968020843" CI_START="-0.475542416545942" EFFECT_SIZE="-0.19904161843286677" ESTIMABLE="YES" MEAN_1="22.7" MEAN_2="25.58" ORDER="8887" SD_1="14.4" SD_2="14.43" SE="0.14107442804769793" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="22.95350478621158"/>
<CONT_DATA CI_END="0.016525757749216885" CI_START="-0.5241219850659682" EFFECT_SIZE="-0.2537981136583756" ESTIMABLE="YES" MEAN_1="909.7" MEAN_2="1031.79" ORDER="8888" SD_1="473.8" SD_2="484.8" SE="0.1379228769201234" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="24.014469054866503"/>
<CONT_DATA CI_END="0.9874088709655348" CI_START="-0.6645817854026289" EFFECT_SIZE="0.1614135427814529" ESTIMABLE="YES" MEAN_1="-72.2" MEAN_2="-76.3" ORDER="8889" SD_1="26.5" SD_2="21.5" SE="0.4214339317964144" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="2.572092625167008"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.33695828117776017" CI_START="-0.20164217871487278" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.06765805123144371" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6224263379498252" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="106" UNITS="" WEIGHT="100.0" Z="0.49241452079053216">
<NAME>Mean Joint Space Width</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33695828117776017" CI_START="-0.20164217871487278" EFFECT_SIZE="0.06765805123144371" ESTIMABLE="YES" MEAN_1="5.17" MEAN_2="5.08" ORDER="8891" SD_1="1.36" SD_2="1.29" SE="0.13740060127151432" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0917048220424865" CI_END="0.5831721682397236" CI_START="0.04980062397233642" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.31648639610603" ESTIMABLE="YES" I2="8.400148116128555" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2008-08-02 23:07:54 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.29609425427876135" P_Q="1.0" P_Z="0.020020384711846088" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="207" UNITS="" WEIGHT="100.0" Z="2.3259656223944702">
<NAME>Minimum Joint Space Width</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9107859601239089" CI_START="0.06921403987609154" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="3.93" MEAN_2="3.44" ORDER="8892" SD_1="1.48" SD_2="1.57" SE="0.214690659340179" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="40.16772279518269"/>
<CONT_DATA CI_END="0.5447720730804566" CI_START="-0.1447720730804563" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.75" MEAN_2="3.55" ORDER="8893" SD_1="1.32" SD_2="1.24" SE="0.1759073512574591" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="59.832277204817316"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.974842722953825" CI_START="-2.7748427229538217" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2008-08-02 15:10:13 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.5779378132750408" Q="0.0" RANDOM="NO" SCALE="11.77" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="317" TOTAL_2="313" UNITS="" WEIGHT="100.0" Z="0.5563994559630944">
<NAME>Patient global assessment of disease status score (0-100mm scale)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.974842722953825" CI_START="-2.7748427229538217" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="35.1" MEAN_2="34.0" MODIFIED="2008-08-02 12:29:02 -0400" MODIFIED_BY="[Empty name]" ORDER="248" SD_1="25.7" SD_2="23.9" SE="1.9769969007176091" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8161298982006477" CI_START="0.8020347487295693" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.206896551724138" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.25914690809156504" LOG_CI_START="-0.09580681518892598" LOG_EFFECT_SIZE="0.08167004645131953" METHOD="MH" MODIFIED="2008-08-04 22:58:18 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="0.0" P_Z="0.3670981233052987" Q="0.0" RANDOM="NO" SCALE="5.12" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="60" WEIGHT="99.99999999999999" Z="0.9019223586721414">
<NAME>Patient global assessment - number responding they are better than at start of trial</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8161298982006477" CI_START="0.8020347487295693" EFFECT_SIZE="1.206896551724138" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.25914690809156504" LOG_CI_START="-0.09580681518892598" LOG_EFFECT_SIZE="0.08167004645131953" MODIFIED="2008-08-02 12:35:12 -0400" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.208501574104228" STUDY_ID="STD-Houpt-1999" TOTAL_1="58" TOTAL_2="60" VAR="0.043472906403940886" WEIGHT="99.99999999999999">
<FOOTNOTE>data presented only in abstract; not presented in main text</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.376598050400801" CI_START="-2.776598050400807" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2008-08-02 15:10:59 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.6610982521138558" Q="0.0" RANDOM="NO" SCALE="10.85" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="317" TOTAL_2="313" UNITS="" WEIGHT="99.99999999999999" Z="0.4383973724574184">
<NAME>Physician global assessment of disease status score (0-100)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.376598050400801" CI_START="-2.776598050400807" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="37.9" MEAN_2="37.1" MODIFIED="2008-08-02 13:48:57 -0400" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="23.3" SD_2="22.5" SE="1.8248284553249718" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.4105287293070194" CI_END="3.4273907037326197" CI_START="1.4864642866664175" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.257142857142857" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="17" I2="77.32698138082144" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.5349636144396266" LOG_CI_START="0.1721544794407048" LOG_EFFECT_SIZE="0.35355904694016577" METHOD="MH" MODIFIED="2008-08-04 22:58:00 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.03571780552057602" P_Q="0.0" P_Z="1.3345897989874663E-4" Q="0.0" RANDOM="NO" SCALE="478.14" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0" Z="3.819986497380175">
<NAME>Physician global assessment of good or excellent response</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.564988984528581" CI_START="1.1345212863013368" EFFECT_SIZE="1.7058823529411764" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="17" LOG_CI_END="0.40908550435281543" LOG_CI_START="0.05481264868854895" LOG_EFFECT_SIZE="0.23194907652068217" MODIFIED="2008-08-02 15:00:22 -0400" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.20810162909610863" STUDY_ID="STD-Drovanti-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.043306288032454364" WEIGHT="97.14285714285714"/>
<DICH_DATA CI_END="315.97733864967614" CI_START="1.3956697081018732" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.4996559368832627" LOG_CI_START="0.14478265258457593" LOG_EFFECT_SIZE="1.3222192947339193" MODIFIED="2008-08-02 15:00:44 -0400" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="1.3832642240078046" STUDY_ID="STD-Pujalte-1980" TOTAL_1="10" TOTAL_2="10" VAR="1.9134199134199137" WEIGHT="2.857142857142857"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.354314898039456" CI_END="1.8314937269247116" CI_START="0.8269611301383074" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.230680349342948" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="213" I2="68.52532441196651" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.2628054354948864" LOG_CI_START="-0.08251490322033044" LOG_EFFECT_SIZE="0.09014526613727802" METHOD="MH" MODIFIED="2008-08-02 15:05:31 -0400" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.04170408128587588" P_Q="0.0" P_Z="0.3061706270098441" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08227274605066473" TOTALS="YES" TOTAL_1="462" TOTAL_2="456" WEIGHT="100.0" Z="1.0232902913462671">
<NAME>Osteoarthritis Research Society International Responder Criteria (OARSI)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2142820181501957" CI_START="0.9341423029284855" EFFECT_SIZE="1.065040938574416" ESTIMABLE="YES" EVENTS_1="192" EVENTS_2="178" LOG_CI_END="0.08431956375933919" LOG_CI_START="-0.029586960312634032" LOG_EFFECT_SIZE="0.02736630172335258" ORDER="8897" O_E="0.0" SE="0.06690925608626484" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" VAR="0.004476848550017369" WEIGHT="47.42988444501452"/>
<DICH_DATA CI_END="2.9060078810565173" CI_START="1.20728937751316" EFFECT_SIZE="1.8730703259005146" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="22" LOG_CI_END="0.4632967877647267" LOG_CI_START="0.08181137945468193" LOG_EFFECT_SIZE="0.27255408360970435" ORDER="8896" O_E="0.0" SE="0.2240864172245469" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" VAR="0.05021472238453371" WEIGHT="31.05594284620724"/>
<DICH_DATA CI_END="1.762910592938614" CI_START="0.4833319450970192" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.24623028735433944" LOG_CI_START="-0.31575449987276333" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="8895" O_E="0.0" SE="0.33011264588676237" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" VAR="0.10897435897435898" WEIGHT="21.514172708778226"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.591352146910083" CI_END="1.0696884119972982" CI_START="0.9137471140430518" CI_STUDY="95" CI_TOTAL="95" DF="12.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9886479147744288" ESTIMABLE="YES" EVENTS_1="414" EVENTS_2="418" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.029257291089873218" LOG_CI_START="-0.03917398169718235" LOG_EFFECT_SIZE="-0.004958345303654557" METHOD="MH" MODIFIED="2008-08-02 15:05:31 -0400" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.6517620057859819" P_Q="0.0" P_Z="0.7763893837324378" Q="0.0" RANDOM="NO" SCALE="6.802910025159775" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1056" TOTAL_2="1061" WEIGHT="100.0" Z="0.2840273992365237">
<NAME>Toxicity (Number of Patients Reporting Adverse Events)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8898" O_E="0.0" SE="0.0" STUDY_ID="STD-Crolle-1980" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8899" O_E="0.0" SE="0.0" STUDY_ID="STD-D_x0027_ambrosio-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8004229497035906" CI_START="0.18136328038845295" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2553745401840746" LOG_CI_START="-0.7414506375566636" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="8900" O_E="0.0" SE="0.5855400437691198" STUDY_ID="STD-Drovanti-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.3428571428571428" WEIGHT="1.671050978302702"/>
<DICH_DATA CI_END="1.1598358597729008" CI_START="0.9456395185989614" EFFECT_SIZE="1.0472758108967564" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="89" LOG_CI_END="0.06439653212450654" LOG_CI_START="-0.02427438676861643" LOG_EFFECT_SIZE="0.020061072677945074" ORDER="8913" O_E="0.0" SE="0.052085736685947896" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" VAR="0.0027129239661178983" WEIGHT="21.44856452967033"/>
<DICH_DATA CI_END="2.835502014913078" CI_START="0.37041296236305254" EFFECT_SIZE="1.0248447204968945" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4526299602326048" LOG_CI_START="-0.4313138238684917" LOG_EFFECT_SIZE="0.010658068182056593" ORDER="8901" O_E="0.0" SE="0.519232954373284" STUDY_ID="STD-Houpt-1999" TOTAL_1="46" TOTAL_2="55" VAR="0.26960286090720875" WEIGHT="1.5221454455826593"/>
<DICH_DATA CI_END="1.2780234658865646" CI_START="0.6708318299203118" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.10653882800977382" LOG_CI_START="-0.17338633898367323" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="8902" O_E="0.0" SE="0.16442942874387492" STUDY_ID="STD-Hughes-2002" TOTAL_1="40" TOTAL_2="40" VAR="0.02703703703703704" WEIGHT="6.445482344881851"/>
<DICH_DATA CI_END="2.5170953163931076" CI_START="0.6963269568793174" EFFECT_SIZE="1.3239038189533239" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.40089966155542645" LOG_CI_START="-0.15718679167301483" LOG_EFFECT_SIZE="0.12185643494120581" ORDER="8903" O_E="0.0" SE="0.32782274519888405" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" VAR="0.10746775226973246" WEIGHT="3.293193147484349"/>
<DICH_DATA CI_END="1.4331769963601397" CI_START="0.26423688477686735" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.15629982877537973" LOG_CI_START="-0.578006559405166" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="8904" O_E="0.0" SE="0.43133520729249664" STUDY_ID="STD-Noack-1994" TOTAL_1="126" TOTAL_2="126" VAR="0.18605006105006106" WEIGHT="3.1033803882764466"/>
<DICH_DATA CI_END="1.2601345086492501" CI_START="0.84315221891628" EFFECT_SIZE="1.0307692307692307" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="65" LOG_CI_END="0.10041690483684977" LOG_CI_START="-0.07409401272090814" LOG_EFFECT_SIZE="0.013161446057970814" ORDER="8905" O_E="0.0" SE="0.10250857681640078" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.010508008320923941" WEIGHT="15.516901941382233"/>
<DICH_DATA CI_END="7.450631558527997" CI_START="0.014912978884848133" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8721930876152056" LOG_CI_START="-1.8264355970545303" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="8906" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Pujalte-1980" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="0.3580823524934362"/>
<DICH_DATA CI_END="1.0820691576110115" CI_START="0.9429194459804258" EFFECT_SIZE="1.0101010101010102" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="99" LOG_CI_END="0.03425501844987295" LOG_CI_START="-0.025525407644972742" LOG_EFFECT_SIZE="0.0043648054024501125" ORDER="8907" O_E="0.0" SE="0.035115318205994034" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" VAR="0.001233085572708216" WEIGHT="23.633435264566785"/>
<DICH_DATA CI_END="2.0717596713813364" CI_START="0.2279174387028158" EFFECT_SIZE="0.6871609403254972" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.31633937489246905" LOG_CI_START="-0.6422224442682454" LOG_EFFECT_SIZE="-0.1629415346878881" ORDER="8908" O_E="0.0" SE="0.5630639575325342" STUDY_ID="STD-Reichelt-1994" TOTAL_1="79" TOTAL_2="76" VAR="0.3170410202721995" WEIGHT="1.7033939004633996"/>
<DICH_DATA CI_END="2.951030912228773" CI_START="0.8093543656790259" EFFECT_SIZE="1.5454545454545454" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4699737587849697" LOG_CI_START="-0.091861286344872" LOG_EFFECT_SIZE="0.18905623622004886" ORDER="8909" O_E="0.0" SE="0.3300246866375959" STUDY_ID="STD-Rindone-2000" TOTAL_1="49" TOTAL_2="49" VAR="0.10891629379024337" WEIGHT="2.6259372516185318"/>
<DICH_DATA CI_END="1.1803554478377696" CI_START="0.3210478376262237" EFFECT_SIZE="0.6155896069287142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.0720128088223598" LOG_CI_START="-0.49343025086868725" LOG_EFFECT_SIZE="-0.21070872102316365" ORDER="8910" O_E="0.0" SE="0.332144052250808" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" VAR="0.11031967144558748" WEIGHT="4.593859923868783"/>
<DICH_DATA CI_END="1.24244959489752" CI_START="0.7512195977617199" EFFECT_SIZE="0.9661016949152542" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="59" LOG_CI_END="0.09427877881228859" LOG_CI_START="-0.12423309075159425" LOG_EFFECT_SIZE="-0.0149771559696528" ORDER="8912" O_E="0.0" SE="0.12835495383302378" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" VAR="0.01647499417347767" WEIGHT="14.084572531408488"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8911" O_E="0.0" SE="0.0" STUDY_ID="STD-Vajaradul-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.361587065244278" CI_END="1.054455200110623" CI_START="0.5513401131804033" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.762471933498313" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="75" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.02302813290617911" LOG_CI_START="-0.2585804089371129" LOG_EFFECT_SIZE="-0.11777613801546691" METHOD="MH" MODIFIED="2008-08-02 15:05:30 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.6805938637066462" P_Q="0.0" P_Z="0.10112633515994457" Q="0.0" RANDOM="NO" SCALE="328.31" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1488" TOTAL_2="1482" WEIGHT="100.0" Z="1.6394175207724258">
<NAME>Toxicity (Number of Withdrawals due to Adverse Events)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8914" O_E="0.0" SE="0.0" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9224773191479056" CI_START="0.33947560767879126" EFFECT_SIZE="0.8078577573845712" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2838612248183248" LOG_CI_START="-0.46919142559873117" LOG_EFFECT_SIZE="-0.09266510039020319" ORDER="8933" O_E="0.0" SE="0.44234685452571737" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" VAR="0.19567073970879617" WEIGHT="14.343228626474605"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8915" O_E="0.0" SE="0.0" STUDY_ID="STD-Crolle-1980" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8916" O_E="0.0" SE="0.0" STUDY_ID="STD-D_x0027_ambrosio-1981" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8917" O_E="0.0" SE="0.0" STUDY_ID="STD-Drovanti-1980" TOTAL_1="40" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3720789033585192" CI_START="0.13858327648875676" EFFECT_SIZE="0.4360587002096436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.1373790868138049" LOG_CI_START="-0.8582891749685096" LOG_EFFECT_SIZE="-0.3604550440773524" ORDER="8932" O_E="0.0" SE="0.5848604656083154" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" VAR="0.3420617642315755" WEIGHT="11.772388967298628"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8918" O_E="0.0" SE="0.0" STUDY_ID="STD-Houpt-1999" TOTAL_1="46" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="8919" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Hughes-2002" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="1.9435547823370378"/>
<DICH_DATA CI_END="3.245291462684915" CI_START="0.0363017627651204" EFFECT_SIZE="0.3432343234323432" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5112537072847412" LOG_CI_START="-1.4400722856917907" LOG_EFFECT_SIZE="-0.46440928920352464" ORDER="8920" O_E="0.0" SE="1.146218547493862" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" VAR="1.3138169586189388" WEIGHT="3.830225034459333"/>
<DICH_DATA CI_END="1.8584084605221154" CI_START="0.21019329619832597" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.26914117394979037" LOG_CI_START="-0.6773811392616399" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="8921" O_E="0.0" SE="0.555991892141409" STUDY_ID="STD-Noack-1994" TOTAL_1="126" TOTAL_2="126" VAR="0.30912698412698414" WEIGHT="10.365625505797535"/>
<DICH_DATA CI_END="1.9439002242181143" CI_START="0.3292350049794475" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.28867396985797816" LOG_CI_START="-0.482493995874091" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="8922" O_E="0.0" SE="0.45298788041401306" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.20519801980198019" WEIGHT="12.95703188224692"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8923" O_E="0.0" SE="0.0" STUDY_ID="STD-Pujalte-1980" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0610967112290663" CI_START="0.6603819722265521" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.3140983703176469" LOG_CI_START="-0.18020479105642043" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="8924" O_E="0.0" SE="0.2903561238312381" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" VAR="0.08430667864630129" WEIGHT="23.322657388044455"/>
<DICH_DATA CI_END="128.29201501010937" CI_START="0.3538326703062774" EFFECT_SIZE="6.7375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.108199626406373" LOG_CI_START="-0.4512020700167825" LOG_EFFECT_SIZE="0.8284987781947951" ORDER="8925" O_E="0.0" SE="1.5034052257216857" STUDY_ID="STD-Reichelt-1994" TOTAL_1="79" TOTAL_2="76" VAR="2.2602272727272723" WEIGHT="0.6602309239361487"/>
<DICH_DATA CI_END="2.6049100552711884" CI_START="0.09597260354310905" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41579273217535734" LOG_CI_START="-1.0178527235033197" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="8926" O_E="0.0" SE="0.842130437325114" STUDY_ID="STD-Rindone-2000" TOTAL_1="49" TOTAL_2="49" VAR="0.7091836734693877" WEIGHT="5.1828127528987675"/>
<DICH_DATA CI_END="1.9788309255635181" CI_START="0.00593083065334093" EFFECT_SIZE="0.10833333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2964086889857738" LOG_CI_START="-2.2268844764673497" LOG_EFFECT_SIZE="-0.965237893740788" ORDER="8927" O_E="0.0" SE="1.482194895889778" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" VAR="2.1969017094017094" WEIGHT="5.904470224821381"/>
<DICH_DATA CI_END="2.2979772578317963" CI_START="0.19340680719520686" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3613457263335411" LOG_CI_START="-0.7135282444449037" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2008-06-20 18:42:42 -0400" MODIFIED_BY="[Empty name]" ORDER="8931" O_E="0.0" SE="0.6313862911472251" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" VAR="0.3986486486486486" WEIGHT="7.774219129348151"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8928" O_E="0.0" SE="0.0" STUDY_ID="STD-Usha-2004" TOTAL_1="30" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8929" O_E="0.0" SE="0.0" STUDY_ID="STD-Vajaradul-1981" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.545522164113119" CI_START="0.014725436980300866" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8776892991343044" LOG_CI_START="-1.8319318085736291" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="8930" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Zenk-2002" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="1.9435547823370378"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-07 09:36:29 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Glucosamine versus NSAIDs (piroxicam, ibuprofen, celecoxib)</NAME>
<CONT_OUTCOME CHI2="18.436534503668362" CI_END="0.10685663247091853" CI_START="-0.654881841838161" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.27401260468362126" ESTIMABLE="YES" I2="83.72796145933455" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2008-06-21 09:27:54 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.5745679585053036E-4" P_Q="1.0" P_Z="0.15851703682830195" Q="0.0" RANDOM="YES" SCALE="1.85" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.11719511688572316" TOTALS="YES" TOTAL_1="501" TOTAL_2="496" UNITS="" WEIGHT="99.99999999999999" Z="1.4100766985074094">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.27681459065329267" CI_START="-0.034587859662293066" EFFECT_SIZE="0.1211133654954998" ESTIMABLE="YES" MEAN_1="149.3" MEAN_2="135.7" ORDER="8937" SD_1="115.9" SD_2="108.3" SE="0.07944086033516139" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="318" WEIGHT="30.57508472138426"/>
<CONT_DATA CI_END="0.10668871358002613" CI_START="-0.5000501119980119" EFFECT_SIZE="-0.19668069920899284" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="4.18" ORDER="8934" SD_1="3.09" SD_2="2.76" SE="0.15478315682428767" STUDY_ID="STD-Qiu-1998" TOTAL_1="87" TOTAL_2="81" WEIGHT="26.75258016264237"/>
<CONT_DATA CI_END="-0.2233682359157304" CI_START="-0.8628715898182521" EFFECT_SIZE="-0.5431199128669912" ESTIMABLE="YES" MEAN_1="24.3" MEAN_2="35.7" ORDER="8935" SD_1="19.3" SD_2="22.4" SE="0.16314160845475797" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" WEIGHT="26.25824002881479"/>
<CONT_DATA CI_END="-0.04711236071338243" CI_START="-1.364019061306454" EFFECT_SIZE="-0.7055657110099182" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.2" ORDER="8936" SD_1="0.5" SD_2="0.6" SE="0.3359517600784156" STUDY_ID="STD-Vaz-1982" TOTAL_1="18" TOTAL_2="20" WEIGHT="16.41409508715857"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.950472134141302" CI_END="0.35422618267484973" CI_START="-1.074886371725222" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.36033009452518616" ESTIMABLE="YES" I2="90.86797365675031" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="9.358072808373086E-4" P_Q="1.0" P_Z="0.32297969529900405" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.24158898964205286" TOTALS="YES" TOTAL_1="173" TOTAL_2="172" UNITS="" WEIGHT="100.0" Z="0.9883532345172753">
<NAME>Lequesne Index</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAID</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAID</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2851367949559636" CI_START="-0.2851367949559636" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="9.6" ORDER="8938" SD_1="5.8" SD_2="5.8" SE="0.1454806298508984" STUDY_ID="STD-Muller_x002d_FassBender-94" TOTAL_1="94" TOTAL_2="95" WEIGHT="50.58572922009525"/>
<CONT_DATA CI_END="-0.40480812555945644" CI_START="-1.0535968608467023" EFFECT_SIZE="-0.7292024932030794" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="7.9" ORDER="8939" SD_1="2.8" SD_2="3.7" SE="0.16551037172233996" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" WEIGHT="49.414270779904754"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.733334220141453" CI_END="0.4366114325025592" CI_START="0.19343702994591866" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2906145535649032" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="90" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.35990489664389524" LOG_CI_START="-0.7134603846388083" LOG_EFFECT_SIZE="-0.5366826406413518" METHOD="MH" NO="3" P_CHI2="0.4345922595123973" P_Q="0.0" P_Z="2.676696099295207E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="285" TOTAL_2="295" WEIGHT="100.00000000000003" Z="5.950288893832903">
<NAME>Toxicity (Number of Patients Reporting Adverse Events)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3854259876306153" CI_START="0.07473014197245664" EFFECT_SIZE="0.1697142857142857" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="35" LOG_CI_END="-0.4140590060685461" LOG_CI_START="-1.1265041926696182" LOG_EFFECT_SIZE="-0.7702815993690821" ORDER="8940" O_E="0.0" SE="0.41849382927002055" STUDY_ID="STD-Muller_x002d_FassBender-94" TOTAL_1="100" TOTAL_2="99" VAR="0.17513708513708512" WEIGHT="39.86922680493618"/>
<DICH_DATA CI_END="0.9712055092406736" CI_START="0.1373701822994412" EFFECT_SIZE="0.3652597402597403" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.01268886269176058" LOG_CI_START="-0.8621075254143652" LOG_EFFECT_SIZE="-0.43739819405306296" ORDER="8941" O_E="0.0" SE="0.4989527271734508" STUDY_ID="STD-Qiu-1998" TOTAL_1="88" TOTAL_2="90" VAR="0.248953823953824" WEIGHT="15.68966066984365"/>
<DICH_DATA CI_END="0.6464959630883521" CI_START="0.20367343742526983" EFFECT_SIZE="0.3628691983122363" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="36" LOG_CI_END="-0.18943418263807496" LOG_CI_START="-0.6910656068949974" LOG_EFFECT_SIZE="-0.4402498947665361" ORDER="8942" O_E="0.0" SE="0.2946607817241135" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="86" VAR="0.08682497628626565" WEIGHT="39.0722564945705"/>
<DICH_DATA CI_END="2.014168376699609" CI_START="0.0980706809235097" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.30409577307705765" LOG_CI_START="-1.0084608092997827" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="8943" O_E="0.0" SE="0.7710022337480251" STUDY_ID="STD-Vaz-1982" TOTAL_1="18" TOTAL_2="20" VAR="0.5944444444444443" WEIGHT="5.368856030649677"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.969155435199715" CI_END="1.4627089606145045" CI_START="0.018248762224931415" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.16337878695390867" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="41" I2="78.52411325855428" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.16515792190585107" LOG_CI_START="-1.738766587487641" LOG_EFFECT_SIZE="-0.7868043327908948" METHOD="MH" NO="4" P_CHI2="0.002947453439645753" P_Q="0.0" P_Z="0.10524823088468699" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="3.751839656280659" TOTALS="YES" TOTAL_1="602" TOTAL_2="613" WEIGHT="100.0" Z="1.619925735019263">
<NAME>Toxicity (Number of Withdrawals due to Adverse Events)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>NSAIDs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NSAIDs</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.420773532467418" CI_START="0.4862955899384585" EFFECT_SIZE="1.2897701667417756" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5341243232773338" LOG_CI_START="-0.3130996688938353" LOG_EFFECT_SIZE="0.11051232719174922" ORDER="8948" O_E="0.0" SE="0.4976635668277431" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="318" VAR="0.24766902574771155" WEIGHT="31.272889432844035"/>
<DICH_DATA CI_END="1.1284229374516657" CI_START="0.017725659548801297" EFFECT_SIZE="0.14142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.05247190547645329" LOG_CI_START="-1.7513975963098671" LOG_EFFECT_SIZE="-0.8494628454167069" ORDER="8944" O_E="0.0" SE="1.0596018746473284" STUDY_ID="STD-Muller_x002d_FassBender-94" TOTAL_1="100" TOTAL_2="99" VAR="1.1227561327561326" WEIGHT="25.658782432807165"/>
<DICH_DATA CI_END="0.9107818240453517" CI_START="0.0031796638868384582" EFFECT_SIZE="0.05381431105854524" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" LOG_CI_END="-0.040585644938286744" LOG_CI_START="-2.4976187856150096" LOG_EFFECT_SIZE="-1.2691022152766482" ORDER="8945" O_E="0.0" SE="1.4432734293437077" STUDY_ID="STD-Qiu-1998" TOTAL_1="88" TOTAL_2="90" VAR="2.083038191849546" WEIGHT="21.435957367788575"/>
<DICH_DATA CI_END="0.4797565607972412" CI_START="0.001800670130595176" EFFECT_SIZE="0.029391891891891894" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="18" LOG_CI_END="-0.3189790774605345" LOG_CI_START="-2.7445658394201056" LOG_EFFECT_SIZE="-1.53177245844032" ORDER="8946" O_E="0.0" SE="1.4248016708231677" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="86" VAR="2.0300598011804905" WEIGHT="21.63237076656023"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8947" O_E="0.0" SE="0.0" STUDY_ID="STD-Vaz-1982" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-08-17 22:58:44 -0400" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Glucosamine versus placebo (adequate allocation concealment)</NAME>
<CONT_OUTCOME CHI2="48.062192110136266" CI_END="0.03808432365600914" CI_START="-0.3597718302192636" CI_STUDY="95" CI_TOTAL="95" DF="10.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.16084375328162723" ESTIMABLE="YES" I2="79.19362484115449" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2008-08-17 22:58:44 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="6.046515171886924E-7" P_Q="1.0" P_Z="0.11302692458176389" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0831566819286172" TOTALS="YES" TOTAL_1="1089" TOTAL_2="1084" UNITS="" WEIGHT="99.99999999999997" Z="1.5847333791351397">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33598585567694017" CI_START="-0.33426480199530306" EFFECT_SIZE="8.605268408185565E-4" ESTIMABLE="YES" MEAN_1="129.72" MEAN_2="129.62" ORDER="8949" SD_1="113.23" SD_2="118.02" SE="0.170985452528489" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="9.165535744848192"/>
<CONT_DATA CI_END="0.1413518156593127" CI_START="-0.17100613591755937" EFFECT_SIZE="-0.014827160129123324" ESTIMABLE="YES" MEAN_1="149.3" MEAN_2="151.0" ORDER="8958" SD_1="115.9" SD_2="113.1" SE="0.07968461513596978" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="11.509124436048335"/>
<CONT_DATA CI_END="-0.025379230972806865" CI_START="-0.5694445904166039" EFFECT_SIZE="-0.29741191069470535" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="6.0" ORDER="8957" SD_1="3.03" SD_2="3.0" SE="0.13879473391738703" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="10.057925536453812"/>
<CONT_DATA CI_END="0.2735347817391287" CI_START="-0.5218541742172914" EFFECT_SIZE="-0.12415969623908137" ESTIMABLE="YES" MEAN_1="7.14" MEAN_2="7.65" ORDER="8950" SD_1="4.01" SD_2="4.13" SE="0.2029090744091082" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="8.28560707300543"/>
<CONT_DATA CI_END="0.47616054074363307" CI_START="-0.4115892476304209" EFFECT_SIZE="0.03228564655660611" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.35" ORDER="8951" SD_1="4.81" SD_2="4.38" SE="0.22647094420522798" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="7.662118107423795"/>
<CONT_DATA CI_END="0.3265229057260645" CI_START="-0.22119178870229833" EFFECT_SIZE="0.0526655585118831" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.6" ORDER="8952" SD_1="3.3" SD_2="4.2" SE="0.13972570382636273" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" WEIGHT="10.032526604036812"/>
<CONT_DATA CI_END="0.14905859627306614" CI_START="-0.4031188395109486" EFFECT_SIZE="-0.12703012161894126" ESTIMABLE="YES" MEAN_1="4.61" MEAN_2="5.03" ORDER="8953" SD_1="3.45" SD_2="3.13" SE="0.14086417917357663" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="10.001411499201435"/>
<CONT_DATA CI_END="0.19112506963873596" CI_START="-0.3475281057110372" EFFECT_SIZE="-0.07820151803615064" ESTIMABLE="YES" MEAN_1="156.1" MEAN_2="164.2" MODIFIED="2008-08-17 22:58:41 -0400" MODIFIED_BY="[Empty name]" ORDER="8954" SD_1="101.9" SD_2="104.5" SE="0.13741404933932477" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="10.095515585445423"/>
<CONT_DATA CI_END="-0.8936109932290024" CI_START="-1.5801671348656527" EFFECT_SIZE="-1.2368890640473276" ESTIMABLE="YES" MEAN_1="24.3" MEAN_2="50.0" MODIFIED="2008-08-17 22:58:44 -0400" MODIFIED_BY="[Empty name]" ORDER="8955" SD_1="19.3" SD_2="22.0" SE="0.17514509119864383" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" WEIGHT="9.049608057897718"/>
<CONT_DATA CI_END="0.29352599391686374" CI_START="-0.23268166989018768" EFFECT_SIZE="0.03042216201333804" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="34.4" ORDER="8959" SD_1="26.8" SD_2="25.6" SE="0.1342391156056209" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="10.18157470601448"/>
<CONT_DATA CI_END="0.8919460976094586" CI_START="-0.7574158044584813" EFFECT_SIZE="0.06726514657548861" ESTIMABLE="YES" MEAN_1="-74.7" MEAN_2="-76.5" ORDER="8956" SD_1="26.3" SD_2="25.1" SE="0.42076331888695306" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="3.9590526496245393"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="26.52125825574295" CI_END="-0.11557904726325119" CI_START="-0.9610844221300128" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.538331734696632" ESTIMABLE="YES" I2="88.68831949422922" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="7.417498981809878E-6" P_Q="1.0" P_Z="0.012566953616410867" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.164455134957202" TOTALS="YES" TOTAL_1="406" TOTAL_2="403" UNITS="" WEIGHT="100.0" Z="2.4958110098510944">
<NAME>Lequesne Index</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07336516615764449" CI_START="-0.6184990662542025" EFFECT_SIZE="-0.3459321162059235" ESTIMABLE="YES" MEAN_1="7.97" MEAN_2="8.96" ORDER="8963" SD_1="3.07" SD_2="2.61" SE="0.1390673258275419" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="25.3129767164394"/>
<CONT_DATA CI_END="0.0529036046255113" CI_START="-0.4533952767244798" EFFECT_SIZE="-0.20024583604948426" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="8.4" ORDER="8960" SD_1="5.5" SD_2="4.4" SE="0.12916025124533206" STUDY_ID="STD-Noack-1994" TOTAL_1="120" TOTAL_2="121" WEIGHT="25.684326945509326"/>
<CONT_DATA CI_END="-0.100983159917506" CI_START="-0.6576293058659679" EFFECT_SIZE="-0.3793062328917369" ESTIMABLE="YES" MEAN_1="7.25" MEAN_2="8.12" ORDER="8961" SD_1="2.3" SD_2="2.27" SE="0.14200417720407507" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="25.199798589487997"/>
<CONT_DATA CI_END="-0.931017954189491" CI_START="-1.6211907720212866" EFFECT_SIZE="-1.2761043631053888" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="9.7" ORDER="8962" SD_1="2.8" SD_2="3.7" SE="0.17606772963069495" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" WEIGHT="23.802897748563275"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9062887840018614" CI_START="1.0798999351472292" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.2801886926287751" LOG_CI_START="0.03338351509181402" LOG_EFFECT_SIZE="0.15678610386029457" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.012767707934543961" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="126" TOTAL_2="126" WEIGHT="100.0" Z="2.4901837142092678">
<NAME>Lequesne Index</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9062887840018614" CI_START="1.0798999351472292" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" LOG_CI_END="0.2801886926287751" LOG_CI_START="0.03338351509181402" LOG_EFFECT_SIZE="0.15678610386029457" ORDER="8964" O_E="0.0" SE="0.14497458299054317" STUDY_ID="STD-Noack-1994" TOTAL_1="126" TOTAL_2="126" VAR="0.021017629713281888" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.742768926123325" CI_END="0.031129352907401896" CI_START="-0.1436319858238589" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.0562513164582285" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.8561306493954493" P_Q="1.0" P_Z="0.20704704412311548" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1010" TOTAL_2="1007" UNITS="" WEIGHT="100.0" Z="1.2617270517780919">
<NAME>WOMAC Pain Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33598585567694017" CI_START="-0.33426480199530306" EFFECT_SIZE="8.605268408185565E-4" ESTIMABLE="YES" MEAN_1="129.72" MEAN_2="129.62" ORDER="8965" SD_1="113.23" SD_2="118.02" SE="0.170985452528489" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="6.798548939721305"/>
<CONT_DATA CI_END="0.1413518156593127" CI_START="-0.17100613591755937" EFFECT_SIZE="-0.014827160129123324" ESTIMABLE="YES" MEAN_1="149.3" MEAN_2="151.0" ORDER="8974" SD_1="115.9" SD_2="113.1" SE="0.07968461513596978" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="31.30297350304111"/>
<CONT_DATA CI_END="-0.025379230972806865" CI_START="-0.5694445904166039" EFFECT_SIZE="-0.29741191069470535" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="6.0" ORDER="8972" SD_1="3.03" SD_2="3.0" SE="0.13879473391738703" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="10.317834920748345"/>
<CONT_DATA CI_END="0.2735347817391287" CI_START="-0.5218541742172914" EFFECT_SIZE="-0.12415969623908137" ESTIMABLE="YES" MEAN_1="7.14" MEAN_2="7.65" ORDER="8966" SD_1="4.01" SD_2="4.13" SE="0.2029090744091082" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="4.827603715140472"/>
<CONT_DATA CI_END="0.47616054074363307" CI_START="-0.4115892476304209" EFFECT_SIZE="0.03228564655660611" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.35" ORDER="8967" SD_1="4.81" SD_2="4.38" SE="0.22647094420522798" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="3.8753378574192876"/>
<CONT_DATA CI_END="0.3265229057260645" CI_START="-0.22119178870229833" EFFECT_SIZE="0.0526655585118831" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.6" ORDER="8968" SD_1="3.3" SD_2="4.2" SE="0.13972570382636273" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" WEIGHT="10.180800813052706"/>
<CONT_DATA CI_END="0.14905859627306614" CI_START="-0.4031188395109486" EFFECT_SIZE="-0.12703012161894126" ESTIMABLE="YES" MEAN_1="4.61" MEAN_2="5.03" ORDER="8969" SD_1="3.45" SD_2="3.13" SE="0.14086417917357663" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="10.016901761122778"/>
<CONT_DATA CI_END="0.19112506963873596" CI_START="-0.3475281057110372" EFFECT_SIZE="-0.07820151803615064" ESTIMABLE="YES" MEAN_1="156.1" MEAN_2="164.2" ORDER="8970" SD_1="101.9" SD_2="104.5" SE="0.13741404933932477" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="10.526215988221102"/>
<CONT_DATA CI_END="0.25039912046134666" CI_START="-0.2757829511563314" EFFECT_SIZE="-0.012691915347492342" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="32.3" ORDER="8973" SD_1="24.1" SD_2="23.0" SE="0.13423258686591566" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="11.031095205647155"/>
<CONT_DATA CI_END="0.8919460976094586" CI_START="-0.7574158044584813" EFFECT_SIZE="0.06726514657548861" ESTIMABLE="YES" MEAN_1="-74.7" MEAN_2="-76.5" ORDER="8971" SD_1="26.3" SD_2="25.1" SE="0.42076331888695306" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.1226872958857437"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.969772309548826" CI_END="0.08435929417856954" CI_START="-0.12622232777117479" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.02093151679630263" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.5476959352739865" P_Q="1.0" P_Z="0.696806229929126" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="697" TOTAL_2="693" UNITS="" WEIGHT="100.0" Z="0.3896353222347111">
<NAME>WOMAC Stiffness Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3776063617435915" CI_START="-0.2927218500065695" EFFECT_SIZE="0.042442255868511" ESTIMABLE="YES" MEAN_1="56.06" MEAN_2="54.0" ORDER="8975" SD_1="47.46" SD_2="49.12" SE="0.17100523709558552" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="9.86883612410344"/>
<CONT_DATA CI_END="0.15815314409059308" CI_START="-0.15420056557471631" EFFECT_SIZE="0.001976289257938382" ESTIMABLE="YES" MEAN_1="70.6" MEAN_2="70.5" ORDER="8980" SD_1="52.2" SD_2="48.8" SE="0.07968353299578859" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="45.45143468640151"/>
<CONT_DATA CI_END="0.20903068268109531" CI_START="-0.5874038205963175" EFFECT_SIZE="-0.1891865689576111" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="3.73" ORDER="8976" SD_1="1.81" SD_2="1.76" SE="0.2031758005656192" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="6.99102411365993"/>
<CONT_DATA CI_END="0.6558465238866641" CI_START="-0.23443281263685908" EFFECT_SIZE="0.21070685562490252" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="3.15" ORDER="8977" SD_1="2.34" SD_2="1.64" SE="0.22711624895812704" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="5.594848691580173"/>
<CONT_DATA CI_END="0.05755394023802565" CI_START="-0.49574164927754905" EFFECT_SIZE="-0.21909385451976168" ESTIMABLE="YES" MEAN_1="1.94" MEAN_2="2.26" ORDER="8978" SD_1="1.47" SD_2="1.44" SE="0.14114942771395284" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="14.48526737941484"/>
<CONT_DATA CI_END="0.2671449964096006" CI_START="-0.2590322329719757" EFFECT_SIZE="0.004056381718812432" ESTIMABLE="YES" MEAN_1="38.2" MEAN_2="38.1" ORDER="8981" SD_1="25.5" SD_2="23.6" SE="0.1342313515789053" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="16.016839850741036"/>
<CONT_DATA CI_END="1.2432622893539196" CI_START="-0.4258407675429788" EFFECT_SIZE="0.40871076090547037" ESTIMABLE="YES" MEAN_1="-59.6" MEAN_2="-70.0" ORDER="8979" SD_1="27.1" SD_2="20.6" SE="0.42579942031143686" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.5917491540990738"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.684191421139586" CI_END="0.00393818070007429" CI_START="-0.17088715653665631" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08347448791829101" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2008-06-28 13:53:33 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.771062318254903" P_Q="1.0" P_Z="0.06125334859902103" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1010" TOTAL_2="1007" UNITS="" WEIGHT="100.00000000000001" Z="1.871662226239374">
<NAME>WOMAC Function Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33842518385221926" CI_START="-0.33182591089201435" EFFECT_SIZE="0.003299636480102473" ESTIMABLE="YES" MEAN_1="419.85" MEAN_2="418.64" ORDER="8982" SD_1="362.09" SD_2="367.42" SE="0.17098556402849457" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="6.8035203057816815"/>
<CONT_DATA CI_END="0.1339257918203895" CI_START="-0.17843757120947712" EFFECT_SIZE="-0.022255889694543826" ESTIMABLE="YES" MEAN_1="531.8" MEAN_2="540.3" ORDER="8989" SD_1="388.6" SD_2="374.1" SE="0.07968599563403944" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="31.32481893773729"/>
<CONT_DATA CI_END="-0.004297077451081155" CI_START="-0.547943853896361" EFFECT_SIZE="-0.27612046567372106" ESTIMABLE="YES" MEAN_1="18.57" MEAN_2="21.66" ORDER="8990" SD_1="11.4" SD_2="10.89" SE="0.13868795057804537" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="10.34129946971749"/>
<CONT_DATA CI_END="0.3153553387407999" CI_START="-0.47958818796505254" EFFECT_SIZE="-0.0821164246121263" ESTIMABLE="YES" MEAN_1="25.98" MEAN_2="27.17" ORDER="8983" SD_1="14.7" SD_2="14.1" SE="0.20279544241023445" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="4.836555714061979"/>
<CONT_DATA CI_END="0.6339480734630959" CI_START="-0.2558269500752697" EFFECT_SIZE="0.18906056169391308" ESTIMABLE="YES" MEAN_1="26.6" MEAN_2="23.32" ORDER="8984" SD_1="19.1" SD_2="15.01" SE="0.2269875953223624" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="3.8605424114129923"/>
<CONT_DATA CI_END="0.10876638338596237" CI_START="-0.4398065756328786" EFFECT_SIZE="-0.1655200961234581" ESTIMABLE="YES" MEAN_1="25.0" MEAN_2="27.0" MODIFIED="2008-06-28 13:53:33 -0400" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="11.2" SD_2="12.8" SE="0.13994465289819466" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" WEIGHT="10.156403754854736"/>
<CONT_DATA CI_END="0.06907668281992704" CI_START="-0.4840452767520258" EFFECT_SIZE="-0.2074842969660494" ESTIMABLE="YES" MEAN_1="16.04" MEAN_2="18.3" ORDER="8985" SD_1="10.67" SD_2="11.03" SE="0.14110513354707235" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="9.990033572847908"/>
<CONT_DATA CI_END="0.18576265371240305" CI_START="-0.3529203396313505" EFFECT_SIZE="-0.08357884295947374" ESTIMABLE="YES" MEAN_1="580.1" MEAN_2="610.8" ORDER="8986" SD_1="364.2" SD_2="367.8" SE="0.13742165611021842" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="10.532760761885905"/>
<CONT_DATA CI_END="0.2004824002965484" CI_START="-0.3258257634372189" EFFECT_SIZE="-0.06267168157033527" ESTIMABLE="YES" MEAN_1="32.6" MEAN_2="34.1" ORDER="8988" SD_1="24.2" SD_2="23.5" SE="0.1342647538131361" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="11.033887108503553"/>
<CONT_DATA CI_END="0.9827429621021682" CI_START="-0.6690699715486685" EFFECT_SIZE="0.15683649527674978" ESTIMABLE="YES" MEAN_1="-73.0" MEAN_2="-77.0" ORDER="8987" SD_1="26.9" SD_2="21.1" SE="0.4213885935354237" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.1201779631964641"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8886532247207573" CI_END="-0.048427282683795564" CI_START="-0.31336933045919135" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.18089830657149347" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="0.71714742925247" P_Q="1.0" P_Z="0.007440315749301129" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="442" TOTAL_2="440" UNITS="" WEIGHT="99.99999999999997" Z="2.6764658061749813">
<NAME>WOMAC Total</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3415703569959785" CI_START="-0.328682057498898" EFFECT_SIZE="0.006444149748540228" ESTIMABLE="YES" MEAN_1="605.62" MEAN_2="602.26" ORDER="8991" SD_1="506.58" SD_2="531.04" SE="0.17098590070576347" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="15.625179067410008"/>
<CONT_DATA CI_END="-0.014859082831001957" CI_START="-0.5587116836150114" EFFECT_SIZE="-0.2867853832230067" ESTIMABLE="YES" MEAN_1="25.43" MEAN_2="29.67" ORDER="8996" SD_1="15.17" SD_2="14.27" SE="0.1387404577517366" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="23.732274226098735"/>
<CONT_DATA CI_END="0.29523963965479566" CI_START="-0.4998953855137384" EFFECT_SIZE="-0.10232787292947138" ESTIMABLE="YES" MEAN_1="36.57" MEAN_2="38.57" ORDER="8992" SD_1="19.5" SD_2="19.3" SE="0.20284429495655473" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="11.102480240246152"/>
<CONT_DATA CI_END="0.07745917968020843" CI_START="-0.475542416545942" EFFECT_SIZE="-0.19904161843286677" ESTIMABLE="YES" MEAN_1="22.7" MEAN_2="25.58" ORDER="8993" SD_1="14.4" SD_2="14.43" SE="0.14107442804769793" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="22.95350478621158"/>
<CONT_DATA CI_END="0.016525757749216885" CI_START="-0.5241219850659682" EFFECT_SIZE="-0.2537981136583756" ESTIMABLE="YES" MEAN_1="909.7" MEAN_2="1031.79" ORDER="8994" SD_1="473.8" SD_2="484.8" SE="0.1379228769201234" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="24.014469054866503"/>
<CONT_DATA CI_END="0.9874088709655348" CI_START="-0.6645817854026289" EFFECT_SIZE="0.1614135427814529" ESTIMABLE="YES" MEAN_1="-72.2" MEAN_2="-76.3" ORDER="8995" SD_1="26.5" SD_2="21.5" SE="0.4214339317964144" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="2.572092625167008"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0917048220424865" CI_END="0.5831721682397236" CI_START="0.04980062397233642" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.31648639610603" ESTIMABLE="YES" I2="8.400148116128555" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2008-08-17 22:53:54 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.29609425427876135" P_Q="1.0" P_Z="0.020020384711846088" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="207" UNITS="" WEIGHT="100.0" Z="2.3259656223944702">
<NAME>Minimum Joint Space Width</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Glucosamine</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9107859601239089" CI_START="0.06921403987609154" EFFECT_SIZE="0.4900000000000002" ESTIMABLE="YES" MEAN_1="3.93" MEAN_2="3.44" ORDER="8997" SD_1="1.48" SD_2="1.57" SE="0.214690659340179" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="40.16772279518269"/>
<CONT_DATA CI_END="0.5447720730804566" CI_START="-0.1447720730804563" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.75" MEAN_2="3.55" ORDER="8998" SD_1="1.32" SD_2="1.24" SE="0.1759073512574591" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="59.832277204817316"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.0073428842578425" CI_END="1.0680459275862144" CI_START="0.914821449452061" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9884691818948083" ESTIMABLE="YES" EVENTS_1="388" EVENTS_2="392" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.02858992841201118" LOG_CI_START="-0.038663661217167" LOG_EFFECT_SIZE="-0.00503686640257794" METHOD="MH" MODIFIED="2008-08-04 14:06:59 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.646409458967262" P_Q="0.0" P_Z="0.7690806260969076" Q="0.0" RANDOM="NO" SCALE="2.607505960859053" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="816" TOTAL_2="824" WEIGHT="99.99999999999997" Z="0.29357769000658845">
<NAME>Toxicity (Number of Patients Reporting Adverse Events)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1598358597729008" CI_START="0.9456395185989614" EFFECT_SIZE="1.0472758108967564" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="89" LOG_CI_END="0.06439653212450654" LOG_CI_START="-0.02427438676861643" LOG_EFFECT_SIZE="0.020061072677945074" ORDER="9008" O_E="0.0" SE="0.052085736685947896" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" VAR="0.0027129239661178983" WEIGHT="22.904968838052163"/>
<DICH_DATA CI_END="2.835502014913078" CI_START="0.37041296236305254" EFFECT_SIZE="1.0248447204968945" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4526299602326048" LOG_CI_START="-0.4313138238684917" LOG_EFFECT_SIZE="0.010658068182056593" ORDER="9000" O_E="0.0" SE="0.519232954373284" STUDY_ID="STD-Houpt-1999" TOTAL_1="46" TOTAL_2="55" VAR="0.26960286090720875" WEIGHT="1.6255024409593772"/>
<DICH_DATA CI_END="1.2780234658865646" CI_START="0.6708318299203118" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.10653882800977382" LOG_CI_START="-0.17338633898367323" LOG_EFFECT_SIZE="-0.0334237554869497" ORDER="9001" O_E="0.0" SE="0.16442942874387492" STUDY_ID="STD-Hughes-2002" TOTAL_1="40" TOTAL_2="40" VAR="0.02703703703703704" WEIGHT="6.883144652944444"/>
<DICH_DATA CI_END="2.5170953163931076" CI_START="0.6963269568793174" EFFECT_SIZE="1.3239038189533239" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.40089966155542645" LOG_CI_START="-0.15718679167301483" LOG_EFFECT_SIZE="0.12185643494120581" ORDER="9002" O_E="0.0" SE="0.32782274519888405" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" VAR="0.10746775226973246" WEIGHT="3.5168081442686336"/>
<DICH_DATA CI_END="1.4331769963601397" CI_START="0.26423688477686735" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.15629982877537973" LOG_CI_START="-0.578006559405166" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="9003" O_E="0.0" SE="0.43133520729249664" STUDY_ID="STD-Noack-1994" TOTAL_1="126" TOTAL_2="126" VAR="0.18605006105006106" WEIGHT="3.3141066847510285"/>
<DICH_DATA CI_END="1.2601345086492501" CI_START="0.84315221891628" EFFECT_SIZE="1.0307692307692307" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="65" LOG_CI_END="0.10041690483684977" LOG_CI_START="-0.07409401272090814" LOG_EFFECT_SIZE="0.013161446057970814" ORDER="9004" O_E="0.0" SE="0.10250857681640078" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.010508008320923941" WEIGHT="16.57053342375514"/>
<DICH_DATA CI_END="1.0820691576110115" CI_START="0.9429194459804258" EFFECT_SIZE="1.0101010101010102" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="99" LOG_CI_END="0.03425501844987295" LOG_CI_START="-0.025525407644972742" LOG_EFFECT_SIZE="0.0043648054024501125" ORDER="9005" O_E="0.0" SE="0.035115318205994034" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" VAR="0.001233085572708216" WEIGHT="25.238197060796292"/>
<DICH_DATA CI_END="1.1803554478377696" CI_START="0.3210478376262237" EFFECT_SIZE="0.6155896069287142" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.0720128088223598" LOG_CI_START="-0.49343025086868725" LOG_EFFECT_SIZE="-0.21070872102316365" ORDER="9006" O_E="0.0" SE="0.332144052250808" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" VAR="0.11031967144558748" WEIGHT="4.905793031372085"/>
<DICH_DATA CI_END="1.24244959489752" CI_START="0.7512195977617199" EFFECT_SIZE="0.9661016949152542" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="59" LOG_CI_END="0.09427877881228859" LOG_CI_START="-0.12423309075159425" LOG_EFFECT_SIZE="-0.0149771559696528" ORDER="9007" O_E="0.0" SE="0.12835495383302378" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" VAR="0.01647499417347767" WEIGHT="15.04094572310082"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.605545958052453" CI_END="1.0732211213560454" CI_START="0.5378773230030681" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7597771408415369" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.030689211146861385" LOG_CI_START="-0.2693167652594037" LOG_EFFECT_SIZE="-0.11931377705627114" METHOD="MH" MODIFIED="2008-06-21 09:21:09 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6781117501142521" P_Q="0.0" P_Z="0.11900261711405041" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1218" TOTAL_2="1217" WEIGHT="100.0" Z="1.5589736490652748">
<NAME>Toxicity (Number of Withdrawals due to Adverse Events)</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9009" O_E="0.0" SE="0.0" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9224773191479056" CI_START="0.33947560767879126" EFFECT_SIZE="0.8078577573845712" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.2838612248183248" LOG_CI_START="-0.46919142559873117" LOG_EFFECT_SIZE="-0.09266510039020319" ORDER="9020" O_E="0.0" SE="0.44234685452571737" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" VAR="0.19567073970879617" WEIGHT="16.35890027694014"/>
<DICH_DATA CI_END="1.3720789033585192" CI_START="0.13858327648875676" EFFECT_SIZE="0.4360587002096436" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.1373790868138049" LOG_CI_START="-0.8582891749685096" LOG_EFFECT_SIZE="-0.3604550440773524" ORDER="9019" O_E="0.0" SE="0.5848604656083154" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" VAR="0.3420617642315755" WEIGHT="13.426777342300742"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="9010" O_E="0.0" SE="0.0" STUDY_ID="STD-Houpt-1999" TOTAL_1="46" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.9453474498525" CI_START="0.01398442444617999" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9001128936458906" LOG_CI_START="-1.8543554030852154" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="9011" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Hughes-2002" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="2.2166849385873864"/>
<DICH_DATA CI_END="3.245291462684915" CI_START="0.0363017627651204" EFFECT_SIZE="0.3432343234323432" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5112537072847412" LOG_CI_START="-1.4400722856917907" LOG_EFFECT_SIZE="-0.46440928920352464" ORDER="9012" O_E="0.0" SE="1.146218547493862" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" VAR="1.3138169586189388" WEIGHT="4.368491293606362"/>
<DICH_DATA CI_END="1.8584084605221154" CI_START="0.21019329619832597" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.26914117394979037" LOG_CI_START="-0.6773811392616399" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="9013" O_E="0.0" SE="0.555991892141409" STUDY_ID="STD-Noack-1994" TOTAL_1="126" TOTAL_2="126" VAR="0.30912698412698414" WEIGHT="11.822319672466062"/>
<DICH_DATA CI_END="1.9439002242181143" CI_START="0.3292350049794475" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.28867396985797816" LOG_CI_START="-0.482493995874091" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="9014" O_E="0.0" SE="0.45298788041401306" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.20519801980198019" WEIGHT="14.777899590582578"/>
<DICH_DATA CI_END="2.0610967112290663" CI_START="0.6603819722265521" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" LOG_CI_END="0.3140983703176469" LOG_CI_START="-0.18020479105642043" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="9015" O_E="0.0" SE="0.2903561238312381" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" VAR="0.08430667864630129" WEIGHT="26.60021926304864"/>
<DICH_DATA CI_END="1.9788309255635181" CI_START="0.00593083065334093" EFFECT_SIZE="0.10833333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2964086889857738" LOG_CI_START="-2.2268844764673497" LOG_EFFECT_SIZE="-0.965237893740788" ORDER="9016" O_E="0.0" SE="1.482194895889778" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" VAR="2.1969017094017094" WEIGHT="6.734232724822441"/>
<DICH_DATA CI_END="21.739748428669788" CI_START="0.1839947694484316" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3372545141443573" LOG_CI_START="-0.7351945228163949" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="9018" O_E="0.0" SE="1.2173668230989303" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" VAR="1.4819819819819822" WEIGHT="1.4777899590582577"/>
<DICH_DATA CI_END="7.545522164113119" CI_START="0.014725436980300866" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8776892991343044" LOG_CI_START="-1.8319318085736291" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="9017" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Zenk-2002" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="2.2166849385873864"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-11-11 23:01:52 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Glucosamine versus placebo (Rotta preparation)</NAME>
<CONT_OUTCOME CHI2="92.88537974242595" CI_END="-0.5687422972177331" CI_START="-1.65704310060192" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.1128926989098264" ESTIMABLE="YES" I2="92.46383013192042" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="-4.440892098500626E-16" P_Q="1.0" P_Z="6.110434409847377E-5" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.5028521909447794" TOTALS="YES" TOTAL_1="472" TOTAL_2="468" UNITS="" WEIGHT="100.00000000000001" Z="4.008505004752498">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4850577420152552" CI_START="-2.07639481120975" EFFECT_SIZE="-1.2807262766125027" ESTIMABLE="YES" MEAN_1="0.21" MEAN_2="1.13" ORDER="9021" SD_1="0.43" SD_2="0.89" SE="0.4059607936030352" STUDY_ID="STD-Crolle-1980" TOTAL_1="15" TOTAL_2="15" WEIGHT="11.544861782184437"/>
<CONT_DATA CI_END="-3.7134659239650682" CI_START="-6.940697000101388" EFFECT_SIZE="-5.327081462033228" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="1.2" ORDER="9022" SD_1="0.12" SD_2="0.19" SE="0.8232883618250914" STUDY_ID="STD-D_x0027_ambrosio-1981" TOTAL_1="15" TOTAL_2="15" WEIGHT="6.52857470407768"/>
<CONT_DATA CI_END="-0.9082085725744987" CI_START="-1.8911551068594425" EFFECT_SIZE="-1.3996818397169706" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="1.88" ORDER="9023" SD_1="0.82" SD_2="0.44" SE="0.2507562746148145" STUDY_ID="STD-Drovanti-1980" TOTAL_1="40" TOTAL_2="40" WEIGHT="13.624853009605095"/>
<CONT_DATA CI_END="-0.025379230972806865" CI_START="-0.5694445904166039" EFFECT_SIZE="-0.29741191069470535" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="6.0" ORDER="9028" SD_1="3.03" SD_2="3.0" SE="0.13879473391738703" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="14.762998762196744"/>
<CONT_DATA CI_END="0.14905859627306614" CI_START="-0.4031188395109486" EFFECT_SIZE="-0.12703012161894126" ESTIMABLE="YES" MEAN_1="4.61" MEAN_2="5.03" ORDER="9024" SD_1="3.45" SD_2="3.13" SE="0.14086417917357663" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="14.746652859028986"/>
<CONT_DATA CI_END="-0.7364458486257748" CI_START="-2.892384263887514" EFFECT_SIZE="-1.8144150562566443" ESTIMABLE="YES" MEAN_1="1.25" MEAN_2="2.36" ORDER="9025" SD_1="0.25" SD_2="0.79" SE="0.5499943958836759" STUDY_ID="STD-Pujalte-1980" TOTAL_1="10" TOTAL_2="10" WEIGHT="9.571041645611798"/>
<CONT_DATA CI_END="0.19112506963873596" CI_START="-0.3475281057110372" EFFECT_SIZE="-0.07820151803615064" ESTIMABLE="YES" MEAN_1="156.1" MEAN_2="164.2" ORDER="9026" SD_1="101.9" SD_2="104.5" SE="0.13741404933932477" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="14.773789638810511"/>
<CONT_DATA CI_END="-0.8936109932290024" CI_START="-1.5801671348656527" EFFECT_SIZE="-1.2368890640473276" ESTIMABLE="YES" MEAN_1="24.3" MEAN_2="50.0" ORDER="9027" SD_1="19.3" SD_2="22.0" SE="0.17514509119864383" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" WEIGHT="14.447227598484748"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="28.672218886427327" CI_END="-0.12042038644627762" CI_START="-0.8204915459933517" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.47045596621981467" ESTIMABLE="YES" I2="86.049213645291" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2008-11-11 23:01:52 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="9.112252093435025E-6" P_Q="1.0" P_Z="0.008432655136908027" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.1365638621462139" TOTALS="YES" TOTAL_1="479" TOTAL_2="472" UNITS="" WEIGHT="100.0" Z="2.634237212969568">
<NAME>Lequesne Index</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07336516615764449" CI_START="-0.6184990662542025" EFFECT_SIZE="-0.3459321162059235" ESTIMABLE="YES" MEAN_1="7.97" MEAN_2="8.96" ORDER="9033" SD_1="3.07" SD_2="2.61" SE="0.1390673258275419" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="20.458420595765432"/>
<CONT_DATA CI_END="0.0529036046255113" CI_START="-0.4533952767244798" EFFECT_SIZE="-0.20024583604948426" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="8.4" ORDER="9029" SD_1="5.5" SD_2="4.4" SE="0.12916025124533206" STUDY_ID="STD-Noack-1994" TOTAL_1="120" TOTAL_2="121" WEIGHT="20.813177743998207"/>
<CONT_DATA CI_END="-0.100983159917506" CI_START="-0.6576293058659679" EFFECT_SIZE="-0.3793062328917369" ESTIMABLE="YES" MEAN_1="7.25" MEAN_2="8.12" ORDER="9030" SD_1="2.3" SD_2="2.27" SE="0.14200417720407507" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="20.350669575535388"/>
<CONT_DATA CI_END="0.13390073990719475" CI_START="-0.5258885009818807" EFFECT_SIZE="-0.19599388053734296" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="8.3" ORDER="9031" SD_1="6.9" SD_2="8.3" SE="0.1683166747178542" STUDY_ID="STD-Reichelt-1994" TOTAL_1="73" TOTAL_2="69" WEIGHT="19.342935558184575"/>
<CONT_DATA CI_END="-0.931017954189491" CI_START="-1.6211907720212866" EFFECT_SIZE="-1.2761043631053888" ESTIMABLE="YES" MEAN_1="5.5" MEAN_2="9.7" ORDER="9032" SD_1="2.8" SD_2="3.7" SE="0.17606772963069495" STUDY_ID="STD-Rovati-1997" TOTAL_1="79" TOTAL_2="77" WEIGHT="19.034796526516395"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.3718194900809073" CI_END="1.9123149812897131" CI_START="1.2006076784275854" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5152359717577109" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.2815594273592995" LOG_CI_START="0.0794011165378182" LOG_EFFECT_SIZE="0.18048027194855887" METHOD="MH" NO="3" P_CHI2="0.5420144410935464" P_Q="0.0" P_Z="4.6598756150123544E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="205" TOTAL_2="202" WEIGHT="100.0" Z="3.4995823966054056">
<NAME>Lequesne Index</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glucosamine</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9062887840018614" CI_START="1.0798999351472292" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="46" LOG_CI_END="0.2801886926287751" LOG_CI_START="0.03338351509181402" LOG_EFFECT_SIZE="0.15678610386029457" ORDER="9034" O_E="0.0" SE="0.14497458299054317" STUDY_ID="STD-Noack-1994" TOTAL_1="126" TOTAL_2="126" VAR="0.021017629713281888" WEIGHT="66.23931623931624"/>
<DICH_DATA CI_END="2.508030192447947" CI_START="1.1161037112332381" EFFECT_SIZE="1.6730875068794717" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="23" LOG_CI_END="0.3993327603622724" LOG_CI_START="0.04770455223916652" LOG_EFFECT_SIZE="0.22351865630071946" ORDER="9035" O_E="0.0" SE="0.20654815003921445" STUDY_ID="STD-Reichelt-1994" TOTAL_1="79" TOTAL_2="76" VAR="0.04266213828462184" WEIGHT="33.76068376068376"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.3809368646324247" CI_END="-0.01004618617323677" CI_START="-0.32463313313583814" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.16733965965453745" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="0.5013412225562672" P_Q="1.0" P_Z="0.03705613691547994" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="2.08514504034444">
<NAME>WOMAC Pain Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.025379230972806865" CI_START="-0.5694445904166039" EFFECT_SIZE="-0.29741191069470535" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="6.0" ORDER="9038" SD_1="3.03" SD_2="3.0" SE="0.13879473391738703" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="33.433300102713616"/>
<CONT_DATA CI_END="0.14905859627306614" CI_START="-0.4031188395109486" EFFECT_SIZE="-0.12703012161894126" ESTIMABLE="YES" MEAN_1="4.61" MEAN_2="5.03" ORDER="9036" SD_1="3.45" SD_2="3.13" SE="0.14086417917357663" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="32.45817414713285"/>
<CONT_DATA CI_END="0.19112506963873596" CI_START="-0.3475281057110372" EFFECT_SIZE="-0.07820151803615064" ESTIMABLE="YES" MEAN_1="156.1" MEAN_2="164.2" ORDER="9037" SD_1="101.9" SD_2="104.5" SE="0.13741404933932477" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="34.10852575015354"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.05755394023802565" CI_START="-0.49574164927754905" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.21909385451976168" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.12061147348158734" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="101" UNITS="" WEIGHT="100.0" Z="1.5522121348147975">
<NAME>WOMAC Stiffness Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.05755394023802565" CI_START="-0.49574164927754905" EFFECT_SIZE="-0.21909385451976168" ESTIMABLE="YES" MEAN_1="1.94" MEAN_2="2.26" ORDER="9039" SD_1="1.47" SD_2="1.44" SE="0.14114942771395284" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0001636939944911" CI_END="-0.03085411397731047" CI_START="-0.34554024979234754" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.188197181884829" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" NO="6" P_CHI2="0.6064810813047974" P_Q="1.0" P_Z="0.019062719397527576" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="311" UNITS="" WEIGHT="100.0" Z="2.3443021887878994">
<NAME>WOMAC Function Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.004297077451081155" CI_START="-0.547943853896361" EFFECT_SIZE="-0.27612046567372106" ESTIMABLE="YES" MEAN_1="18.57" MEAN_2="21.66" ORDER="9042" SD_1="11.4" SD_2="10.89" SE="0.13868795057804537" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="33.505922886438476"/>
<CONT_DATA CI_END="0.06907668281992704" CI_START="-0.4840452767520258" EFFECT_SIZE="-0.2074842969660494" ESTIMABLE="YES" MEAN_1="16.04" MEAN_2="18.3" ORDER="9040" SD_1="10.67" SD_2="11.03" SE="0.14110513354707235" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="32.367817555709735"/>
<CONT_DATA CI_END="0.18576265371240305" CI_START="-0.3529203396313505" EFFECT_SIZE="-0.08357884295947374" ESTIMABLE="YES" MEAN_1="580.1" MEAN_2="610.8" ORDER="9041" SD_1="364.2" SD_2="367.8" SE="0.13742165611021842" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="34.126259557851796"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.20022669123928366" CI_END="-0.08954678223113385" CI_START="-0.4046409900684169" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.24709388614977537" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" NO="7" P_CHI2="0.9047349415965377" P_Q="1.0" P_Z="0.002112304630012038" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="314" TOTAL_2="312" UNITS="" WEIGHT="100.0" Z="3.0739702959166664">
<NAME>WOMAC Total</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="9045" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Cibere-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.014859082831001957" CI_START="-0.5587116836150114" EFFECT_SIZE="-0.2867853832230067" ESTIMABLE="YES" MEAN_1="25.43" MEAN_2="29.67" ORDER="9046" SD_1="15.17" SD_2="14.27" SE="0.1387404577517366" STUDY_ID="STD-Herrero_x002d_Beaumont-2007" TOTAL_1="106" TOTAL_2="104" WEIGHT="33.56745538367728"/>
<CONT_DATA CI_END="0.07745917968020843" CI_START="-0.475542416545942" EFFECT_SIZE="-0.19904161843286677" ESTIMABLE="YES" MEAN_1="22.7" MEAN_2="25.58" ORDER="9043" SD_1="14.4" SD_2="14.43" SE="0.14107442804769793" STUDY_ID="STD-Pavelka-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="32.465946603754475"/>
<CONT_DATA CI_END="0.016525757749216885" CI_START="-0.5241219850659682" EFFECT_SIZE="-0.2537981136583756" ESTIMABLE="YES" MEAN_1="909.7" MEAN_2="1031.79" ORDER="9044" SD_1="473.8" SD_2="484.8" SE="0.1379228769201234" STUDY_ID="STD-Reginster-2001" TOTAL_1="106" TOTAL_2="106" WEIGHT="33.96659801256825"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-06-21 09:21:33 -0400" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Glucosamine versus placebo (non-Rotta preparation)</NAME>
<CONT_OUTCOME CHI2="13.600098028859822" CI_END="0.04580311592349808" CI_START="-0.15058146692321786" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.05238917549985989" ESTIMABLE="YES" I2="33.8240064086176" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="0.13727862699823679" P_Q="1.0" P_Z="0.29569384912053565" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="804" TOTAL_2="799" UNITS="" WEIGHT="100.0" Z="1.0457124044163804">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33598585567694017" CI_START="-0.33426480199530306" EFFECT_SIZE="8.605268408185565E-4" ESTIMABLE="YES" MEAN_1="129.72" MEAN_2="129.62" ORDER="9047" SD_1="113.23" SD_2="118.02" SE="0.170985452528489" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="8.584999683468947"/>
<CONT_DATA CI_END="0.1413518156593127" CI_START="-0.17100613591755937" EFFECT_SIZE="-0.014827160129123324" ESTIMABLE="YES" MEAN_1="149.3" MEAN_2="151.0" ORDER="9056" SD_1="115.9" SD_2="113.1" SE="0.07968461513596978" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="39.52843761190328"/>
<CONT_DATA CI_END="0.2735347817391287" CI_START="-0.5218541742172914" EFFECT_SIZE="-0.12415969623908137" ESTIMABLE="YES" MEAN_1="7.14" MEAN_2="7.65" ORDER="9048" SD_1="4.01" SD_2="4.13" SE="0.2029090744091082" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="6.096150330587079"/>
<CONT_DATA CI_END="0.47616054074363307" CI_START="-0.4115892476304209" EFFECT_SIZE="0.03228564655660611" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.35" ORDER="9049" SD_1="4.81" SD_2="4.38" SE="0.22647094420522798" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="4.8936581282657725"/>
<CONT_DATA CI_END="0.3265229057260645" CI_START="-0.22119178870229833" EFFECT_SIZE="0.0526655585118831" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.6" ORDER="9050" SD_1="3.3" SD_2="4.2" SE="0.13972570382636273" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" WEIGHT="12.856003910902315"/>
<CONT_DATA CI_END="0.3167615683181636" CI_START="-0.47550830461059157" EFFECT_SIZE="-0.07937336814621399" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.4" ORDER="9051" SD_1="2.5" SD_2="2.5" SE="0.20211337534211823" STUDY_ID="STD-Rindone-2000" TOTAL_1="49" TOTAL_2="49" WEIGHT="6.144244618970784"/>
<CONT_DATA CI_END="0.29352599391686374" CI_START="-0.23268166989018768" EFFECT_SIZE="0.03042216201333804" ESTIMABLE="YES" MEAN_1="35.2" MEAN_2="34.4" ORDER="9055" SD_1="26.8" SD_2="25.6" SE="0.1342391156056209" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="13.928374749546565"/>
<CONT_DATA CI_END="-0.1540231993132215" CI_START="-1.2159345454638881" EFFECT_SIZE="-0.6849788723885548" ESTIMABLE="YES" MEAN_1="0.65" MEAN_2="1.16" ORDER="9052" SD_1="0.71" SD_2="0.76" SE="0.27090072943352217" STUDY_ID="STD-Usha-2004" TOTAL_1="30" TOTAL_2="28" WEIGHT="3.42009570275887"/>
<CONT_DATA CI_END="-0.22035777750709318" CI_START="-1.3303287707044493" EFFECT_SIZE="-0.7753432741057713" ESTIMABLE="YES" MEAN_1="0.18" MEAN_2="0.69" ORDER="9053" SD_1="0.16" SD_2="0.92" SE="0.28316106876265734" STUDY_ID="STD-Vajaradul-1981" TOTAL_1="28" TOTAL_2="26" WEIGHT="3.1303400810992774"/>
<CONT_DATA CI_END="0.8919460976094586" CI_START="-0.7574158044584813" EFFECT_SIZE="0.06726514657548861" ESTIMABLE="YES" MEAN_1="-74.7" MEAN_2="-76.5" ORDER="9054" SD_1="26.3" SD_2="25.1" SE="0.42076331888695306" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.4176951824971082"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3738616050925481" CI_END="0.22356247068097462" CI_START="-0.2658994578267707" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.02116849357289805" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="0.8295011842650337" P_Q="1.0" P_Z="0.8653789911363785" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="129" UNITS="" WEIGHT="100.0" Z="0.16953099962785462">
<NAME>WOMAC Total</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3415703569959785" CI_START="-0.328682057498898" EFFECT_SIZE="0.006444149748540228" ESTIMABLE="YES" MEAN_1="605.62" MEAN_2="602.26" ORDER="9057" SD_1="506.58" SD_2="531.04" SE="0.17098590070576347" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="53.32870770795106"/>
<CONT_DATA CI_END="0.29523963965479566" CI_START="-0.4998953855137384" EFFECT_SIZE="-0.10232787292947138" ESTIMABLE="YES" MEAN_1="36.57" MEAN_2="38.57" ORDER="9058" SD_1="19.5" SD_2="19.3" SE="0.20284429495655473" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="37.89274484542155"/>
<CONT_DATA CI_END="0.9874088709655348" CI_START="-0.6645817854026289" EFFECT_SIZE="0.1614135427814529" ESTIMABLE="YES" MEAN_1="-72.2" MEAN_2="-76.3" ORDER="9059" SD_1="26.5" SD_2="21.5" SE="0.4214339317964144" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="8.778547446627393"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5905012883510514" CI_END="0.09842228459388541" CI_START="-0.11175397911943227" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.006665847262773427" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2008-06-21 09:21:33 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9965567117110506" P_Q="1.0" P_Z="0.9010599233892638" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="697" TOTAL_2="696" UNITS="" WEIGHT="100.0" Z="0.12432251226333867">
<NAME>WOMAC Pain Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33598585567694017" CI_START="-0.33426480199530306" EFFECT_SIZE="8.605268408185565E-4" ESTIMABLE="YES" MEAN_1="129.72" MEAN_2="129.62" ORDER="9060" SD_1="113.23" SD_2="118.02" SE="0.170985452528489" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="9.833153915588342"/>
<CONT_DATA CI_END="0.1413518156593127" CI_START="-0.17100613591755937" EFFECT_SIZE="-0.014827160129123324" ESTIMABLE="YES" MEAN_1="149.3" MEAN_2="151.0" ORDER="9066" SD_1="115.9" SD_2="113.1" SE="0.07968461513596978" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="45.27539026344126"/>
<CONT_DATA CI_END="0.2735347817391287" CI_START="-0.5218541742172914" EFFECT_SIZE="-0.12415969623908137" ESTIMABLE="YES" MEAN_1="7.14" MEAN_2="7.65" ORDER="9061" SD_1="4.01" SD_2="4.13" SE="0.2029090744091082" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="6.982456226370616"/>
<CONT_DATA CI_END="0.47616054074363307" CI_START="-0.4115892476304209" EFFECT_SIZE="0.03228564655660611" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.35" ORDER="9062" SD_1="4.81" SD_2="4.38" SE="0.22647094420522798" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="5.605136326116134"/>
<CONT_DATA CI_END="0.3265229057260645" CI_START="-0.22119178870229833" EFFECT_SIZE="0.0526655585118831" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.6" ORDER="9063" SD_1="3.3" SD_2="4.2" SE="0.13972570382636273" STUDY_ID="STD-McAlindon-2004" TOTAL_1="101" TOTAL_2="104" WEIGHT="14.725110058970616"/>
<CONT_DATA CI_END="0.25039912046134666" CI_START="-0.2757829511563314" EFFECT_SIZE="-0.012691915347492342" ESTIMABLE="YES" MEAN_1="32.0" MEAN_2="32.3" ORDER="9065" SD_1="24.1" SD_2="23.0" SE="0.13423258686591566" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="15.954942440862048"/>
<CONT_DATA CI_END="0.8919460976094586" CI_START="-0.7574158044584813" EFFECT_SIZE="0.06726514657548861" ESTIMABLE="YES" MEAN_1="-74.7" MEAN_2="-76.5" ORDER="9064" SD_1="26.3" SD_2="25.1" SE="0.42076331888695306" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.6238107686509846"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.664920283176911" CI_END="0.12649472269965217" CI_START="-0.10122465867293012" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.012635032013361018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2008-06-21 09:21:33 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7514783310045149" P_Q="1.0" P_Z="0.8278205894328271" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="596" TOTAL_2="592" UNITS="" WEIGHT="100.0" Z="0.21749758444302403">
<NAME>WOMAC Stiffness Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3776063617435915" CI_START="-0.2927218500065695" EFFECT_SIZE="0.042442255868511" ESTIMABLE="YES" MEAN_1="56.06" MEAN_2="54.0" ORDER="9067" SD_1="47.46" SD_2="49.12" SE="0.17100523709558552" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="11.540509829914157"/>
<CONT_DATA CI_END="0.15815314409059308" CI_START="-0.15420056557471631" EFFECT_SIZE="0.001976289257938382" ESTIMABLE="YES" MEAN_1="70.6" MEAN_2="70.5" ORDER="9072" SD_1="52.2" SD_2="48.8" SE="0.07968353299578859" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="53.15041431289046"/>
<CONT_DATA CI_END="0.20903068268109531" CI_START="-0.5874038205963175" EFFECT_SIZE="-0.1891865689576111" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="3.73" ORDER="9068" SD_1="1.81" SD_2="1.76" SE="0.2031758005656192" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="8.17522770570769"/>
<CONT_DATA CI_END="0.6558465238866641" CI_START="-0.23443281263685908" EFFECT_SIZE="0.21070685562490252" ESTIMABLE="YES" MEAN_1="3.58" MEAN_2="3.15" ORDER="9069" SD_1="2.34" SD_2="1.64" SE="0.22711624895812704" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="6.5425553236582035"/>
<CONT_DATA CI_END="0.2671449964096006" CI_START="-0.2590322329719757" EFFECT_SIZE="0.004056381718812432" ESTIMABLE="YES" MEAN_1="38.2" MEAN_2="38.1" ORDER="9071" SD_1="25.5" SD_2="23.6" SE="0.1342313515789053" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="18.72991864665604"/>
<CONT_DATA CI_END="1.2432622893539196" CI_START="-0.4258407675429788" EFFECT_SIZE="0.40871076090547037" ESTIMABLE="YES" MEAN_1="-59.6" MEAN_2="-70.0" ORDER="9070" SD_1="27.1" SD_2="20.6" SE="0.42579942031143686" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.86137418117344"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2297621199920123" CI_END="0.09927692531963117" CI_START="-0.1283658241787805" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.014544449429574675" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2008-06-21 09:21:33 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9419904309891657" P_Q="1.0" P_Z="0.8022391378636281" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="596" TOTAL_2="592" UNITS="" WEIGHT="100.0" Z="0.25045029652595546">
<NAME>WOMAC Function Subscale</NAME>
<GROUP_LABEL_1>Glucosamine</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Glucosamine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.33842518385221926" CI_START="-0.33182591089201435" EFFECT_SIZE="0.003299636480102473" ESTIMABLE="YES" MEAN_1="419.85" MEAN_2="418.64" ORDER="9073" SD_1="362.09" SD_2="367.42" SE="0.17098556402849457" STUDY_ID="STD-Cibere-2004" TOTAL_1="71" TOTAL_2="66" WEIGHT="11.535397933583567"/>
<CONT_DATA CI_END="0.1339257918203895" CI_START="-0.17843757120947712" EFFECT_SIZE="-0.022255889694543826" ESTIMABLE="YES" MEAN_1="531.8" MEAN_2="540.3" ORDER="9078" SD_1="388.6" SD_2="374.1" SE="0.07968599563403944" STUDY_ID="STD-Clegg-2006" TOTAL_1="317" TOTAL_2="313" WEIGHT="53.11136520562468"/>
<CONT_DATA CI_END="0.3153553387407999" CI_START="-0.47958818796505254" EFFECT_SIZE="-0.0821164246121263" ESTIMABLE="YES" MEAN_1="25.98" MEAN_2="27.17" ORDER="9074" SD_1="14.7" SD_2="14.1" SE="0.20279544241023445" STUDY_ID="STD-Houpt-1999" TOTAL_1="45" TOTAL_2="53" WEIGHT="8.200401010376973"/>
<CONT_DATA CI_END="0.6339480734630959" CI_START="-0.2558269500752697" EFFECT_SIZE="0.18906056169391308" ESTIMABLE="YES" MEAN_1="26.6" MEAN_2="23.32" ORDER="9075" SD_1="19.1" SD_2="15.01" SE="0.2269875953223624" STUDY_ID="STD-Hughes-2002" TOTAL_1="39" TOTAL_2="39" WEIGHT="6.545566258879359"/>
<CONT_DATA CI_END="0.2004824002965484" CI_START="-0.3258257634372189" EFFECT_SIZE="-0.06267168157033527" ESTIMABLE="YES" MEAN_1="32.6" MEAN_2="34.1" ORDER="9077" SD_1="24.2" SD_2="23.5" SE="0.1342647538131361" STUDY_ID="STD-Rozendaal-2008" TOTAL_1="111" TOTAL_2="111" WEIGHT="18.708003038171658"/>
<CONT_DATA CI_END="0.9827429621021682" CI_START="-0.6690699715486685" EFFECT_SIZE="0.15683649527674978" ESTIMABLE="YES" MEAN_1="-73.0" MEAN_2="-77.0" ORDER="9076" SD_1="26.9" SD_2="21.1" SE="0.4213885935354237" STUDY_ID="STD-Zenk-2002" TOTAL_1="13" TOTAL_2="10" WEIGHT="1.899266553363762"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-11-11 22:43:31 -0500" MODIFIED_BY="[Empty name]"/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-11 22:40:00 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-06-18 17:49:30 -0400" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-06-18 17:49:27 -0400" MODIFIED_BY="[Empty name]">Electronic search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-06-18 17:49:30 -0400" MODIFIED_BY="[Empty name]">
<P>1. exp osteoarthritis/<BR/>2. (degenerative adj2 arthritis). tw.<BR/>3. osteoarthr$.tw.<BR/>4. or/1-3<BR/>5. exp glucosamine/<BR/>6. glucosamine.rn, tw.<BR/>7. acetylglucosamine.tw, rn.<BR/>8. n-acetylglucosamine.tw.<BR/>9. n-acetyl-d-glucosamine.tw.<BR/>10. or/5-9<BR/>11. 4 and 10<BR/>12. limit 11 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>